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Abstract 
Although immunosuppressive treatments and therapeutic drug monitoring have significantly 
contributed to the increased success of thoracic transplantation, there is currently no 
consensus on the best immunosuppressive strategies. Maintenance therapy typically consists 
of a triple-drug regimen including corticosteroids, a calcineurin inhibitor (cyclosporine or 
tacrolimus) and either a purine synthesis antagonist (mycophenolate mofetil or azathioprine) 
or a mTOR inhibitor (sirolimus or everolimus). The incidence of acute and chronic rejection 
and of mortality after thoracic transplantation is still high compared to other types of solid 
organ transplantation. The high allogeneicity and immunogenicity of the lungs justify the use 
of higher doses of immunosuppressants, putting lung transplant recipients at a higher risk for 
drug-induced toxicities. All immunosuppressants are characterized by a large intra- and inter-
individual variability of their pharmacokinetics and by a narrow therapeutic index. It is 
essential to know their pharmacokinetic properties and to use them for treatment 
individualization through therapeutic drug monitoring (TDM) in order to improve treatment 
outcome. Unlike the kidneys and the liver, the heart and the lungs are not directly involved in 
drug metabolism and elimination, which may be the cause of pharmacokinetic differences 
between patients from all these transplant groups. 
TDM is mandatory for most immunosuppressants, and has become an integral part of 
immunosuppressive drug therapy. It is usually based on trough concentrations (C0) 
monitoring, but other TDM tools include the area under the concentration-time curve over the 
dosing interval (AUC0-12) or over the first 4 hours post-dose (AUC0-4), as well as other single 
concentration-time points, such as the concentration 2 hours after dosing (C2). Given the 
peculiarities of thoracic transplantation, a review of the pharmacokinetics and TDM of the 
main immunosuppressants used in thoracic transplantation is presented in this article. Even 
more so than in other solid organ transplant populations, their pharmacokinetics is 
characterized by wide inter- and intra-individual variability in thoracic transplant recipients. 
The pharmacokinetics of cyclosporine in heart and lung transplant recipients has been 
explored in a number of studies, but less is known about that of mycophenolate and 
tacrolimus in these populations, while there are also hardly any studies on the 
pharmacokinetics of sirolimus and everolimus. Given the increased use of these molecules in 
thoracic transplant recipients, their pharmacokinetics deserves to be explored more in depth. 
There is very little data, some of which is conflicting, on the practices and outcomes of the 
TDM of immunosuppressants after thoracic transplantation. The development of sophisticated 
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TDM tools dedicated to thoracic transplantation are awaited, in order to evaluate accurately 
and precisely patients’ exposure to drugs in general and in particular, to immunosuppressants. 
Finally, large cohort TDM studies definitely need to be conducted in thoracic transplant 
patients, in order to identify the most predictive exposure indices, and their target values, and 
to validate the clinical usefulness of improved TDM in these conditions. 
Keywords: Heart transplantation; lung transplantation; cyclosporine; tacrolimus; 
mycophenolate; sirolimus; everolimus; therapeutic drug monitoring; systemic exposure. 
List of abbreviations 
AcMPAG: acyl glucuronide of MPA – AUC0-τ: area under the concentration-time curve over 
the dosing interval – AZA: azathioprine – BOS: bronchiolitis obliterans syndrome – BPAR: 
biopsy-proven acute rejection – CAV: cardiac allograft vasculopathy – CF: cystic fibrosis – 
CL/F: apparent clearance – Cmax: maximum concentration – CNI: calcineurin inhibitor – 
CYP: cytochrome P450 – D: dose – EMB: endomyocardial biopsy – FEV1: forced expiratory 
volume in one second – LVEF: left ventricular ejection fraction – MAT: mean absorption 
time – MMF: mycophenolate mofetil – MPA: mycophenolic acid – MPAG: 7-O-
mycophenolic acid glucuronide – P-gp: P-glycoprotein – PD: pharmacodynamics – PK: 
pharmacokinetics – TDM: therapeutic drug monitoring – ISHLT: International Society for 
Heart and Lung Transplantation – T1/2: elimination half-life – tmax: time to maximum 
concentration – UGT: uridine diphosphate glucuronyl transferase – V1/F: apparent volume of 
the central compartment – Vd/F: apparent volume of distribution. 
Introduction 
Heart and lung transplantations are life-saving interventions for patients suffering from end-
stage cardiac or pulmonary failure. Many fields have been improved since the first 
transplantations of these organs (in 1963 for the lung and 1967 for the heart): optimal patient 
selection, donor management, organ preservation, histocompatibility testing, surgical 
techniques, post-operative management and immunosuppressive treatment and monitoring 
have all significantly contributed to this progress.[1] In the past 20 years (1986 to 2005), a 
large increase has been observed in the number of heart (from 2,158 to 3,095 per year) and 
lung (from 1 to 2,169 per year) transplantations in adults, as reported by the Registry of the 
International Society for Heart and Lung Transplantation (ISHLT).[2,3] The survival of heart 
and lung transplant recipients has improved in parallel, with 1-year rates of 90 and 80%, 
respectively, and 5-year rates of approx. 70 and 50%, respectively.[2,3]  
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Heart and lung transplantations are not comparable with the transplantation of other solid 
organs in terms of morbidity and mortality. First, contrary to graft failure in kidney transplant 
recipients which can often be treated by dialysis, graft loss in heart or lung transplant patients 
generally results in death. Secondly, the lung is a highly allogeneic and immunogenic organ 
because it is in direct contact with the environment (airborne organisms, polluting particles) 
through respiration, and the lung tissue is highly lymphoid.[4] Thirdly, unlike the kidneys and 
the liver, the heart is not directly involved in drug metabolism and elimination, other than by 
providing blood supply to the other organs, while the lungs are rich in metabolism enzymes 
that participate in the elimination of certain drugs and are characterized by a very large 
contact surface area between the alveoli wall and the blood stream. These peculiarities may be 
the cause of pharmacokinetic (PK) differences between patients from all of these transplant 
groups. 
The increasing success of thoracic transplantation is largely attributable to the development of 
effective immunosuppressive regimens.[5] The strategies used in thoracic transplantation were 
initially derived from clinical trials performed in other solid organ transplant settings, such as 
kidney transplantation. However, there is no consensus on immunosuppressive strategies after 
heart[2] or lung[3] transplantation to date. Maintenance therapy typically consists of a triple-
drug regimen including corticosteroids, a calcineurin inhibitor (CNI, i.e. cyclosporine or 
tacrolimus) and either a purine synthesis antagonist (mycophenolate mofetil –MMF– or 
azathioprine –AZA) or a mTOR inhibitor (sirolimus or everolimus). Between 2002 and 2006, 
the maintenance regimen of approximately 75% of heart or lung transplant recipients at both 1 
and 5 years after transplantation was comprised of a calcineurin inhibitor plus a purine 
synthesis antagonist. More precisely, the combination of tacrolimus and MMF has now 
become the most widely used combination internationally.[2,3]  
Despite the improvement of immunosuppressive strategies, the incidence of acute and chronic 
rejection and of mortality after thoracic transplantation remains high compared to other types 
of solid organ transplantation. In 2007, 35 to 45% of heart[2] and 40 to 50% of lung[3] 
transplant recipients were treated for acute rejection during their first year post-
transplantation. Moreover, many studies in lung transplantation have shown that acute 
rejection is a significant risk factor for the development of chronic rejection.[6,7] Chronic 
allograft rejection (in the form of cardiac allograft vasculopathy in heart, and of bronchiolitis 
obliterans syndrome in lung transplantation) and infections are the main threats to long-term 
survival and quality of life.[2,3,8-10] Therefore, further improvements in the treatment of heart 
and lung transplant recipients must be sought. 
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Optimal immunosuppression is essential to maintain a viable allograft. The well-known large 
intra- and inter-individual variability of the PK of the immunosuppressive agents as well as 
their narrow therapeutic index represent a challenge to the clinicians, who need to select the 
best treatment and the best dosage for a given patient. Knowing the PK properties of these 
drugs and using them for treatment individualization through therapeutic drug monitoring 
(TDM) is thus crucial to improve treatment outcome. Since the introduction of cyclosporine, 
TDM has become an integral part of immunosuppressive drug therapy, because of the high 
correlation between systemic exposure and clinical outcomes.[11] The pre-dose concentration 
(so-called trough level or C0) is routinely used for individualizing the dose of most 
immunosuppressive drugs. For cyclosporine, the area under the concentration-time curve over 
the dosing interval (AUC0-12) or over the first 4 hours post-dose (AUC0-4) were also identified 
as good, or even better predictors of outcome in renal transplant patients.[12,13] TDM based on 
cyclosporine concentration 2 hours after dosing (C2) has also been proposed, because it has 
been  shown to be highly correlated with the AUC0-4 and with the incidence of acute rejection 
in kidney and liver transplant recipients.[14,15] Based on these observations, TDM has become 
mandatory for cyclosporine. It is also mandatory for tacrolimus, sirolimus and everolimus, for 
which it is usually based on C0 monitoring. On the opposite, MMF is usually administered at 
a fixed dose, possibly adapted on clinical signs of inefficacy or toxicity. However, there is 
increasing evidence in renal transplantation that MMF TDM should also become standard 
clinical practice, particularly in the early post-transplantation period.[16]  
Heart and lung transplant patients display particularities when compared to the other solid 
organ transplant patients. First, lung transplant recipients usually require higher maintenance 
immunosuppression as compared to recipients of heart, liver or kidney grafts because of the 
high immunogenicity of the lung tissue, putting them at a higher risk for immunosuppressant-
induced toxicities. Secondly, given the potential PK differences between populations, the PK 
of immunosuppressants may be different in heart and lung transplant recipients from that of 
liver or kidney transplant recipients and thus deserves to be specifically studied. For instance, 
heart and lung transplant patients often suffer from gastroparesis as a result of their initial 
pathology (e.g., cystic fibrosis) or of the transplantation procedure, which may modify the 
absorption and thus the PK profile of drugs.[17,18] More generally, the lung transplant 
population is very heterogeneic as a consequence or the diverse indications for lung 
transplantation, which is also in favour of individual therapy and dose adjustment. Finally, 
close TDM in thoracic transplant patients may be justified given the high morbidity and 
mortality rates in these populations.  
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The aim of the present article was therefore to review the state of the art on the PK and TDM 
of the main immunosuppressants used in thoracic transplantation, and to determine what 
fields need to be further explored in future PK and TDM studies in these conditions in order 
to improve transplantation success and patients survival. All numerical results presented in 
this review are expressed as mean±SD, unless otherwise specified. 
In preparing this review, the authors conducted a search of Medline (January 1975 to June 
2008) for English-language articles using the following search terms: “cyclosporine”, 
“cyclosporin”, “tacrolimus”, “calcineurin inhibitor”, “mycophenolate”, “mycophelonic acid”, 
“MMF”, “MPA”, “sirolimus”, “rapamycin”, “everolimus”, “mTOR inhibitor”, “heart 
transplantation”, “lung transplantation”, “thoracic transplantation”, “pharmacokinetics”, 
“metabolism”, “drug interactions”, and “therapeutic drug monitoring”. This search was 
supplemented by a bibliographic review of all the relevant articles. Given the notably high 
number of articles on cyclosporine, only those considered as fair to high quality were kept for 
the review. Those rejected either concerned a very limited number of patients, or only 
reported mean C0 values in a given population, without connection with clinical data or other 
exposure indices. On the contrary, as there were only a few articles on tacrolimus, MMF and 
mTOR inhibitors, almost all were considered. Overall, around 80% of the original list of cited 
articles were included in this review.   
1 Calcineurin inhibitors 
According to the ISHLT database, calcineurin inhibitors represent the cornerstone of 
immunosuppression after thoracic transplantation.[2,3] 
1.1 Cyclosporine 
Cyclosporine penetrates into the cells and forms complexes with intracytoplasmic proteins 
(cyclophilins), inhibiting calcineurin, hence IL-2 production and T-cell activation. 
Cyclosporine has become an essential component of standard treatment after heart or lung 
transplantation, improving drastically patients’ survival and quality of life. In 2007, the 
ISHLT registry indicated that 21 and 26% of all lung transplant recipients received 
cyclosporine as part of their maintenance immunosuppressive regimen at 1 and 5 years post-
transplantation, respectively.[3] 
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1.1.1 Pharmacokinetics 
Cyclosporine PK can be affected by drug formulation (Neoral® vs Sandimmune®), drug-drug 
interactions, pre-existing conditions (age, ethnic origin, pathology, diet, activity of metabolic 
enzymes and drug transporters), clinical status (time after transplantation, gastro-intestinal 
motility and bile flow, blood lipoprotein content, haematocrit, etc.), potentially altering blood 
concentrations and total exposure, and thus the degree of immunosuppression. 
The vast majority of PK studies performed in thoracic transplantation were descriptive, using 
model-independent PK methods, where mean and standard deviation of exposure indices, PK 
parameters and, to a lesser extent, factors of variability in the evaluated population were 
calculated from individual data (Tables I and II).[4,6,19-28] Some authors used the iterative two-
stage (ITS) method, for which they either set up their own PK models or used already existing 
PK models in order to determine individual exposure indices and PK parameters and then to 
calculate mean PK parameters in the population.[29-32] To our knowledge, only one population 
PK (popPK) study was performed in heart transplant recipients[33] and one in heart-lung 
transplant recipients (Table III).[34]  
In most cases, PK studies were performed in contexts where cyclosporine monitoring was 
based on C0 or on C2.  
1.1.1.1 Absorption 
Cyclosporine is a highly lipophilic molecule. Early PK studies with the first oil-based 
formulation Sandimmune® showed a poor and highly variable relative oral bioavailability. 
The microemulsion formulation (Neoral®) designed in a second time to increase the solubility 
of cyclosporine in the small bowel improved bioavailablity and decreased absorption 
variability, with a higher maximum concentration (Cmax), shorter time to maximum 
concentration (tmax), higher AUC, and lower intra-patient variability on absorption than with 
Sandimmune®
.
[35]
  
An increased and more consistent exposure to cyclosporine after Neoral® than Sandimmune® 
administration was also reported in heart[29] and heart-lung[28] transplant recipients. As a 
consequence, Neoral® became the core maintenance immunosuppressant chosen by most 
thoracic transplantation centers worldwide.[1] However, the high intra- and inter-patient 
variability of Neoral® absorption was confirmed by Johnston et al in a study performed in 15 
de novo heart transplant recipients, in which three PK profiles were collected during the first 
year post-transplantation. Intra-patient and inter-patient variability of cyclosporine 
concentrations was the highest within the first two hours post-dose.[36]  
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Cyclosporine absorption typically lasts 4 hours, as illustrated by many studies in thoracic 
transplantation where Cmax usually occurred between 1 and 3 hours post-dose.[4,19,23-26,29,32] In 
a randomized study comparing Neoral® to Sandimmune® in 35 heart transplant recipients, 
absolute oral bioavailability based on AUC0-12 with respect to IV administration was 57±9% 
and 47±12%, respectively (p = 0.02), at 12 weeks post-transplantation.[23] A significant 
difference of absolute bioavailability between Neoral® and Sandimmune® was also reported 
by Baraldo et al in 20 stable heart transplant recipients on cyclosporine three times daily, 8 of 
whom were on diltiazem (75±19% for Neoral® vs 66±16% for Sandimmune; p < 0.001).[29]. 
However, these two studies employed a non-specific cyclosporine assay (FPIA for TDx), 
which cross-reacts with cyclosporine metabolites. Oral bioavailability might have been 
overestimated as blood concentrations of cyclosporine metabolites are higher after oral than 
after IV administration due to the first-pass hepatic and intestinal effects, which are 
particularly important for substrates of CYP3A isoforms such as cyclosporine. 
The PK models developed for cyclosporine by three groups[29,33,34] described absorption as 
following a first-order process, however with inconsistent mean values for the absorption rate 
constant ka. The first study[33] was a popPK study performed in 69 heart transplant patients on 
Sandimmune® during the first three months post-transplantation. Unfortunately, the fixed ka 
value (0.3 h-1) implemented in the model did not take into account the important variability of 
cyclosporine absorption, leading to an overestimation of cyclosporine concentrations by 150 
to 400 µg/L. The second study[34] was a retrospective popPK analysis of data collected from 
48 heart-lung transplant recipients, followed throughout their first year post-transplantation. 
Unfortunately, this study focused on apparent clearance (CL/F) and volume of distribution 
(Vd/F) and fixed ka to values estimated by the same group in one of their previous works (0.25 
and 1.35 h-1 for Sandimmune® and Neoral®, respectively).[19] The model chosen led to a large 
residual random variability of 44.0 % (proportional) + 76.4 µg/L (additive). As pointed out by 
Saint-Marcoux et al, this model systematically underestimated C2 values, showing the limits 
of a linear model for cyclosporine absorption.[37] In the third study,[29] the PK of cyclosporine 
was investigated using the ITS-method in 20 stable heart transplant males grafted for more 
than 3 years, switched from Sandimmune® to Neoral®. The absorption rate constant was ka = 
1.99±1.42 h-1 and 2.71±1.47 h-1, respectively (p < 0.05). It is therefore noticeable that ka 
differed almost 8-fold between studies for Sandimmune®, and 2-fold for Neoral®. 
Considering that model-independent PK methods or first-order absorption could not 
accurately describe the erratic and variable absorption of cyclosporine, our group used an 
original absorption model based on a Gamma distribution, initially developed for renal 
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transplant recipients.[38] In this model, the absorption rate is described as an asymmetrical 
peak and the absorbed fraction of the dose as a function of time as an S-shaped curve. This 
model was evaluated in a subpopulation of 14 de novo heart transplant recipients on Neoral® 
enrolled in study OLN351, in whom a PK profile of cyclosporine was drawn at three post-
transplantation periods: the first week (W1), the third month (M3) and the end of the first year 
(Y1).[32] Population exposure indices and PK parameters were estimated using the standard 
ITS-method. The PK model fitted well with the concentration-time data at all periods, with an 
excellent correlation between observed and modelled concentration values. For each period, 
the mean relative bias on concentrations was less than 1% and precision was good (> 88%). 
This model was also tested successfully on a population of 19 stable lung and heart-lung 
transplant recipients, with or without cystic fibrosis (CF). Three consecutive profiles were 
collected in each patient within 5 days. Good correlation and non significant differences were 
observed between measured and modeled concentration values, in non-CF (r² = 0.986) as well 
as in CF patients (r² = 0.976), confirming the robustness of the Gamma model (Table I). The 
mean absorption time (MAT) was not different between the two groups, with corresponding 
CV% of 21% and 25% in CF and non-CF patients, respectively.  
1.1.1.2 Distribution and elimination 
Cyclosporine is mainly metabolized by the cytochrome P450 (CYP) 3A enzymes in the liver 
and the gut. It is also a substrate of P-glycoprotein (P-gp), particularly in the intestinal 
mucosa. Hence, it may interact with many of the substrates, inducers and inhibitors of both of 
these systems. Vd/F, CL/F and elimination half-life (T1/2) of cyclosporine in thoracic 
transplantation were estimated in a few studies using non-compartmental analysis,[19,21] the 
ITS-method[29,32] or population PK analysis.[34]  
Formal comparison of Vd/F between studies is not presented here because only four of them 
addressed this parameter, unfortunately with different models and units. Two studies used a 2-
compartment model, one of which expressed the apparent volume of the central compartment 
(V1/F) in liters,[32] the other in L/kg.[29] In the two remaining studies, Vd/F was expressed in 
L/kg.[21,27] The same issue was faced for clearance, which was reported in studies using two-, 
single- or non-compartment models and expressing clearance or CL/F in L.h-1 or in L.h-1/kg. 
In 15 stable heart transplant recipients on Neoral®, Vd/F was 2.42±0.95 L/kg, CL/F was 
5.7±1.7 mL.min-1/kg (0.342±0.102 L.h-1/kg) and T1/2 was 5.0±1.3 h.[21] In 47 stable heart 
transplant adults switched from Sandimmune® to Neoral®, CL/F (as dose/AUC0-12) was 
significantly lower with Neoral® in the two patient subgroups who were not on ketoconazole, 
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but there was no significant difference in the other two subgroups who received 
ketoconazole.[19] This is obviously due to improved bioavailability, as illustrated earlier. In 20 
stable heart transplant patients who consecutively received Sandimmune®, IV cyclosporine 
then Neoral®, CL/F and the volume of distribution of the central compartment V1/F were 
0.20±0.04 L.h-1/kg and 1.86±0.72 L/kg after IV infusion, 0.21±0.04 L.h-1/kg and 1.00±0.43 
L/kg after Neoral®. T1/2 was longer than usually reported, ranging between 17.27±3.23 
(Sandimmune®) and 18.83±3.58 h (Neoral®).[29] Finally, using the ITS method in 19 lung and 
heart-lung transplant patients (of whom 9 with CF) on Neoral®, CL/F was 50±20 and 50±14 
L/h and V1/F = 88±41 and 74±44 L in CF and non-CF patients, respectively (ns).[32]  
In the popPK study in heart-lung (21) and lung transplant recipients (27) performed by 
Rosenbaum et al, using a one-compartment PK model, the results were expressed as pooled 
Sandimmune® and Neoral® data. Vd/F was 147 L (range, 130-164 L) and CL/F was 22.1 L/h 
(range, 19.5-24.7 L/h) on average.[34] The inter-patient variability on modelled clearance was 
17.1%, but no intra-patient variability was reported for this PK parameter. The following 
factors were reported to influence CL/F: co-administration of itraconazole, weight, and CF. 
No inter- or intra-patient variability of, and no covariates on Vd/F were reported. In a popPK 
study performed in heart transplant recipients, Parke et al proposed an estimation of clearance 
based on body weight and the co-administration of diltiazem.[33] The inter-patient variability 
on clearance was 20.2%. 
1.1.1.3 Drug-drug interactions 
Lipid-lowering therapy is commonly administered to transplant patients to overcome 
hyperlipidemia and prevent coronary-artery disease.[39] Considering the affinity of 
cyclosporine for plasma lipoproteins, it was hypothesized that the modification of lipoprotein 
concentration may influence cyclosporine disposition and PK. Akhlaghi et al evaluated the 
effect of simvastatin on cyclosporine PK in heart transplant patients with a population 
approach using the P-PHARM program, though only to estimate cyclosporine elimination 
based on C0, which might have limited the power of this study.[40] The authors found a 
moderate increase in cyclosporine CL/F in patients on lipid lowering agents. However, the 
difference in clearance before and after simvastatin administration did not reach statistical 
significance, whether patients received ketoconazole or not. 
Diltiazem is another enzyme and transporter inhibitor often given early after heart 
transplantation to prevent coronary-artery narrowing and coronary artery disease on the 
transplant. Lung transplant patients often need azole antifungals such as ketoconazole, 
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itraconazole or voriconazole as prophylactic or curative treatments, because they risk 
developing invasive fungal infections of the graft. To our knowledge, the impact of enzyme or 
transporter inhibitors on the PK of cyclosporine after thoracic transplantation was evaluated in 
only two studies.[19,41] One hundred and eighty two patients receiving Sandimmune® as part of 
their immunosuppressive regimen after cardiothoracic transplantation were recruited in the 
first study.[41] The authors defined a linear relationship between cyclosporine dose rate (DR) 
and trough concentrations at steady-state (“Csstrough”). The relationship was described as 
follows: DR = θ x Csstrough, where θ was the dose rate-steady-state trough concentration ratio, 
assuming that the PK of cyclosporine is linear. Posterior Bayesian estimation using P-
PHARM indicated that the concomitant administration of metabolic inhibitors influenced 
significantly θ, probably because of a change in CL/F (although a modification of 
cyclosporine distribution could not be excluded). A dramatic reduction (-82%) of θ was 
caused by the co-administration of ketoconazole and diltiazem, while co-administration of 
either ketoconazole, itraconazole or diltiazem resulted in 75%, 40% and 23% reduction, 
respectively. Consistently, patients who had been administered ketoconazole had a 75% 
reduction in cyclosporine dose and those on diltiazem a 23% decrease.  
 The 47 stable heart transplant recipients included in the second study were switched from 
Sandimmune® to Neoral® and were divided into four groups depending on the long-term 
(beyond two years) co-administration of enzyme inhibitors (diltiazem and/or ketoconazole or 
none).[19] Cyclosporine AUC was significantly higher after administration of Neoral® 
compared to Sandimmune® only in patients who were either receiving no metabolic inhibitors 
(4,911±935 vs 3,655±1,120 h.µg/L, p < 0.05) or diltiazem alone (4,747±923 vs 3,605±1,079 
h.µg/L, p < 0.05), but not in those taking concomitant ketoconazole or a combination of 
ketoconazole and diltiazem. Similarly, cyclosporine CL/F was significantly lower with 
Neoral® formulation, but only for patients on diltiazem (26.8±9.0 vs 36.7±14.1 L/h, p < 0.05) 
or on no metabolic inhibitor (31.8±9.5 vs 46.7±21.1 L/h, p < 0.05). The authors hypothesized 
that in patients on ketoconazole, maximal cyclosporine absorption was already achieved, so 
that no further increase was possible by switching to Neoral®. The mechanism of metabolic 
inhibition by ketoconazole is not completely known, but it seems that it inhibits the 
metabolism and enhances the absorption of cyclosporine in the gastrointestinal mucosa by a 
complete blockage of prehepatic metabolism and inhibition of intestinal P-gp. On the other 
hand, diltiazem appeared here to have very little, if any, effect on cyclosporine PK.[19]  
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1.1.1.4 Special populations 
1.1.1.4.1 Pediatric transplantation 
According to the ISHLT registry, between January 1998 and June 2006, 32.8% of heart and 
heart-lung transplant recipients were aged less than 19 years at the time of transplantation.[3] 
Since 2001, there has been a slow rise in the total number of transplant procedures performed 
in children: 77 were reported in 2005 versus 59 in 2001. CF is the main indication for thoracic 
transplantation in children (69% of patients aged 12 to 17 years who underwent 
transplantation between January 1991 and June 2006).[42]  
The PK of cyclosporine in paediatric patients is known to be highly variable,[43] and different 
from that of adults in terms of gastro-intestinal absorption, volume of distribution and 
systemic clearance (hepatic metabolism).[44,45]  
To our knowledge, no study has been specifically designed to evaluate the PK of cyclosporine 
in children after thoracic transplantation. One study performed in both adults and children, in 
different types of transplantation (renal, cardiac, hepatic and bone marrow transplantation) 
reported PK parameters of cyclosporine in 12 heart-transplant patients (apparently mainly 
children).[46] Their mean Vd/F and mean residence time were 7.4±1.8 L/kg and 10.7±4.4 h 
respectively, with no significant difference compared to other types of transplantation. 
Given the high proportion of children among patients benefiting from thoracic transplantation, 
more studies are definitely needed to better characterize cyclosporine PK in this population. 
1.1.1.4.2 Cystic fibrosis 
CF is a major indication for lung and heart-lung transplantation. Despite the administration of 
exogeneous pancreatic enzymes, patients with CF are poor absorbers (gastro-intestinal 
disorders and malabsorption of lipids owing to pancreatic insufficiency). They exhibit higher 
variability on absorption compared with non-CF patients, with erratic PK profiles and a 
delayed tmax, and consequenly require different dosage regimens.[8,25-27,47]  
A study in 31 heart and lung transplant candidates (mainly adults) reported lower 
cyclosporine bioavailability, higher apparent oral clearance and shorter mean residence time 
in subjects with CF as compared to those with Eisenmenger’s syndrome. The authors 
suggested that the difference on cyclosporine CL/F may be due to the lower bioavailability in 
CF patients.[47] In a retrospective case-control study, the same authors compared the PK of 
cyclosporine in CF patients (n = 11), vs non-CF patients (n = 11), following heart-lung 
transplantation. Patients’ daily dose was 16.7±7.2 mg/kg vs 8.2±19 mg/kg, respectively (p < 
0.01). Cyclosporine PK parameters were estimated using a Bayesian approach.[48] A 
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statistically significant difference on cyclosporine CL/F was found between CF and non-CF 
patients (3.5±1.3 vs 1.7±0.5 mL.min-1/kg, respectively; p = 0.003), but not on Vd/F (7.2±5.3 
vs 4.3±2.2 L/kg, respectively; ns).[27] The authors proposed that patients with CF be given 1.5 
to 2 times higher oral doses of cyclosporine than patients without CF.[27,47]. Higher drug doses 
were required in 9 CF vs 41 non-CF patients (p < 0.001) on either Sandimmune® or Neoral®, 
resulting in lower dose-normalized AUC0-6 (p < 0.001).[28]  
Several studies in limited numbers of mixed, adult and paediatric CF patients addressed the 
potential benefit of improved cyclosporine oral absorption after Neoral® rather than 
Sandimmune® administration. Three studies reported that Neoral® allowed a substantial 
increase in AUC0-12 (by 2.63; 1.44 and 1.48-fold, respectively) and Cmax (by 2.28; 2.28 and 
1.91, respectively) when compared to Sandimmune®, with inconsistent findings regarding 
C0.[24,26,49] The intra-individual and inter-individual coefficient of variation on C0 and on 
AUC0-12 were less with Neoral® than Sandimmune®, confirming improved PK consistency.[26] 
Increased exposure was attributed to higher bioavailability, with CL/F significantly and Vd/F 
numerically higher in CF than non-CF patients.[50]  
The PK of cyclosporine was also studied in 10 CF and 10 non-CF clinically stable lung and 
heart-lung transplant recipients on Neoral® in an open-label trial, with a non-compartmental 
approach.[25] Cyclosporine exposure was similar in patients with and without CF, but 
exposure-per-milligram-dose was approx. 25% lower in CF patients, due to lower 
bioavailability. Rousseau et al conducted a retrospective study of the data collected from 
19/20 patients included in this trial,[32] confirming that although CF patients received higher 
doses (250±76 mg BID vs 175±52 mg BID, respectively, p < 0.025), no statistically 
significant difference was found for measured C2 values between the 2 groups, resulting in 
lower C2/dose ratios in CF patients (p < 0.001). Similarly, lower AUC0-12/dose and AUC0-
4/dose ratios were found in CF patients (p < 0.005). No significant difference was found 
between CF and non-CF patients, in V1/F (88±41 and 74±44 L, respectively) and CL/F 
(50±20 and 50±14 L/h, respectively), maybe due to the small number of patients. The two 
elimination constants were significantly different between CF and non-CF patients, the first 
higher and the second lower, which is consistent with the similar CL/F values.[32]  
1.1.2 Therapeutic drug monitoring 
Cyclosporine is characterized by a marked inter- and intra-patient variability in its PK 
parameters and a narrow therapeutic index: subtherapeutic exposure may be associated with 
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rejection and supratherapeutic exposure with drug-induced toxicity (e.g., nephrotoxicity: end-
stage renal failure requiring dialysis occurs in up to 6.5% of heart transplant recipients[51]). 
TDM of cyclosporine has been recognized as an essential tool in the management of allograft 
transplant recipients and has been performed routinely in transplantation for almost 20 
years.[52,53] However, there is still no consensus about the optimal method for monitoring 
cyclosporine, and very little data is available on the practices and outcomes of cyclosporine 
monitoring after thoracic transplantation. Much of the available information has been 
extrapolated from data obtained in other types of organ transplantation. Table IV presents a 
summary of TDM methods together with their advantages and limitations, derived from 
reviews and tables by Fernandez de Gatta et al[43] and Dumont et al.[53]  
1.1.2.1 Single concentrations monitoring 
The traditional method for cyclosporine dose adjustment is trough concentration monitoring, 
and it is widely used in most clinical settings. However, many studies in thoracic 
transplantation have evidenced a poor correlation between C0 and exposure to cyclosporine, 
expressed either by the full AUC over the dosing interval (AUC0-12) or by an abbreviated 
AUC (AUC0-4, AUC0-6). 
Correlation coefficients between C0 and AUC0-12 or AUC0-4 reported in adult heart 
transplantation, ranged from 0.06 to 0.6, and from 0.16 to 0.4, respectively.[21,23,54-56] Similar 
results were reported after lung or heart-lung transplantation: in a study of 50 patients on 
cyclosporine after heart-lung transplantation, Trull et al found that C0 was well correlated 
with AUC0-6 estimated from three time-points (C0, C2, C6) using the linear-log trapezoidal rule 
(r² = 0.574 and 0.671 for Sandimmune® and Neoral® respectively).[28] Surprisingly, using the 
same database, apparently limited however to 48 patients, Akhlaghi et al reported a poor 
correlation between C0 and AUC0-6 (r² = 0.267).[20] This may be due to the fact that 
Sandimmune® and Neoral® data were pooled and the linear rather than the linear-log 
trapezoidal rule employed. Jaksch et al[4] reported a correlation coefficient of 0.64 between C0 
and AUC0-4 in 20 lung transplant recipients, and Hangler et al[6] a correlation coefficient of 
0.31 between C0 and AUC0-6 in 12 lung transplant recipients.  
As it was recognized that C0 values were rather poorly correlated with the AUC,[52] 
monitoring, another single concentration was proposed as an alternative to C0 monitoring. The 
immunosuppressive effect of cyclosporine is maximal and most consistent around tmax, which 
is usually within 2 hours post-dose. C2 has been demonstrated as an excellent predictor of 
AUC0-4 in renal transplantation.[14,57] In thoracic transplantation, a series of studies have 
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shown that C2 quite reliably predicts AUC0-12 and abbreviated AUC: coefficients of 
determination between C2 and AUC0-12 ranged from 0.94 to 0.99 in heart transplant 
recipients;[21,54,55] lower coefficients of determination between C2 and AUC0-12 were reported 
in one study in heart-lung transplantation (0.76 and 0.66 in CF and non-CF patients, 
respectively);[25] coefficients of determination reported between C2 and AUC0-4 were 
comprised between 0.78 and 0.98 in all types of transplantation.[4,25,54,56]  
Some authors also reported a good correlation between C2 and AUC0-6 (r² > 0.80).[6,20,28] 
However, in two of them,[20,28] performed on the same database, AUC0-6 was estimated using 
only three time-points (C0, C2, C6) and the trapezoidal rule, which necessarily implies a good 
correlation with each of the three points, particularly with the middle one which is used twice 
for the trapezes calculation. 
In another paper analysing the same database of 47 heart transplant patients as Akhlaghi et 
al[19] (though with inconsistencies in patients’ numbers and classification, as well as AUC 
values despite the use of identical samples, analytical method and method of calculation), Ray 
et al considered AUC0-5 and concluded that in general, it was poorly predicted by both C2 (r² = 
0.197 to 0.898) and C0 (r² = 0.022 to 0.710), but that C0 did better than C2 in patients on 
cyclosporine alone (r2 = 0.710, p = 0.001, vs 0.197), while C2 did better than C0 in patients co-
administered ketoconazole (± ditiazem) (r2 = 0.870, p < 10-4, vs 0.176 and 0.898, p < 10-4, vs 
0.022) and both were weak predictors in patients on cyclosporine and ditiazem (but no 
ketoconazole) (r2 = 0.65 for both).[58] However, these conclusions were drawn from very 
small numbers of patients in each group.   
In conclusion, C2 seems to be a better single-time-point surrogate marker than C0 for 
cyclosporine AUC0-12, and is now strongly encouraged. It seems to be of particular interest in 
CF patients and in patients in whom cyclosporine-induced toxicity is suspected, despite 
acceptable C0.[9] Unfortunately, the optimal concentration range for cyclosporine C2 has not 
been established for thoracic transplant recipients. Moreover, rigid collection timing is a 
drawback of C2 monitoring, and the pertinence of C2 may be compromised by all the factors 
of variability of cyclosporine absorption or exposure, including CF (see above).[30,58]  
Alternatives to C0 or C2 monitoring are other single concentrations measured at specific times 
post-dose. Several time-points have been proposed, based on the results of linear regression 
analyses intended for developing sparse sampling strategies.[53] C6 was proposed for heart 
transplant recipients, based on efficacy, toxicity and cost in 20 patients.[59] A good correlation 
was found between C4 and AUC0-12 (r² = 0.95) in 15 heart transplant patients.[21] In heart-lung 
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transplant recipients, the best correlation was between C3 and AUC0-12, in CF as well as in 
non-CF patients (r² = 0.87 and 0.82, respectively).[25]  
Single concentration monitoring (whether based on C0, C2, C3 or C6) is widely used in clinical 
routine. However, as further discussed in paragraph 1.1.2.3.1 (“C0 monitoring”), robust data 
on the correlation between such concentrations and overall exposure to cyclosporine and 
target values is still lacking, especially in populations such as children or CF patients. Further 
exploration is still needed, and a consensus on such tools, with the definition of target 
concentrations, is awaited. 
1.1.2.2 AUC monitoring 
1.1.2.2.1 Full AUC 
The inter-dose AUC over the dosing interval (AUC0-τ) is believed to be a better surrogate 
marker of cyclosporine efficacy and toxicity than single concentrations, as it gives a complete 
picture of its absorption and elimination and is proportional to the mean concentration over 
the dosing interval (AUC = Css × τ). Indeed, in the absence of any evidence that cyclosporine 
effects are linked to its maximal or minimal blood levels, the mean concentration is supposed 
to better reflect its activity on calcineurin.[60,61] As a consequence, AUC monitoring has 
become the gold standard for the TDM of cyclosporine.[62] However, proper calculation of 
AUC requires repeated blood sampling, followed by the calculation of AUC from 
cyclosporine blood concentrations using the trapezoidal method.[53] As a consequence of the 
intensive sampling strategy, it is uncomfortable for the patients, inconvenient for the clinical 
team and costly to the health-care provider, which explains why it is only performed 
infrequently.  
1.1.2.2.2 Abbreviated AUC 
As full AUC0-12 is impractical to obtain, abbreviated AUCs have been tested. The 4-hour 
AUC (AUC0-4) has been validated as a reliable estimate of AUC0-12.[57,63] Indeed, the largest 
part of cyclosporine AUC0-12 variability occurs in the first 4 hours following administration. 
The AUC0-4 reflects the highly variable absorption profile of cyclosporine, suggesting it is a 
more accurate measure of exposure than C0.[36]  
A retrospective study of 156 de novo renal graft recipients showed that cyclosporine AUC0-4 
(sampling at 0, 1, 2, 3, 4h) measured in the first 2-4 days post-transplantation (but not C0) was 
lower in patients who experienced acute rejection at 3 months than those who did not.[12] In 
addition, AUC0-4 was reported to be a sensitive marker of nephrotoxicity (contrary to C0). In a 
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second time, the same authors performed a prospective, non comparative study in 59 de novo 
renal transplant patients, with cyclosporine dose adjustment based on AUC0-4 (target range: 
4,400 – 5,500 h.µg/L).[64] They found that the incidence of acute rejection was 3% when 
AUC0-4 at day 3 was > 4,400 h.µg/L (n = 33) vs 45% when it was < 4,400 h.µg/L (n = 22) (p 
= 2.10-4). Again, they did not note any nephrotoxicity episodes when AUC was < 5,500 
h.µg/L. 
Unfortunately, no equivalent or better designed studies were conducted in thoracic transplant 
patients. 
1.1.2.2.3 Sparse sampling strategies 
Rather than replacing AUC0-12 monitoring by the determination of the abbreviated AUC0-4, 
some authors sought for other clinically applicable methods to accurately estimate AUC0-12. 
This led to the development of sparse sampling strategies, in which specific algorithms allow 
AUC estimation from a limited number of blood samples collected at precisely defined times. 
A sparse sampling strategy is developed using full AUC values in a sample population. 
Stepwise multiple regression (MLR) analysis is then performed on the concentration-time 
points sampled. The points that do not correlate well with AUC are removed until a regression 
equation consisting of 2 or 3 concentration-time points is left. The AUC estimate obtained 
using the retained equation must have a high coefficient of correlation with the full AUC, 
calculated using a reference method. A good predictive performance (bias and precision) of 
the sparse sampling strategy is also mandatory.  
To our knowledge only a few studies have developed such sparse sampling strategies and 
MLR equations for thoracic transplant recipients (Table V). Sparse sampling strategies 
simplify AUC monitoring but there are some limitations that need to be pointed out. First, the 
sampling strategies that were originally developed in renal transplantation proposed 
impracticable collection times in an outpatient setting.[65] To be clinically applicable, such 
strategies should be limited to the first 4 hours post dose. This prerequisite was fulfilled by 
most sparse sampling strategies developed in thoracic transplantation.[6,21,66] Secondly, sparse 
sampling strategies developed using Sandimmune® are no longer applicable because of the 
PK differences between Neoral® and Sandimmune®.[53] Fortunately, all the sparse sampling 
strategies developed in thoracic transplantation were developed using Neoral®. Thirdly, no 
study has been conducted to date to demonstrate the superiority in terms of outcome of sparse 
sampling strategies over C0 or C2 monitoring. As a consequence, there are no evidence-based 
data justifying the use of a sparse sampling strategy which requires 2 or 3 blood samples, 
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rather than a single concentration. In addition, although few blood samples are needed, 
multiple linear regression requires a strict respect of sampling times, which is not easily 
feasible in a clinical setting. Moreover, in most cases, sparse sampling strategies were chosen 
solely on the basis of high coefficients of correlation[6,21] rather than looking for other criteria 
such as bias or prediction error.[53,66,67] In addition, to be applicable routinely, sparse sampling 
strategies should be validated in external populations, which is seldom the case.[6,21] Finally, 
the algorithm proposed should allow AUC calculation over an appropriate dosing interval 
(AUC0-12 or AUC0-8 for patients receiving cyclosporine two or three times daily, respectively); 
unfortunately, the actual dosing interval was only reported in 2/4 studies.[21,68] The algorithm 
proposed by Hangler et al[6] allows the determination of AUC0-6 which is of a limited interest, 
as the clinical pertinence of AUC0-6 in patients dosed twice daily has never been 
demonstrated, nor have any targets been proposed. The algorithm proposed by Dumont et 
al[66] also presents major drawbacks rendering it useless: first of all, there is no indication on 
the type of lung transplant patients (CF or not) in whom the strategy was developed; secondly, 
the algorithm allows the calculation of “AUC0-τ” without any precision on the value of τ. 
In brief, only one published sparse sampling strategy seems to be clinically applicable in heart 
transplantation (i.e., with a maximum of 3 samples collected within the first 4 hours post-
dose, actually C1 and C4), although it still needs external validation.[21] There is currently no 
applicable sparse sampling algorithm for lung transplant patients. 
1.1.2.2.4 Bayesian forecasting 
Maximum a posteriori (MAP) Bayesian forecasting based on a population model allows 
simultaneous estimation of individual PK parameters and exposure indices, which helps 
define the dose and administration schedule needed to achieve the desired exposure in a given 
patient, whatever the targeted exposure index (single concentration value, full AUC or 
abbreviated AUC).[32] Bayesian forecasting of cyclosoporine AUC0-12 has been proposed as a 
TDM tool in renal transplantation,[69-72] but seldom in thoracic transplantation.  
In heart transplantation, the first such study intended to develop a Bayesian estimator based 
on a routinely applicable sparse sampling strategy to accurately estimate cyclosporine AUC0-
12.
[31]
 Concentration-time data was obtained from 14 heart transplant recipients at three 
periods during the first year post-transplantation. The popPK parameters were evaluated using 
the standard two-stage method. The accuracy of the model was evaluated using the Jackknife 
method. A MAP-Bayesian estimator was built using the distribution of the population 
parameters, and all sparse sampling strategies combining a maximum of three sampling times 
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within 4 hours post-dose were tested. The best sampling time combination, with respect to its 
predictive performance for AUC0-12 estimation and to the D-optimality criterion (a statistical 
test) applied to Bayesian estimation, was found to be T0, T1h and T3h, whatever the period 
post-transplantation, yielding excellent correlation with the “reference” AUC0-12 calculated 
using the linear trapezoidal rule: r² = 0.887 to 0.998, bias = -0.20 to +3.06%.  
In a second study performed in 31 heart transplant recipients, cyclosporine AUC0-12 was 
calculated with Bayesian estimation and multiple linear regression in parallel, using 
previously reported estimator and equations.[54] The Bayesian estimator used for this purpose 
was originally designed for renal transplant recipients.[69] The authors investigated the 
correlation between AUC0-12 Bayesian estimates and measured C0 (r² = 0.43) or C2 (r² = 0.85) 
values, confirming that C2 was a better surrogate marker of AUC0-12. Unfortunately, as they 
did not compare the values of AUC0-12 obtained using the different methods, Bayesian 
estimation could not be validated, neither vs multiple linear regression nor vs the linear 
trapezoidal rule.[54]  
The third study[30] was performed on a database of cyclosporine concentrations previously 
collected from 47 adult heart transplant recipients (although presenting discrepancies with the 
original description of the population, notably on patient numbers and classification as already 
mentioned).[19] Patients were divided into four groups based on the long-term concomitant 
administration of enzyme inhibitors (no enzyme inhibitor, diltiazem and/or ketoconazole). 
The structural PK model was selected from the literature,[73] and parameters for model 
building were selected from a previously published PK study in stable heart transplant 
recipients on Neoral®.[29] Of note, the authors added a “disposition factor” of 0.76 on Vd for 
patients on ketoconazole + diltiazem and of 0.5 on CL for patients on ketoconazole with or 
without diltiazem, thus improving the model and AUC estimation.[30] The Bayesian models 
tested included one, two or three concentrations out of four (C0, C1, C2 and C7). 
Unfortunately, no other sampling times were tested, although C0.5, C3 and C5 were available. 
AUC0-12 Bayesian estimates were compared to the “reference” AUC0-12 calculated with the 
linear trapezoidal rule, based on linear regression analysis, bias and precision RMSE%. The 
best prediction of AUC0-12 was obtained with samples collected at 0, 1 and 2 hours after 
cyclosporine administration in the four groups of patients. In patients who did not receive 
concomitant enzyme inhibitors, a good correlation was observed (r² = 0.871), with a bias of 
11.7% and a RMSE% of 13.4%. However, the predictive performance was not so good for 
patients on enzyme inhibitors, with a bias ranging between -14.2% for patients on 
ketoconazole and diltiazem and +19.0% for patients on diltiazem only. In these groups, 
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squared correlation coefficients were 0.818 and 0.791 and RMSE% 16.9 and 22%, 
respectively.[30]  
In heart-lung transplantation, Bayesian estimators for cyclosporine AUC0-12 forecasting and 
dose adjustment using a limited number of blood samples were also developed by our 
team,[32] using data from a previous trial where repeated cyclosporine profiles were collected 
from 19 stable transplant patients (9 CF patients).[25] Three PK models and Bayesian 
estimators were designed using a similar method as that presented for heart transplant patients 
above. The best sampling strategy was also 0, 1 and 3 hours in both groups of patients (CF 
and non-CF), allowing accurate estimation of AUC0-12 in all patients. The comparison 
between AUC0-12 calculated by non-linear regression (PK modelling using all available time 
points) and AUC0-12 calculated using the Bayesian method found bias values of  +3.0% (ns) 
and +5.3% (p < 0.05) in CF and non-CF patients, respectively, with a good precision in both 
groups (RMSE% = 8.7% and 10.0%, respectively). In non-CF patients (where bias was 
statistically significant, though small), the examination of individual AUC0-12 showed relative 
estimation errors in the range of -20.2 to +23.7%, of which only 3 were outside the ±20% 
interval.[32]  
In conclusion, blood sampling schedules such as T0, T1h and T2h or T0h, T1h and T3h can easily 
be integrated into clinical practice because they do not require a prolonged hospital stay. 
Moreover, as opposed to multiple linear regression and single concentrations monitoring such 
as C2, Bayesian forecasting is characterized by its flexibility in sampling times, as long as the 
true sampling times are reported to the pharmacologists. Another advantage is that such a 
method can estimate several PK parameters and exposure indices simultaneously. Therefore, 
it could help to identify absorption and elimination problems in diabetic or CF patients, for 
instance. 
1.1.2.3 Impact of cyclosporine TDM on patient outcome 
Studies on Bayesian forecasting for cyclosporine after thoracic transplantation have not 
evaluated patient and graft survival, and only a few have looked for relationships between 
global exposure as expressed by the AUC and surrogate markers of efficacy or toxicity. A 
number of studies describing other TDM tools, particularly C0 and C2, collected indicators of 
efficacy (e.g., acute rejection, graft loss, left ventricular ejection fraction (LVEF), graft 
atherosclerosis, mortality, forced expiratory volume in one second (FEV1), depending on the 
type of graft) (Table VI) or toxicity (renal dysfunction, infections) (Table VII). 
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1.1.2.3.1 C0 monitoring 
Various observational studies sought for a relationship between C0 and clinical outcome, with 
contrasted conclusions (Tables VI to VIII). 
A significant relationship between C0 and clinical outcome was established in a series of 
studies. 
In a study in 48 adult heart transplant recipients, on a steroid-free regimen containing 
Sandimmune® and azathioprine, who were at least 8 months beyond transplantation, an 
inverse relationship was found between cyclosporine C0 and the probability of cellular 
rejection (p < 0.03):[74] C0 = 211 µg/L was associated with a 2.5% probability of rejection ≥ 
grade 1B and a 1.1% probability of rejection ≥ grade 3A. The lowest probability of acute 
cellular rejection was obtained with C0 > 300 µg/L. On the other hand, no correlation was 
found between cyclosporine C0 and simultaneously obtained serum creatinine measurements, 
but this may well be due to the partly cumulative mechanism of cyclosporine nephrotoxicity. 
Results from a retrospective analysis of 1,407 endomyocardial biopsies (EMB) and 
cyclosporine concentrations in 105 heart transplant adults (time post transplantation not 
reported) showed significantly lower C0 in patients with grade 3A cellular rejection compared 
to patients with no rejection (173 [95%CI = 148-197] vs 206 [95%CI = 182-230] µg/L, p = 
0.005).[75] Again, no correlation was found between cyclosporine C0 and serum creatinine 
levels. 
In a randomized clinical trial performed in 50 lung or heart-lung transplant recipients, the 
mean C0 observed in patients who did not experience acute rejection was 449 vs 394 µg/L in 
patients who had at least one rejection episode (p = 0.042).[28] Once again, C0 did not correlate 
with any of the markers of nephrotoxicity. Based on those results, the authors recommended 
the use of C0 rather than C2 as a monitoring strategy. However, this study was not designed to 
establish a potential relationship between exposure parameters and effects but to compare 
clinical outcomes between patients on Sandimmune® and patients on Neoral®. In a 
retrospective analysis of 32 heart or heart-lung transplant recipients in their first three months 
post-transplantation, the same authors had previously reported a relationship between log(C0) 
and renal function (1/Cr) evaluated at the same time or in the subsequent 5-day period, 
showing r² = -0.33 and -0.69, respectively.[76,77]  
In a recent study in 70 de novo heart transplant adults, mean C0 levels over the first week 
post-transplantation were significantly lower in patients with vs without acute rejection during 
the first year post-transplantation (126±56 vs 169±48 µg/L, p = 0.003).[78] ROC curve analysis 
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showed that patients whose mean C0 during the first week was > 150 µg/L had a significantly 
lower incidence of acute rejection (30.3 vs 64.9%, p = 0.009). 
In a small study performed in 15 adult lung transplant recipients on cyclosporine (dose-
adjusted on C0, same target whatever the period) during the first year post-transplantation, 
significantly higher C0 were reported in patients who developed CMV infection or disease 
than in patients who did not (289±93 vs 222±82 µg/L, p < 0.05).[79] C0 and C2 displayed the 
same sensitivity (84.6%) but C0 yielded better specificity (66.7%) than C2 (57.1%). 
Cyclosporine C0 may not always be an appropriate TDM tool, however, as shown by a series 
of studies in which there was no correlation between C0 and clinical outcomes. 
In 31 heart-lung transplanted adults followed during the first 3 months after transplantation, 
no relationship was found between C0 and subsequent rejection. The authors put more 
emphasis on the evidence of C0 variability as a risk factor for subsequent rejection, with intra-
individual CV > 40% resulting in a relative risk of 1.51 (95%CI = 1.01-2.27) for rejection.[80]  
In a more recent study in 48 patients who underwent lung or heart-lung transplantation, 
treated by either Sandimmune® or Neoral® and followed for one year after transplantation, no 
statistically significant difference on C0 was found between patients who experienced 2 acute 
graft rejection episodes or more, and patients who experienced less than 2 episodes. No 
relationship was found either between C0 and infections or the deterioration of renal 
function.[20]  
The same observations were made in another study performed in 31 heart transplant recipients 
between 3 weeks and 2 years post-transplantation, cyclosporine dose-adjusted on C0, and in 
whom no relationship was found between C0 and acute graft rejection or impairment of renal 
function.[54]  
1.1.2.3.2 C2 monitoring 
A significant number of observational studies demonstrated that C2 monitoring is an efficient 
TDM tool in solid organ transplant patients receiving cyclosporine: it allows the reduction of 
incidence of acute and chronic rejection and of hypertension after transplantation. 
Unfortunately, most of these studies were performed in hepatic or renal transplantation.[81-83] 
As a consequence, although C2 targets were validated in various other solid organ transplant 
settings,[81-83] there is no published consensus to date for C2 target levels after heart or lung 
transplantation. 
In thoracic transplantation, a number of authors succeeded in establishing a relationship 
between C2 and clinical outcomes and thus advocated C2 monitoring.[10,56,84-88]  
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C2 was an excellent tool to predict AUC0-12 and AUC0-4 in CF and non-CF patients in small 
single-center studies.[4,6,21,25,54] A longitudinal follow-up was conducted in 114 adults who had 
undergone heart transplantation more than one year prior to the study.[10] Follow-up was 
performed in two phases: cyclosporine dose was adjusted on C2 during the first phase (target: 
300 to 600 µg/L) then adjusted on C0 during the second phase (target: 100 to 200 µg/L). The 
primary endpoint was the clinical benefit, defined by the authors as a composite criterion 
comprised of positive cardiac outcomes (no mortality, no acute rejection, no decrease in 
LVEF > 10%) and positive renal outcomes (absence of increase in serum creatinine > 10%). 
There was no difference between the two phases in terms of incidence of acute rejection or 
mortality, but there was a significant clinical benefit of C2 monitoring vs C0 monitoring, with 
a relative “risk” of positive outcome of 1.6 (p = 10-5). Moreover, there was a lower incidence 
of serum creatinine increase > 10% during phase 1, with a relative risk of 0.37 (p < 10-4). 
However, one limitation of this study is that it was a non-randomized sequential assessment of 
2 strategies for Neoral® dose adjustment: as this concerns a chronic, progressive pathology, 
there is no certainty that patients were comparable between phases I and II in terms of both 
cardiac and renal functions. 
Another prospective study was performed in 30 stable heart transplant adults who were 
randomized to either C0 or C2 monitoring.[56] None of the patients experienced biopsy-proven 
acute rejection ≥ grade 2 according to the ISHLT classification. As a consequence, this study 
could not report any relationship between any monitoring tool and the clinical outcome, and 
was rather a study on the correlation between single concentration time points and AUC0-4. 
In a similar prospective study, Delgado et al performed parallel determination of C0 and C2 
levels in 58 adults with orthotopic heart transplantation.[86] Follow-up consisted of two 
phases: during phase 1 (6-months follow-up on C0), the authors found no significant 
difference on C0 between patients who experienced rejection and those who did not (195±121 
vs 197±100 µg/L, p = 0.96) but C2 was lower in patients with rejection than in patients 
without (777±326 vs 1,015±422 µg/L, p = 0.022). During phase 2 (6-months follow-up on 
C2), no significant difference was found between C0 levels (204±85 vs 209±138 µg/L, p = 
0.88), whereas rejection was associated with lower C2 levels (765±297 vs 967±470 µg/L, p = 
0.03). There was no difference on serum creatinine, creatinine clearance or infections between 
the two phases. As a consequence, the authors concluded that higher C2 levels were associated 
with significantly fewer rejection episodes and that C2 monitoring was safe in terms of 
preservation of renal function and infection rates.  
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In lung transplantation, Glanville et al conducted a single-arm, single-center pilot study on 15 
stable transplanted adults with renal dysfunction.[87] Cyclosporine monitoring was switched 
from C0 to C2 (C2 target: 300 to 600 µg/L), resulting in cyclosporine dosage being divided by 
two within three months, with a significant improvement in renal function. Lung function 
remained stable in all patients, except for one acute rejection episode. Based on these results, 
the authors concluded that C2 monitoring allows safe dose reductions in patients with altered 
renal function, in cases where AUC monitoring is not feasible.  
The same team performed a study in 50 de novo lung or heart-lung transplant patients, 20 of 
whom with CF, using 338 (73 CF) historic controls.[88] The authors concluded that C2 
monitoring and dose adjustment on C2 brought a clinical benefit compared to C0 monitoring 
in terms of survival, incidence of acute rejection, occurrence of BOS and renal dysfunction. 
Unfortunately, the comparison with historic controls is of limited interest given the significant 
time bias and the lower proportion of patients with CF or bilateral lung transplant in the 
control group. 
In another study, Caforio et al retrospectively compared C0 vs C2 as predictors of rejection 
and renal dysfunction in 269 adults after 1 year post-heart transplantation.[85] Dose adjustment 
was based on C0 (target: 100 to 250 µg/L). Patients with higher C2 levels (> 740 µg/L) had 
higher severe rejection score at 2 years than patients with lower C2 (p = 0.02), whereas no 
significant association was found with C0. However, based on the rejection history of the 
patients, the authors used higher cyclosporine dose and C0 targets even in the long term in 
patients considered high rejectors vs the low rejectors, which probably accounts for this quite 
unexpected result. 
Finally, Baraldo et al compared the distribution and variability of C2 values after Neoral® 
twice daily (BID) or three times daily (TID) between 2 groups of 25 stable heart transplant 
recipients followed for one year.[84] Cyclosporine dose adjustment was based on C0 (target: 
250 to 350 µg/L). Significantly higher C2 variability was observed in the BID than in the TID 
regimen (CV = 25.3 vs 15.1%, p < 0.001), but it is not quite clear whether the authors referred 
to intra-patient or inter-patient variability or a mixture of the two (overall C2 variability). 
There was no significant difference in rejection incidence or cardiac function (LVEF) 
between the 2 groups, but the TID regimen led to a lower incidence of nephrotoxicity. Based 
on these results, the authors suggested that in stable heart transplant patients, cyclosporine 
TID would lead to similar (or better, considering a lesser variability on cyclosporine 
concentrations) cardiac outcomes than BID, with decreased nephrotoxicity (decreased C2 and 
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decreased variability on C2), with a target range for C2 of 650 to 850 µg/L. However, these 
statements are speculative and have never been confirmed by a prospective trial. 
To our knowledge, only one prospective study compared C0 to C2 monitoring, in 50 de novo 
pediatric heart transplant recipients.[55] No significant difference was found on C0 between 
patients with or without acute graft rejection, but C2 was significantly higher in children who 
did not experience acute rejection, whatever the post-transplantation period. The ROC curve 
analysis for C0 and C2 found better sensitivity and specificity for C2, with respective values of 
100% and 83% for a C2 target of 600 µg/L.  
On the other hand, many observational studies failed to evidence a relationship between C2 
and clinical outcome. In 7 consecutive male adults on Neoral® followed for one year after 
heart transplantation, no statistically significant difference in C2 was found between patients 
with and without acute rejection, which might be due to the fact that cyclosporine dose was 
adjusted in all the patients according to C2 (target range: 300-600 µg/L)[89] and, above all, that 
too few patients were included in order to perform a powerful analysis. 
In another retrospective study, Cantarovich et al analyzed the results of 517 EMB from 39 
adult heart transplant recipients during the first year post-transplantation.[90] When EMB were 
split into 2 groups based on the degree of acute rejection (≤ 2 or ≥ 3A according to the ISHLT 
classification), no statistically significant difference in C2 values was found. However, 
cyclosporine monitoring was not homogeneous in all patients, being based on C0 in 13 of 
them and on C2 in the 26 others, and cyclosporine was assayed using different analytical 
methods throughout the study (EMIT or CEDIA), which may have introduced confusing 
factors in the analysis. In another study, a prospective analysis of 2 consecutive periods was 
performed in 22 de novo heart transplant patients.[22] In group I, follow-up was based on C0 
whereas in group II, follow-up was based on C2 (targets depending on time post-
transplantation). Of note, all patients received MMF but the dose was different between the 
groups (1 g twice daily in group I vs 1.5 twice daily in group II). No significant difference 
was found between the 2 groups on the following: the incidence of acute rejection episodes ≥ 
grade 3A according to the ISHLT classification, time to acute rejection, death, LVEF, 
incidence of graft atherosclerosis, nephrotoxicity or infections. 
More recently, Cantarovich et al performed a multi-centre randomized open-label study in 87 
de novo adult heart transplant recipients, with the objective of determining the minimal 
effective exposure to cyclosporine with C2 monitoring.[91] Patients were stratified into 2 
cohorts based on renal function, and three C2 ranges were defined (high, intermediate and low 
C2), which varied with time post-transplantation. Again, the study failed to show any 
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statistically significant difference between groups, in terms of acute rejection incidence or 
renal function. The authors finally concluded that it was safe to monitor Neoral® with a “low” 
C2 range (< M1: 1,200-1,400 µg/L; M2-M3: 1,000-1,200 µg/L; M4-M5: 800-1,000 µg/L; M6-
M12: 700-900), preserving renal function without increasing the risk of acute rejection. 
The studies performed by Trull et al[28] and Akhlaghi et al[20] in 50 lung or heart-lung 
transplant recipients during the first year post-transplantation did not show any relationship 
between C2 and the incidence of treated acute rejection episodes, and C2 did not correlate with 
any of the markers of cyclosporine nephrotoxicity. 
A prospective randomized controlled study, the aim of which was to compare C0 (target: 80 to 
120 µg/L) to C2 (target: 300 to 600 µg/L) monitoring in terms of clinical outcomes, was 
performed in 125 heart transplant recipients after 1 year post-transplantation, followed-up for 
6 months.[51] The study failed to detect a possible effect of C2 vs C0 monitoring on acute 
rejection, infections or nephrotoxicity, probably because it was not powered to detect a small 
effect. However, a significant difference between the two groups was found for the primary 
endpoint: cyclosporine daily dose decreased by 26 mg over the follow-up period in patients 
monitored on C2, vs 11 mg in patients monitored on C0 (p = 0.0025). 
In lung transplantation, a study was performed on 2 sequential groups of 18 de novo bilateral 
lung transplant patients, 17 of whom had CF.[92] In the first group, cyclosporine dose was 
adjusted on C0 (target at W1: 450 µg/L; at M3: 250 µg/L) whereas in the second group, dose 
was adjusted on C2 (target at W1: 1200 µg/L; at M3: 800 µg/L). Acute rejection rates were 
similar in both groups and there was no statistically significant difference on FEV1 and on the 
incidence of infections between the two groups of patients. A greater increase of serum 
creatinine from baseline was observed in the C0 group. However, these two groups were not 
comparable as patients in the C0 group were older and their baseline serum creatinine was 
lower (no mention was made of creatinine clearance). Moreover, the associated 
immunosuppressive treatment was different, as 14 of the 18 patients in the C0 group were on 
azathioprine whereas 16 of the 18 patients in the C2 group were on MMF.  
1.1.2.3.3 C6 monitoring 
One study in heart transplantation investigated the use of C6 as monitoring tool. In this 
prospective study, 20 adults were randomized into 2 groups: in the first group, monitoring 
was based on C0 (target: 150 to 250 µg/L) whereas in the second group, cyclosporine dose 
was adjusted on C6 (same target). The two groups were similar in terms of efficacy and 
toxicity, but patients of group II received a significantly lower dose of cyclosporine (2.6±0.6 
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vs 3.5±1 mg/kg/day, p = 0.002), with a significantly lower total cyclosporine cost 
(3,589±1,116 vs 5,106±1,045 CDN $, p = 0.005).[59] The result is however evident and 
directly depends on the protocol, but in no way guarantees that C6 is as safe and as efficient as 
C0 monitoring on the long term. 
1.1.2.3.4 AUC monitoring 
Our literature search allowed us to identify only three studies in which a potential relationship 
between AUC and clinical outcomes was evaluated (Tables VI & VII). 
Thirty-one patients were included in the first study, in which the main objective was to 
determine the clinical significance of C2 compared with C0 following heart transplantation.[54] 
No significant difference on AUC0-12 and AUC0-4 was found between patients who 
experienced acute rejection and those who did not (whether these AUCs were calculated by 
Bayesian estimation or using sparse-sampling algorithms). 
The aim of the second study, performed in 50 children, was to assess the relative value of C0 
and C2 monitoring to prevent acute rejection in pediatric de novo heart transplant patients.[55] 
A subgroup analysis was performed in 10 children, 5 with and the other 5 without acute 
rejection. A statistically significant difference was found between the two groups on AUC0-12 
(rejectors vs non-rejectors: 3,615±508 vs 5,530±889, p < 0.001) and on AUC0-4 (rejectors vs 
non-rejectors: 1,498±132 vs 2,713±536, p < 0.001), both calculated using the linear 
trapezoidal rule. However, this is only a case-control study in a very small number of patients, 
which does not permit definitive conclusions to be drawn, even more so in that the first study 
(also conducted in a small population) did not confirm this finding. 
The third study enrolled 60 heart transplant patients, who were divided in 2 groups: “constant 
absorbers” (group A, CV of mean individual AUC < 15%); and “inconstant absorbers” (group 
B, CV of mean individual AUC > 15%).[93] Mean AUC levels were not different between the 
2 groups (5,585 vs 5,772 h.µg/L), but patients with more variable absorption profiles were at 
higher risk for rejection (rejection rate of 19% vs 41% in groups A and B, respectively; p < 
0.05). 
In conclusion, the vast majority of these studies may have been of sufficient size to study the 
correlation between C0 or C2 and AUC, but underpowered for studying the relationship 
between drug concentrations and clinical outcome. Also, we did not find any study designed 
to evaluate the relationship between exposure measured by the AUC and efficacy (acute graft 
rejection, graft loss) or cyclosporine toxicity. Despite more than 20 years of use, no 
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prospective trial compared cyclosporine dose adjustment based on full AUC and C0 or C2 in 
any type of allograft transplantation, let alone thoracic transplantation.[53]  
Available data has to be expanded to propose recommendations for optimal cyclosporine 
TDM in thoracic transplant recipients, including the identification and validation of the best 
exposure index and the definition of optimized target alues. Further investigations in special 
populations such as CF patients with gastroparesis are also awaited. 
1.2 Tacrolimus 
Tacrolimus (FK506, Prograf®) is a 10-100 times more potent immunosuppressant than 
cyclosporine in vitro.[8,9,94] Despite a chemical structure different from that of cyclosporine, 
tacrolimus suppresses the immune system by similar mechanisms: it inhibits the synthesis of 
IL-2 through the binding of a specific immunophilin, FK506 binding protein (FKBP12) and 
inhibition of calcineurin by this complex.[9]  
Tacrolimus was proposed as an alternative to cyclosporine in combination with AZA or MMF 
after thoracic transplantation, leading to lower rates of acute rejection, similar infection rates 
and slightly higher incidence of new onset diabetes mellitus compared to cyclosporine-based 
therapy.[95-97] There has been a clear trend over the past decade to use tacrolimus instead of 
cyclosporine as part of maintenance immunosuppressive regimens after thoracic 
transplantation.[3] Tacrolimus is now the main calcineurin inhibitor given to adult and 
paediatric thoracic transplant recipients (approx. 60% of the patients).[2,3,42]  
Some guidelines have been proposed for the use of tacrolimus after thoracic transplantation, 
with a recommended initial oral tacrolimus dose of 0.05 to 0.15 mg/kg/day in heart transplant 
patients.[95] and of 0.1 to 0.15 mg/day in lung transplant recipients.[98] Administration of 
tacrolimus sublingually or via a naso-gastric tube may be useful in some specific situations, 
such as in patients with severe gastro-intestinal troubles. In the early post-transplantation 
period, IV tacrolimus may be used when necessary[99] (for instance, during the very first days 
post-transplantation, or to treat resistant rejection), via continuous infusion over 24 hours, 
with a dose ranging between 0.015 and 0.10 mg/kg/day. Nevertheless, there are some 
concerns regarding neurotoxicity and nephrotoxicity when it is administered by this route.[9]  
1.2.1 Pharmacokinetics 
The PK of tacrolimus has been previously described in healthy volunteers and in diverse solid 
organ transplant settings (kidney, liver).[100] As with cyclosporine, it is characterized by a 
large inter-individual and intra-individual variability.[101,102] However, PK and variability data 
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on tacrolimus used after thoracic transplantation is relatively scarce and inconsistent (Tables 
IX & X). In many published studies, exposure indices and PK parameters were considered 
after the first dose.[100,103-105] Except for two studies[100,103] in which tacrolimus was assayed by 
HPLC-MS/MS, the PK studies we identified used immunoassays (mostly MEIA) to measure 
tacrolimus concentrations. Such assays (also including ELISA, EMIT, ACMIA, CEDIA and 
CMIA technologies) all lack specificity because of cross-reactivity of the assay antibody with 
metabolites, hence overestimating the actual blood levels (as assessed using the reference 
technique HPLC-MS/MS). Moreover, immunoassays may interact with haemoglobin: some 
authors observed a negative correlation between haematocrit and tacrolimus concentrations 
determined by MEIA.[106] This observation was confirmed in subsequent publications, which 
reported that both low haematocrit values and low albumin concentrations are likely to show 
artificially high concentrations of tacrolimus when measured by MEIA.[107,108] Finally, the 
majority of the PK studies performed in thoracic transplantation were descriptive in nature 
and used model-independent PK methods, where mean and standard deviation of exposure 
indices and PK parameters in the evaluated population were calculated from individual 
data.[100,102,103,105,109-111] One used the iterative two-stage (ITS) method, for which a specific 
PK model was set up in order to determine individual exposure indices and PK parameters 
and thus to calculate mean PK parameters in the population.[112] We could not find any popPK 
study of tacrolimus in thoracic transplantation. 
The intra- and inter-individual variability of tacrolimus PK is related to factors such as erratic 
bioavailability, time post-transplantation, concomitant pathologies and drug-drug interactions, 
which unfortunately were rarely explored.  
1.2.1.1 Absorption 
Generally, the bioavailability of tacrolimus after oral administration is poor, averaging 25%, 
but is also characterized by a large inter-individual and intra-individual variability, ranging 
from 5% to 93% depending on the reports.[8,52,94,100,101] This low and variable bioavailability is 
caused by an extensive presystemic metabolism by CYP3A isoenzymes and by active 
transport by the trans-membrane efflux pump P-gp, all localized in the gut wall in addition to 
the liver.[8,101] Poor aqueous solubility and alterations in gut motility (e.g. in CF) may also be 
responsible for poor and erratic drug uptake.[101] Tacrolimus bioavailability can be reduced 
when the molecule is administered with low-fat food.[8,101] On the contrary, some authors 
reported an increased bioavailability in patients with persisting diarrhea, resulting in an 
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increase in tacrolimus trough levels.[113] However, in contrast to cyclosporine, tacrolimus is 
absorbed in a completely bile-independent manner.[8,94,101]  
In most subjects, tacrolimus is rapidly absorbed following oral administration, tmax occuring 
usually around 2 hours after single administration[102,103,105] and between 0.5 and 1.5 hours at 
steady-state (Table IX).[52,100,101,103,111] However, drug uptake can also last longer, resulting in 
a flat absorption profile, an extended lag-time or secondary peaks, with maximum blood 
concentrations occurring up to 8 hours after dosing.[8,94,100,101,105,109,110,112]  
With oral dosing, steady-state blood concentrations are usually achieved within approximately 
48 to 72 hours.[95] In heart transplant patients, Cmax was characterized by a coefficient of 
variation ranging between 41 and 56% after single oral administration,[103,105] and between 36 
and 49% at steady-state[100,103,105,109] and between 53 and 68% in lung and heart-lung 
transplant patients.[112,114]  
The rate of absorption of tacrolimus has been reported to be highly variable.[101] In heart 
transplant patients, absorption was characterized by a rate constant of absorption ka ranging 
from 0.13 to 1.76 h-1 (CV > 40%) and a lag-time comprised between 0.1 and 0.5 hours.[115] In 
stable lung transplant recipients (with or without CF), tacrolimus absorption was best fitted 
using two Gamma distributions (double, sigmoid absorption profile with two different 
velocities), describing an early peak and a possible secondary peak of absorption.[112] This 
resulted in the calculation of two mean absorption times (MAT1 and MAT2), with similar 
values in CF and non-CF patients (MAT1 = 1.10±0.68 h and 0.92±0.43 h; MAT2 = 5.14±2.11 
h and 5.47±2.30 h, respectively). 
1.2.1.2 Distribution 
Tacrolimus is highly lipophilic and binds extensively to erythrocytes, with higher blood than 
plasma concentrations. In plasma, it binds strongly to proteins (99%), mainly α1-acid 
glycoprotein, lipoproteins, globulins and albumin.[101] After IV administration, tacrolimus 
concentration undergoes a rapid initial decline due to distribution, which slows down over the 
next 24 hours after reaching distribution equilibrium.[94] To our knowledge, tacrolimus Vd/F 
in thoracic transplant recipients was reported in only three studies, in two of which tacrolimus 
PK was fitted with a one-compartment model. In the first one,[112] Vd/F was determined at 
steady-state in 22 heart-lung transplant patients, with a significant difference between patients 
with and those without CF (2,011±1,740 L vs 444±326 L, respectively; p < 0.01), whereas in 
the second one[102] Vd/F ranged between 1.3 and 3.9 L/kg after single dose administration in 
14 heart transplant recipients. In the third study,[115] performed in 19 heart transplant 
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recipients, the authors used a 2-compartment model and reported a mean V1/F = 1.69±0.61 
L/kg and 1.13±0.38 L/kg at ten days and two months after transplantation, respectively (p < 
0.01). These rather inconsistent results might be partly explained by the different study 
conditions, the obviously large inter-patient variability (in the 3 studies, Vd/F coefficients of 
variation ranged from 33 to 86%) as well as by the generally suboptimal estimation of Vd/F 
by classical PK models, which usually estimate clearance more accurately than volume of 
distribution. 
1.2.1.3 Metabolism and elimination 
Like cyclosporine, tacrolimus is extensively metabolized (mainly by CYP3A4 and CYP3A5 
isoenzymes in the liver and intestinal wall). More than 95% of tacrolimus metabolites are 
excreted in the bile, and less than 0.5% of tacrolimus dose appears unchanged in the urine or 
faeces.[52,94,101] As a consequence, its potential for drug-drug interactions seems similar to that 
of cyclosporine. One exception is that tacrolimus does not seem to interact with MMF PK like 
cyclosporine does, leading to greater MPA exposure when tacrolimus and MMF are used in 
combination.[52]  
A few studies reported tacrolimus clearance values in thoracic transplant patients. In heart 
transplant patients, tacrolimus clearance after continuous IV infusion was 2.4 L/h.[103] After 
tacrolimus oral administration, CL/F was 0.23±0.08 L.h-1/kg after a single dose,[102] 0.19±0.08 
L.h-1/kg ten days and 0.23±0.15 L.h-1/kg two months after transplantation,[115] with high 
coefficients of variation (42-65%). In a cohort of 12 lung and heart-lung transplant patients, 
CL/F = was 68.2±29.8 L/h in CF patients and 36.49±18.98 L/h in non-CF patients (p < 
0.05),[112] which is higher than the above mentioned values (considering a mean bodyweight 
of 70 kg) and than those reported by Aumente-Rubio et al[109] in heart transplant patients 
(11.6±5.5 L/h); this may be explained by the difference in patients (heart-lung transplant vs 
heart recipients) and by the difference in the PK approach (one-compartment PK model vs 
non-compartmental PK analysis). 
T1/2 was determined mainly using non-compartmental PK analysis and was also found to be 
highly variable (CV = 30-64%).[100,102,103,105,114] When tacrolimus was assayed using a HPLC-
MS/MS method, T1/2 at steady-state was 10.7±5.3 h in heart transplant patients[100] and 
7.9±2.3 h in lung transplant recipients.[114] The elimination half-life determined from 
tacrolimus concentrations measured by immunoassays may be overestimated due to the lack 
of specificity and the cross-reactions reported between the assay antibody and tacrolimus 
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metabolites. Indeed, in a cohort of 8 heart transplant patients, T1/2 reached 33.3 h (mean: 13.8 
h, 95%CI = 7.0-20.7 h). [111]  
1.2.1.4 Drug-drug interactions 
We did not find any formal PK studies investigating tacrolimus drug interactions in thoracic 
transplant recipients. Shitrit et al reported an interaction between itraconazole and tacrolimus 
in 40 patients with lung transplantation followed for more than one year.[116] All patients were 
on tacrolimus and received prophylactic itraconazole for the first 6 months post-
transplantation. In those patients, the mean dose of tacrolimus required rose by 76% after 
itraconazole withdrawal (3.26±2.1 mg/day during the first 6 months compared to 5.74±2.9 
mg/day during the following 6 months, p < 10-4). 
In other solid organs transplantation, various lists of drugs that may increase or decrease 
whole blood concentrations have been compiled.[101] Since tacrolimus is a substrate for 
CYP3A and P-gp like cyclosporine, the expected drug interactions are essentially the same[95] 
and any drug known to induce or inhibit these systems may increase or decrease its blood 
concentrations (erythromycin, calcium-channel blockers, imidazole anti-fungal agents). 
1.2.1.5 Special populations 
The PK of tacrolimus changes in time after transplantation and is affected by many factors, 
including liver function, patient age (pediatric transplant recipients require 2- to 4-fold higher 
doses of tacrolimus than adults to maintain similar C0[101]), time of administration (diurnal 
variations, co-administration of food), associated drugs, and modifications in the GI tract 
motility and secretions observed in CF patients.[101,109]  
Lower bioavailability of tacrolimus has been reported in CF patients, probably partly because 
of fat malabsorption due to pancreatic insufficiency.[110,112]  
Walker et al reported that heart-lung and double lung transplant recipients with CF required a 
39% higher dose of tacrolimus than patients without CF in order to reach similar C0.[117] In a 
study performed in 22 heart-lung transplant patients (11 CF), tacrolimus CL/F after oral 
administration was higher in CF patients (68.22±29.80 vs 36.49±18.98 L/h, p < 0.05),[112] who 
required significantly higher doses to reach comparable exposure. In those patients, AUC0-
12/dose and AUC0-4/dose were approx. half of those of non-CF patients (p < 0.004 and p < 
0.001, respectively).[110] Comparatively to non-CF patients, exposure indices in CF patients 
(C0, C3, Cmax, AUC0-12, AUC0-4) were characterized by higher inter-individual variability 
(CV% 24 to 46% vs 19 to 30%) and comparable intra-individual variability (CV% 16 to 40% 
vs 17 to 37%).[110]  
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1.2.2 Therapeutic drug monitoring 
Issues relating to the TDM of tacrolimus have been addressed by numerous authors and 
recently reviewed by Staatz & Tett.[101] Like cyclosporine, tacrolimus is characterized by a 
narrow therapeutic index and significant systemic side effects.[8,52,115] As stressed above, 
tacrolimus absorption is erratic and incomplete with a variable metabolism mediated by 
intestinal and hepatic CYP3A isoenzymes, resulting in high intrapatient and interpatient PK 
variability. As a result, the correlation between dose and blood concentrations is poor,[52,115] 
confirming that the administered dose cannot reliably predict systemic exposure to tacrolimus, 
rendering it difficult to propose a suitable a priori dosing regimen for heart and lung 
transplant patients.[100] This was the rationale for monitoring tacrolimus blood concentrations 
to optimize immunosuppression.[52,94] However, the poor sensitivity and specificity of the first 
commercial assays used was an obstacle in the exploration of tacrolimus PK for optimizing 
TDM.[52]  
1.2.2.1 Single concentrations monitoring 
Most results of clinical studies in kidney and liver transplantation suggest that C0 levels of 
tacrolimus are, to some extent, predictive of efficacy and toxicity.[52] Accordingly, tacrolimus 
dose after thoracic transplantation is mainly adapted to C0 levels. The following target C0 
were proposed: in lung transplantation, 10-25 µg/L for the first 2 weeks, 10-20 µg/L for the 
next 6 to 10 weeks, and 10-15 µg/L thereafter;[98] after heart transplantation, 15-20 µg/L for 
the first 2 months, 10-15 µg/L from the third to the sixth month, and 8-10 µg/L after 6 
months.[95] However, the authors did not mention on which assay these target levels were 
based, making it difficult to correctly interpret them, and to implement them in routine 
clinical practice. 
Studies of the correlation between tacrolimus C0 and AUC0-12 have reported a wide range of 
results, from r² = 0.20[111] to around 0.80 (Table IX).[103,104,109] Some studies have shown that 
the correlation between blood concentration and AUC can be improved by using different 
time points: a good correlation was found between AUC0-12 and C3[110] or C4.[104,105,109]  
In other transplant types (mainly kidney), the reliance on C0 monitoring has been questioned 
due to the observations that stable function, rejection or toxicity may be associated with the 
same range of tacrolimus concentrations.[101,109] Unfortunately, no study in thoracic 
transplantation has been performed with the intent of exploring the relationship between 
single concentrations (C0 or other concentrations) and efficacy or toxicity. 
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1.2.2.2 AUC monitoring 
As with cyclosporine, tacrolimus AUC rather than single concentrations may be used for 
TDM, as it is a better marker of patient’s exposure to tacrolimus.  
In studies in thoracic transplantation, tacrolimus AUC0-12 was mainly calculated using the 
linear trapezoidal rule.[100,102-105,109-111] As with cyclosporine, AUC0-4 was considered as a 
surrogate exposure index and AUC0-4 values reported in a few studies in heart[109] and in 
heart-lung[110,112] transplant recipients. However, AUC0-4 still has to be validated as a reliable 
estimate of AUC0-12 and as a reliable marker of clinical outcomes in heart or lung transplant 
patients. 
As another way to avoid the numerous blood samples needed for the determination of AUC0-
12, some authors investigated sparse sampling strategies. In heart transplantation, Aumente 
Rubio et al proposed two algorithms, one with 3 sampling times (0, 2 hours and 4 hours, r² = 
0.97 with trapezoidal AUC0-12) and one with only 2 sampling times (0 and 2 hours, r² = 
0.95).[109] In lung transplantation, Morton et al failed to find an efficient sparse sampling 
strategy,[114] but Saint-Marcoux et al developed and validated Bayesian estimators for the 
determination of tacrolimus AUC0-12 in CF and non-CF patients, and proposed the following 
sampling strategy: 0, 1 hour and 3 hours for non-CF patients and 0, 1.5 hours and 4 hours for 
CF patients.[112]  
In a study of 25 primary heart transplant recipients, the authors found a significant difference 
in the AUC0-12 after the first oral dose between patients who experienced acute rejection and 
those who did not (71 vs 168 h.µg/L, p = 0.012).[103] However, this paper does not provide 
any detail about patient’s follow-up, so there is no information on when acute rejection 
occurred.  
So far, no prospective studies have been conducted in thoracic transplantation to investigate 
the relationships between tacrolimus inter-dose AUC and clinical outcome. A fortiori, the use 
of AUC as a monitoring tool still remains to be validated in prospective controlled studies, 
and optimal AUC targets to be defined in heart and lung transplantation. 
2 Mycophenolate, purine synthesis antagonist  
Two compounds containing mycophenolate are currently available, mycophenolate mofetil 
(MMF, Cellcept®) and mycophenolate sodium (EC-MPS, Myfortic®). As mycophenolate 
sodium has been released later and its use in thoracic transplantation more rarely reported, this 
review will focus on MMF only. 
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Following oral administration, MMF, the 2,4-morpholino-ester of the active moiety 
mycophenolic acid (MPA), is rapidly hydrolyzed to MPA by esterases in the stomach, small 
intestine, blood, liver and tissues.[118,119] MPA exerts its immunosuppressive effects by 
reversibly inhibiting inosine 5’-monophosphate deshydrogenase (IMPDH),[120] a key enzyme 
in the de novo pathway of purine biosynthesis,[121,122] essential for DNA replication when cells 
proliferate. Through IMPDH inhibition, MPA specifically blocks the proliferation and clonal 
expansion of T and B lymphocytes, providing effective immunosuppression in transplant 
patients.[121-124]  
The use of MMF has dramatically increased in the past decade, MMF-based regimens 
representing now approx. 80% and 50% of maintenance strategies in adult heart and lung 
transplant recipients, respectively, and 50% in pediatric lung transplant recipients.[2,3,42,125]  
MMF is available in oral (capsules, tablets and powder for oral suspension) and IV 
formulations.[122] It is generally combined with a calcineurin inhibitor and corticosteroids for 
rejection prophylaxis after solid organ transplantation.[124,126] Reduced rejection rates, 
improved graft and patient survival with MMF compared with AZA have lead it to 
progressively replace AZA as the antiproliferative agent of choice after thoracic 
transplantation, although it has not been approved by most of the national health agencies in 
lung transplantation.[2,5,127,128] There has been a growing interest in MMF-based as part of 
calcineurin inhibitor- or steroid-sparing strategies, as MMF is free of toxicities adversely 
affecting long-term patient and graft survival (nephrotoxicity, hypertension, metabolic 
perturbations).[120]  
2.1 Pharmacokinetics 
As opposed to other immunosuppressants, MMF dose in adults is not based on patient body 
size or weight. MMF is usually administered at a fixed oral dose of 0.75-1.5 g twice daily, 
depending on the associated calcineurin inhibitor.[119,120,124,129] Oral suspension can be 
administered via a nasogastric tube, if necessary.[118]  
Little is known about the PK of MPA after thoracic transplantation.[119,124] Most PK studies 
have been conducted in renal transplant patients, in whom MMF exhibits time-dependant PK 
(concentrations increase with time following transplantation over the first 1-3 months).[124] 
However, data derived from renal transplant recipients cannot be readily extrapolated to 
thoracic organ transplant patients, as neither the heart nor the lungs are involved in the 
elimination of mycophenolate. Although blood pressure may have some impact on MPA 
glomerular filtration rate, cardiac and pulmonary functions do not impact so much MPA 
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plasma concentrations.[119,124] In a PK study of MMF in 50 stable thoracic (23 heart and 27 
lung) transplant recipients (0.2-19.7 years post-transplantation), no significant variations in 
MPA exposure indices or PK parameters was observed with post-transplantation time (Tables 
XI & XII).[130] On the contrary, an increase of MPA C0 throughout the follow-up period of 
40.0±20.5 months was reported (p = 0.0162) in 57 “stable” lung transplant recipients (all non-
CF patients), but the time elapsed between transplantation and enrolment was not reported 
and the authors did not give any hypothesis on the cause of this increase.[131] Consequently, 
currently available data on thoracic transplantation does not allow any reliable conclusion to 
be drawn on the evolution of MPA PK parameters with post-transplantation time, even in the 
early periods.  
Like calcineurine inhibitors, the PK of MMF is complex and somewhat erratic,[118] with large 
intra- and inter-individual variability.[8,9,52,120,124,126,132,133] All studies we identified in thoracic 
transplant patients were performed using a model-independent PK approach, reporting mean 
and standard deviation, or range of exposure indices and PK parameters derived from 
individual data (Tables XI & XII).[119,121,122,124,130,132,134-137] We could not find any study using 
either the iterative two-stage (ITS) method or popPK analysis. Exposure indices of MPAG 
and AcMPAG were reported in 3 studies.[122,130,136] Finally, except for four studies in which 
MPA was assayed by EMIT[123,126,134,135] and one in which the analytical method was not 
reported,[137] all the PK studies we identified measured MPA, MPAG and AcMPAG 
concentrations with HPLV-UV.  
2.1.1 Absorption, bioavailability 
The PK of MPA after oral and IV MMF administration is characterized by an important 
variability. In a study involving 9 heart transplant patients who received 1.5 g BID MMF by 
IV infusion over three hours, immediately after transplantation and for 5 days, Cmax displayed 
large inter-individual variations, occurring between 1 and 3 hours and ranging from 2.2 to 
18.4 mg/L.[122] Following oral administration, MMF is rapidly absorbed (within 5 minutes of 
ingestion) in the upper gastro-intestinal tract because of its high solubility at a low pH.[8] 
Hydrolysis to MPA is responsible for the rapid disparition of MMF from the plasma.[118] 
MPA Cmax after oral dosing is also highly variable, with a coefficient of variation ranging 
from approximately 30 to 80% depending on the studies,[119,121,124] and usually occurs within 1 
to 2 hours following oral MMF administration (range 20 minutes-12 
hours).[119,121,122,130,134,135,137] Delayed absorption has been reported when the drug is taken 
with food.[131]  
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In a review by Shaw et al, the bioavailability of MPA was reported to be incomplete, 
suggesting metabolism in the gastro-intestinal tract. This pre-systemic metabolism may take a 
part in the high overall PK variability of MPA.[133] On the contrary, the above mentioned 
study performed in 9 heart transplant patients reported excellent, high and consistent MPA 
bioavailability after MMF oral dosing compared with the IV formulation (oral F = 71 to 
125%).[122]  
Secondary peaks of MPA plasma concentration have been observed between 6 and 12 hours 
after drug administration and have been attributed to enterohepatic circulation.[8,124,131,138,139] 
This phenomenon is believed to contribute 10-60% to MPA exposure.[118,130,140] However, 
these secondary peaks are sometimes higher than the first peaks and in such cases, cannot be 
accounted for by enterohepatic cycling.[141] Further exploration of the absorption of MPA 
would thus be of major interest.  
2.1.2 Distribution 
In whole blood, MPA is poorly distributed into cellular fractions, with over 95% found in 
plasma.[118] In patients with normal renal and liver function, MPA is extensively and tightly 
bound to human serum albumin (97-99%).[118-120,133,142] The variations in MPA PK and 
pharmacodynamics (PD) may be partly explained by this affinity for serum albumin. Indeed, 
as only unbound MPA is pharmacologically active, variations in the free fraction may be 
responsible for variations of IMPDH inhibition and thus of the therapeutic 
response.[118,119,133,142] Moreover, in clinical situations with decreased serum albumin levels, 
such as severe hepatic impairment, or decreased serum albumin binding capacity, such as 
severe renal impairment, the increased proportion of free MPA may result in a higher 
clearance.[119,133] It has been suggested that in such situations with variations of plasma serum 
albumin, free MPA concentration might be worth monitoring,[119,120] though no paper reported 
that free MPA was better correlated to effects than total MPA plasma levels. Moreover, 
measuring free MPA is out of reach of traditional immunoassays.  
Data on MPA protein binding in heart and lung transplantation was reported in only a few 
papers. In a cohort of 38 heart transplant patients (time post-transplantation: 310±278 days), 
the free MPA fraction (f) was 1.9±0.4%, with a free MPA AUC0-12 (fAUC0-12) = 0.83±0.30 
h.mg/L,[132] which is consistent with those reported in 7 lung transplant patients (time post-
transplantation: 4.4±3.9 years), in whom f = 2.9±0.6%, and fAUC0-τ = 1.29±0.50 h.mg/L;[119] 
as well as with the free fraction reported in 7 heart transplant recipients (time post-
transplantation: 6-23 days), in whom f = 3.6±3.9%.[143] In another group of 7 heart (n = 3) and 
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lung (n = 4) transplant patients, f was higher, decreasing from 6.1±2.8% immediately after 
transplantation (15±13 days) to 4.4±3.0% later on (125±73 days), with corresponding fAUC0-τ 
of 2.22±2.32 h.mg/L and 1.50±2.16 h.mg/L, respectively.[124] However, these results are to be 
interpreted cautiously, as f was determined in each patient after pooling all the plasma 
samples of a given profile. Indeed, averaging fractions is mathematically different from 
dividing the mean free by the mean total concentration and is simply not coherent. Finally, a 
recent study performed in a cohort of 23 heart (and heart-kidney) and 27 lung transplant 
recipients (time post-transplantation: 0.2-19.7 years) in whom MMF was associated to 
cyclosporine or tacrolimus, reported f values ranging between 0.2 and 15%, with fAUC0-12 
normalized to a 1 g-MMF dose of 0.05 to 19.0 h.mg/L.[130] Although they were discussed, the 
factors potentially linked with these high variations in free fraction were not investigated (nor 
reported). 
Once absorbed, MPA is rapidly distributed in the tissues, within approx. 2 hours after tmax.[133] 
Values for MPA Vd/F were reported in only one study, conducted in 27 lung and 23 heart 
(and heart-kidney) transplant recipients who received MMF associated with either 
cyclosporine or tacrolimus.[130] In the lung transplant group, mean Vd/F = 248 L (range: 54-
645) and 125 L (range: 30-607) in the patients on cyclosporine (n = 11) and on tacrolimus (n 
= 16), respectively. In the heart transplant group, mean Vd/F = 102 L (range: 37-1,141) and 
111 L (range: 53-261) in the patients on cyclosporine (n = 14) and on tacrolimus (n = 9), 
respectively. A statistically significant difference on Vd/F was found neither between heart 
and lung transplant recipients, nor between patients on cyclosporine and those on tacrolimus. 
2.1.3 Metabolism and elimination 
MPA is primarily metabolized by uridine diphosphate glucuronyl transferases (UGT, mainly 
UGT1A9, 1A7 and 1A8) into its pharmacologically inactive metabolite, 7-O-mycophenolic 
acid glucuronide (MPAG).[144] MPAG accounts for more than 90% of all MPA metabolites, 
but at least 4 other metabolites have been identified in plasma from renal, liver and cardiac 
transplant recipients,[144-147] including the acyl glucuronide of MPA (AcMPAG), which 
inhibits IMPDH in vitro.[122,148] The primary site of conversion is the liver, but MPA may also 
be glucuronidated in the gastro-intestinal tract mucosa and the kidney.[8,94,118] As for MPA, 
concentrations of MPAG and AcMPAG are highly variable throughout the dose interval. 
MPAG plasma concentrations are said to be usually 20 to 100 times higher than MPA 
concentrations,[118] but this seems to be variable across sampling times and studies. In 9 heart 
transplant patients, MPAG C0 was on average 65-106 times higher than MPA C0 after IV or 
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oral MMF administration, whereas MPAG Cmax was only 10 to 16 times higher than MPA 
Cmax.[122] This study was the only one we identified reporting MPAG Cmax (51 to 187 mg/L) 
and tmax (40 minutes to 8 hours). In another set of 26 heart transplant recipients, MPAG C0 
was only 22-30 times higher than MPA C0.[136] The overall difference in exposure between 
MPAG and MPA may be more precisely evaluated by comparing their AUC. The AUC of 
MPAG was reported in two studies in thoracic transplantation, and was on average 9 to 32 
times higher than that of MPA.[122,130] In a study conducted in 7 heart transplant recipients,[143] 
MPAG free fraction was estimated to be 26±8%, which is consistent with literature reports in 
renal transplant recipients (MPAG free fraction of 18-37% in 27 “stable” patients; time post-
transplantation not reported).[149] MPAG is excreted into the bile by a mechanism probably 
involving the multidrug resistance protein 2 (MRP2). Upon delivery to the GI tact, through 
the action of β-glucuronidases shed by gastro-intestinal tract bacteria, part of MPAG is 
deconjugated back to MPA, which then undergoes enterohepatic recirculation.[8,94,118,133]  
As opposed to MPAG, AcMPAG was once thought to display a pharmacological activity 
similar to that of MPA as it did in vitro with the recombinant enzyme,[146] but a more recent in 
vitro study suggested that, due to a lower intrinsic inhibitory activity, a lower ability to cross 
cell membranes and lower plasma concentrations, AcMPAG probably exhibits a negligible 
IMPDH inhibition activity in vivo. (Gensburger O et al, unpublished observations) AcMPAG 
tmax varies between 40 minutes and 6 hours, AcMPAG C0 and Cmax are 2 to 4 times lower and 
8 to 11 times lower than MPA C0 and Cmax, respectively.[122] In two studies, AcMPAG AUC 
was 2.5 to 6 times lower than MPA AUC [122,130], which seems to be higher than the average 
of 10.3% reported in renal transplantation – though in this study AcMPAG was determined as 
MPAG equivalent due to the absence of a standard compound for quantification.[150]  
We found two studies reporting MPA CL/F, with diverging results, showing the difficulty of 
estimating this PK parameter using a non-compartmental approach. The first study, performed 
in 14 heart transplant recipients who were all on MMF-cyclosporine, reported CL/F = 
1,397±389 L/h.[137] The second study included 27 lung and 23 heart transplant recipients who 
received MMF associated with either cyclosporine (n = 25) or tacrolimus (n = 25).[130] In the 
lung transplant group, mean CL/F was 54 L/h (range: 29-295 L/h) and 21 L/h (9-121) in 
patients on cyclosporine and tacrolimus, respectively (p = 0.026). In the heart transplant 
group, mean CL/F was 21 L/h (5-59) and 11 L/h (6-24) in patients on cyclosporine and 
tacrolimus, respectively (ns). CL/F in the lung transplant group was significantly higher than 
in the heart transplant group, regardless of the associated calcineurin inhibitor (36 vs 13 L, p = 
5.10-4). One of the hypotheses made by the authors to explain this difference between heart 
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and lung transplant recipients is that the higher albumin levels observed in the heart transplant 
group may have contributed to an increase in MPA protein binding and thus a decrease in 
total CL/F of MPA.  
Apparent half-life of MPA estimated from apparent distribution volume and clearance 
reported in the abovementioned study[130] was comprised between 3.2 and 7.0 hours, which is 
shorter compared to 18 hours reported in a review published in 1997.[94]  
2.1.4 Drug-drug interactions 
The variability in MPA concentrations may be partly explained by drug-drug interactions 
affecting the MPA concentrations achieved for a given MMF dose. Indeed, the PK of MPA is 
known to be altered by concomitant medications.[142] First, it is strongly affected by the nature 
of the associated calcineurin inhibitor. Such observations were initially made in renal 
transplant patients on tacrolimus, who displayed significantly higher MPA C0 and AUC than 
patients on cyclosporine.[151] In heart transplantation, a randomized study in 60 patients found 
significantly lower MMF dose requirements for patients on tacrolimus (n = 30) than on 
cyclosporine (n = 30) to achieve MPA C0 targets of 0.45 to 4.0 mg/L (1.6±0.8 vs 2.8±1.0 
g/day at one year post-transplantation, p = 4.10-5).[152] A prospective, randomized controlled 
study in 50 heart transplant patients compared the MMF – tacrolimus (n = 25) and the MMF – 
cyclosporine (n = 25) combinations in terms of efficacy, toxicity and PK.[153] Both groups 
displayed similar MPA C0 (2.3±0.5 µg/L vs 2.7±0.6 µg/L), although the patients on 
cyclosporine received higher doses of MMF (3.3±0.5 g/day vs 2.1±0.7 g/day, p = 0.04). In 30 
adult stable lung transplant recipients (7 CF) over the first 2 years post-transplantation, MPA 
C0 were 50% lower in patients on cyclosporine (n = 16, C0 estimated at approx. 1.3 mg/L) 
than in patients on tacrolimus (n = 14, C0 estimated at approx. 2.7 mg/L, p < 10-5) despite 
substantially higher MMF doses (estimated at approx. 25 vs 22 mg/kg/day).[142] In a study in 
26 heart transplant patients aged 1 month to 33 years, lower MPA concentrations and higher 
MPAG/MPA C0 ratios were reported in a subset of 8 children on cyclosporine compared to 8 
others on tacrolimus (C0 = 1.6±1.5 vs 3.0±2.2 mg/L, p = 0.04 and average MPAG/MPA C0 
ratio = 25.2 vs 11.9, p = 0.005).[136] Unfortunately, the MMF dose was only reported in 
children on cyclosporine, allowing no dose comparison.  
Two other studies compared MPA C0 (assayed by EMIT) in patients on cyclosporine vs 
tacrolimus,[123,126] but both pooled data from kidney and lung transplant recipients. The first 
one included 120 kidney and 20 lung transplant patients and reported higher MPA C0 in 
patients on tacrolimus than in patients on cyclosporine (3.63±2.63 vs 2.14±1.22 mg/L, p < 
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0.01) despite similar MMF doses (2 g/day).[126] The second one included 49 kidney and 11 
lung transplant recipients and reported higher median dose-to-concentration (D/C) ratios in 
patients on cyclosporine than in patients on tacrolimus (p < 10-4),[123] which is an atypical 
presentation of results similar to those of the previous studies. 
This was confirmed by a later study where 27 lung transplant patients were included together 
with 23 heart (heart-kidney) transplant recipients,[130] where the difference between dose-
normalized AUC (DN-AUC) of lung transplant recipients on cyclosporine (n = 11) or 
tacrolimus (n = 16) was significant (DN-AUC = 18.6 h.mg/L, range: 3.4-35.1, vs 41.4 
h.mg/L, range: 8.3-115.3, p = 0.022). Consistently, MPAG/MPA AUC ratios were higher in 
patients on cyclosporine (28.5, range: 9.8-55.2) compared to patients on tacrolimus (12.6, 
range: 2.4-25.8, p = 0.002). On the contrary, no significant difference on DN-AUC was found 
between the 14 heart transplant recipients on cyclosporine (50.9 h.mg/L, range: 16.9-218.7) 
and the 9 on tacrolimus (106.8 h.mg/L, range: 40.9-180.5, p = 0.14). Neither was the 
difference between MPAG/MPA AUC ratios of these 2 groups of heart transplant recipients 
significant (11.9, range: 0.9-28.6 in patients on cyclosporine vs 8.7, range: 2.3-13.4 in patients 
on tacrolimus, p = 0.10).  
In summary, dose-adjusted MPA concentrations are significantly higher and MPAG/MPA 
concentrations ratios lower when MMF is associated with tacrolimus than cyclosporine.[136,142]  
The mechanisms underlying the interactions between MPA and calcineurin inhibitors are still 
being investigated. At first, some authors postulated that the increase of MPA concentrations 
in patients on tacrolimus was caused by the inhibition of UGTs and thus of MPA 
glucuronidation by tacrolimus.[154] However, most authors now agree that these differences in 
MPA concentrations are due to a diminution in exposure caused by cyclosporine, rather than 
an increase caused by tacrolimus.[133] Indeed, it has been suggested that cyclosporine 
decreases MPA exposure by inhibiting the biliary excretion of MPAG into the gut, reducing 
back-transformation of MPAG into MPA through enterohepatic circulation.[126,133,142,155,156] It 
has also been suggested that cyclosporine might inhibit the deglucuronidation of MPAG to 
MPA by inactivating the β-glucuronidases in the gastro-intestinal tract.[157]  
Consistently, in a recent study in 62 heart transplant recipients, exposure to MPA was shown 
to be higher in patients on sirolimus compared to those on cyclosporine for similar doses of 
MMF, as evidenced by significantly higher dose-adjusted AUC0-12 in patients on sirolimus 
(31.9±16.1 vs 61.0±27.4 h.mg/L/1000 mg MMF, p < 0.001),[134] which is in favour of 
cyclosporine being the interacting drug rather than tacrolimus and sirolimus.  
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In conclusion, the associated immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus) 
need to be taken into account when defining MMF dose, as the under-immunosuppression 
potentially resulting from decreased MPA exposure in patients on cyclosporine may strongly 
influence clinical outcome.[142] Also, the influence of corticoids, which are known to induce 
the expression of the UGTs and have been shown to induce MPA metabolism in renal 
transplant patients,[158] might be worth investigating in thoracic transplantation. 
2.1.5 Special populations 
The PK of mycophenolate can be affected by several other factors such as pre-existing 
conditions (age, pathology, activity of UGTs and drug transporter MRP-2), and clinical status 
(time post-transplantation, gastro-intestinal motility, hypoalbuminemia, liver disease, renal 
dysfunction). These factors can alter plasma MPA, MPAG and AcMPAG total and free 
concentrations and global exposure, hence the degree of immunosuppression. 
Pediatric thoracic transplantation will be briefly presented before focussing on CF. 
2.1.5.1 Paediatrics 
Children display different PK profiles from those of adults’[44,45] and different MMF 
disposition rates are expected in children vs adults, based on the ontogeny of UGTs.[159] Very 
little information is available on appropriate dosing or on PK of MMF in children. Similarly 
to adults, MMF in children is rapidly absorbed and hydrolyzed to MPA, with a first peak 
occurring approximately 45 minutes after intake and a potential second peak at a variable 
time. However, there is no information on the correlation between MPA exposure and clinical 
outcome in this population.[160] The recommended MMF starting dose is 1800 mg/m2/day in 
two divided doses in children < 2 years and 1200 mg/m2/day in older children and 
adolescents.[120,159] We identified two studies performed in heart transplant children. The first 
one was a retrospective review of MPA C0 in 44 children (aged 7 days to 18 years; associated 
calcineurin inhibitor not reported).[160] MMF doses (in mg/kg and mg/m²) required to reach 
the target C0 < 3 mg/L tended to decrease with increasing age (2.2±0.7 g/m² between 0 and 1 
year, 2.2±0.9 g/m² between 1 and 5 year, 1.8±0.9 g/m² between 5 and 10 years, 1.6±0.8 
between 10 and 16 years, and 1.6±0.6 beyond 16 years). However, the authors emphasized the 
limitations of their study, which included the retrospective design and more importantly the 
diversity of the population in terms of indication for MMF treatment (acute rejection 
prophylaxis or treatment) and time post-transplantation (7 days to 10 years). In the second 
study, a comparison was made between 8 children (with no more precision) and 10 adults 
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who received MMF in association with cyclosporine.[136] Adults and children received 
comparable MMF daily doses (1,280±360 vs 1,180±260 mg/m², ns) and displayed 
comparable MPA C0 (2.3±2.2 vs 2.2±2.0 mg/L, ns), but MPAG C0 and MPAG/MPA C0 ratios 
were significantly higher in adults (98±47 vs 49±38, p < 10-4 and 37.7±40.2 vs 25.2±21.7, p = 
0.016). The authors hypothesized that this might be explained by the existence of an alternate 
pathway in children with enhanced MPAG clearance compared to adults, or by higher 
glomerular filtration and tubular secretion rates in children, or even that cyclosporine-
mediated inhibition of MPAG excretion may also be a pathway specific to adults, not active 
(or to a lesser extent) in younger patients. In our opinion, not all these hypotheses have the 
same credibility, and we would rather favour the higher renal excretion of MPAG in children, 
which can also be put forward for CF patients. 
2.1.5.2 Cystic fibrosis 
In CF patients, chronic hepatic and gastro-intestinal disorders affect drug absorption, and 
lower serum albumin levels may result in an increased plasma clearance of protein-bound 
drugs, resulting in potentially higher risks for under-immunosuppression and therapeutic 
failure.[142] Unfortunately, little data is available on the PK of MPA in this population.[124] In a 
study of lung transplant recipients, patients with CF received on average 30% higher MMF 
doses than weight-matched patients without CF, all being given tacrolimus (doses estimated at 
approx. 32 vs 22 mg/kg/day, p < 10-5), to reach MPA C0 of approx. 2.5 vs 1.5 mg/L (ns).[142] 
Among the 21 patients recruited in another study, 5 had CF and received similar MMF doses 
compared to the remaining 16 patients (data not shown).[161] In CF patients, the metabolic 
AUC ratio of MPAG/MPA was significantly lower than in non-CF patients (14.3 vs 25.1, p < 
0.01), which according to us could result from increased renal MPAG excretion, decreased 
hepatic metabolism or increased biliary excretion in CF patients, in order of decreasing 
probability. However, due to the small number of patients, these results would need to be 
confirmed and further investigations on the metabolism of MPA in CF patients would be of 
major interest. 
2.2 Therapeutic drug monitoring 
The advantages and limitations of TDM of MMF in transplantation were discussed recently in 
two reviews.[120,162] While TDM is mandatory for calcineurin inhibitors, it is not for MPA and 
MMF is usually administered at a fixed oral dose (adults: 2-3 g/day in combination with 
cyclosporine and 1.5-2 g/day in combination with tacrolimus; children, at least in renal 
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transplantation: 600 mg/kg body weight twice daily, up to a maximum daily dose of 2 g). As a 
consequence, MPA levels have not been routinely monitored despite PK and PD (variations 
of IMPDH inhibition) variability comparable to that of calcineurin inhibitors.[8,124,163] 
However, a significant relationship between MPA AUC and clinical outcomes and the clinical 
benefits of MMF monitoring for dose individualization have been demonstrated in a growing 
number of studies, including prospective concentration-controlled clinical trials, notably in 
renal transplantation and, to some extent, in heart transplantation.[16,124,132,164-166] Controlled 
exposure to MPA is essential to maximize its immunosuppressive effects and minimize its 
toxicity.[120] Despite this, MPA monitoring is still debated and no consensus has been reported 
on the best TDM tool for the optimal management of graft rejection and adverse effects 
(diarrhea, leucopenia, infections).[118,120,135] TDM guidelines for MMF in heart and lung 
transplant patients are even more limited.[120]  
2.2.1 Single concentrations monitoring 
When performed, MMF monitoring is sometimes based on MPA C0 concentrations. In heart 
transplantation, the current recommendation is an MPA C0 target of 1.2-3.5 mg/L when MPA 
is assayed by HPLC (C0 ≥ 2 mg/L when MPA is assayed by EMIT).[120]  
Studies of the relationship between MPA C0 and AUC0-12 in heart transplantation have 
reported poor correlation, with coefficients of determination (r2) ranging from 0.36 to 
0.69.[132,134,135,137] A better correlation was found with different time points, such as C40min (r² 
= 0.82),[134] C4 (r² = 0.86), C6 (r² = 0.85) or C8 (r² = 0. 93) (Table XI).[135] However, AUC0-12 
was not always measured and was sometimes estimated using multiple linear regression 
equations developed in other populations or transplant types.[134]  
It is noteworthy that C0 may not be the minimal concentration during the dosing interval, 
because of secondary peaks that occur between 6 and 12 hours after drug administration and 
of more or less delayed absorption, which translates into decreasing blood levels in the 10-60 
min post-dose.[141] These secondary peaks may also explain the poor correlation of MPA C0 
with AUC0-12.[124,163]  
2.2.2 AUC monitoring 
2.2.2.1 Full AUC 
Mycophenolate is characterized by a poor correlation between blood concentrations and dose. 
In a study performed in 120 kidney and 20 lung transplant recipients on MMF and 
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cyclosporine (n = 107) or tacrolimus (n = 33), no correlation was found between MMF dose 
and MPA C0 assayed by EMIT.[126]  
As with calcineurin inhibitors, AUC0-12 is likely to be the most useful TDM tool rather than 
single concentrations. The recommended therapeutic range for MPA AUC0-12 after renal 
transplantation is 30-60 h.mg/L.[120] In thoracic transplantation, MPA AUC0-12 was calculated 
using the linear trapezoidal rule in almost all studies we identified. In two studies in heart 
transplant patients co-administered cyclosporine or sirolimus,[132,134] AUC0-12 was estimated 
using the EMIT assay and sparse sampling algorithms previously developed using HPLC in 
adult kidney transplant recipients treated with MMF-cyclosporine. The estimation precision is 
thus questionable because, as previously discussed sparse sampling strategies are usually 
specific of the transplant population, analytical method and associated immunosuppressant, 
unless validated in another population of interest. Fortunately, in these two studies the AUC 
estimates were not used for dose adjustment.  
2.2.2.2 Sparse sampling strategies 
As discussed previously, the determination of full AUC0-12 is impractical compared to other 
strategies such as C0 or abbreviated sampling estimation of the drug’s exposure. No 
abbreviated AUC has been proposed as a surrogate exposure index in thoracic transplantation. 
Experience of sparse sampling strategies is limited to three studies, two in heart and one in 
lung transplantation (Table XI). In heart transplant patients, the proposed sampling strategies 
included three or four MPA concentrations: at 1.25h, 2h, 6h and possibly 4h after MMF 
administration in the first study[121]; and at 0.5h, 1h, 2h and possibly the trough in the 
second.[167] In lung transplantation, an algorithm was proposed for the estimation of 
log(AUC0-12), based on the log(concentration) measured at pre-dose and either 1.5h or 2h 
post-dose.[138] Of note, both algorithms were developed using concentration-time profiles 
from a small number of patients. Clinical acceptability of sparse sampling strategies is better 
when the samples are drawn within 4 hours post-dose, which is not the case of the former. On 
the other hand, samples drawn before 6 to 8 hours post-dose are likely to miss MPA 
enterohepatic recycling,[118] unless Bayesian estimators, able to compensate for this, are 
used.[168]  
2.2.2.3 Bayesian forecasting 
To our knowledge, MAP-Bayesian procedures using popPK models have been developed for 
the estimation of AUC0-12 in renal transplant patients,[168,169] but not in thoracic 
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transplantation. Much still has to be done in order to refine TDM strategies for MMF after 
thoracic transplantation. 
2.2.3 Impact of MMF TDM on patient outcome 
Only a few studies have evaluated the relationship between exposure to MPA and clinical 
outcomes in heart transplantation,[129,132,136,139,163,170] and one in lung transplantation,[142] most 
of which were retrospective and dealt only with C0 (Table XIII). 
2.2.3.1 C0 monitoring 
In a retrospective study conducted in 215 heart transplant patients who received MMF 
associated with either cyclosporine (n = 191) or tacrolimus (n = 24), the incidence of acute 
rejection was higher when patients had MPA C0 < 2 mg/L (EMIT) compared to patients with 
MPA C0 > 2 mg/L (14.9 vs 8.8% between 0 and 6 months post-transplant and 11.3 vs 4.2% 
between 6 and 12 months post-transplant, p = 0.05 for both).[139] However, this difference was 
not further observed in patients beyond the first year post-transplantation. More importantly, 
patients who were within the therapeutic range for the associated calcineurin inhibitor in 
addition to MPA C0 > 2 mg/L had lower rejection rates compared to patients who had only 
MPA C0 > 2 mg/L (3.6 vs 15.5%, p = 0.002). 
Forty-eight EMB were performed at the time of blood sampling in 26 heart transplant patients 
on MMF associated with cyclosporine or tacrolimus.[163] In the cyclosporine group, the 
overall acute rejection incidence was approximately 20% with MPA C0 values of 1.65±0.97 
mg/L (cyclosporine C0 < 175 µg/L in all samples), whereas in the tacrolimus group, the 
overall acute rejection incidence was approximately 60% (p = 0.02) with MPA C0 values of 
2.86±2.07 mg/L, (tacrolimus C0 < 10 µg/L in 52% of samples). These results are obviously 
very surprising and might be due to the dispersion of the individual exposure to both MPA 
and calcineurin inhibitor, even though the difference in MPA levels between rejectors and 
non-rejectors was not statistically significant. 
In another retrospective study of 147 EMB from 20 patients in the first year after 
transplantation, the mean MPA C0 (assayed by EMIT) was significantly lower in patients with 
acute rejection (n = 11, C0 = 1.36 mg/L) than in those without (n = 9, C0 = 1.76 mg/L, p = 
0.015).[170]  
In 26 heart transplant adults and children aged 1 month to 33 years who received MMF 
associated with either cyclosporine (n = 8 children + 10 adults) or tacrolimus (n = 8 children), 
lower MPA C0 were associated with EMB grade ≥ 2 (ISHLT classification) compared to 
 49 
grade < 2 (1.2±0.9 vs 2.5±2.3 mg/L, p = 0.02).[136] and no patient experienced grade 2 or 3A 
rejection when MPA C0 was > 2.5 mg/L. Of note, issues regarding the heterogeneity of the 
population in this study have already been addressed in the PK section. 
A statistically lower MPA C0 (assayed by EMIT) was also reported in lung transplant patients 
with (n = 14, 28 acute rejection episodes) compared to patients without (n = 16) acute 
rejection (2.11±0.08 vs 2.71±0.11 mg/L, p < 10-5).[142]  
A prospective study conducted in 45 patients was organized in 2 phases:[129] during the first 
phase, 15 patients received fixed-dose of MMF (2 g/day, resulting in 5/15 patients without 
acute rejection; during the second phase, 30 patients received MMF at doses adjusted on C0 
with a target of 2.5 to 4.5 mg/L, resulting in 27/30 rejection-free patients, which, even if not 
statistically significant and despite the sequential design of the study, advocates for further 
trials.  
2.2.3.2 AUC monitoring 
The relationship between MPA AUC0-12 and acute rejection was demonstrated in renal 
transplant recipients[120] and confirmed by a recent study which demonstrated that TDM of 
MMF based on MPA AUC0-12 (estimated using Bayesian forecasting) compared to fixed-dose 
MMF resulted in a significant decrease of the acute rejection incidence:[16] patients who 
benefited from MPA TDM had fewer acute rejection episodes compared to patients of the 
fixed dose group (12% vs 30%, p = 0.01). Interestingly, a more than 10-fold inter-individual 
variability of MPA AUC values was reported in heart transplant patients receiving a fixed 
dose of MMF.[133]  
In a cohort study, thirty-eight cardiac transplant recipients were divided into 3 groups based 
on the rejection severity on their biopsy (grade 0, n = 22; grade 1, n = 13; grade 2/3, n = 
3).[132] Patients with grade 2 or 3 rejection had a lower mean total MPA AUC0-12 (26.1±6.6 vs 
42.8±14.0 h.mg/L, p < 0.08) and unbound MPA AUC0-12 (0.49±0.11 vs 0.81±0.25 h.mg/L, p 
< 0.05) compared with patients without rejection (EMIT assay). However, due to the very 
limited number of patients with grade 2/3 rejection in this study and the already mentioned 
methodological limitations (estimation algorithm developed for renal transplantation and 
HPLC assay), this finding is to be used with caution. 
Some authors hypothesized that high concentrations of MPA and AcMPAG may account for 
adverse effects such as gastro-intestinal disturbances and bone marrow suppression.[150,164,171-
173]
 According to other authors, the occurrence of GI toxicity is probably not related to 
systemic exposure to MPA or MPAG, but rather to high concentrations of MPA and/or its 
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metabolites in the gut.[94,133] No study except for one[129] addressed the relationship between 
exposure to MPA and toxicity, more particularly gastro-intestinal toxicity, in heart or lung 
transplantation. In this study performed in 45 heart transplant recipients, the incidence of 
gastro-intestinal toxicity was 40% in patients who received fixed dose of MMF (2 g/day), and 
30% in patients who benefited from MMF dose adjustment on C0 (target: 2.5-4.5 mg/L). 
Unfortunately, no formal statistical comparison was made between the 2 groups, preventing 
us from drawing any conclusion from this observation.  
To conclude, though prospective clinical validation is still missing, there is much indirect 
evidence that optimized exposure to MPA is crucial for successful thoracic transplantation 
and that MMF therapy can be improved by TDM.   
3 mTOR inhibitors  
Sirolimus and everolimus display a distinctive mechanism of action from that of calcineurin 
inhibitors. They form a complex with FKBP12, which inhibits the mTOR (mammalian target 
of rapamycine) involved in the proliferation of lymphocytes, blocking DNA and protein 
synthesis and consequently the proliferation of IL2 activated B and T cells. mTOR inhibitors 
reduce T-cell activation in cell cycle stages later than calcineurin inhibitors: their mechanism 
of action is downstream of and complementary to that of calcineurin inhibitors. [1,9,174,175]  
3.1 Sirolimus 
Sirolimus (rapamycin, Rapamune®) has been used mainly in renal transplantation, usually in 
combination with a calcineurin inhibitor or MMF and a corticosteroid, or as a calcineurin-
sparing agent (because it allows the associated calcineurin inhibitor to be discontinued or its 
dose to be decreased). In thoracic transplantation, although used off-label, sirolimus has been 
of great interest as a rescue therapy when other immunosuppressants are inefficient or contra-
indicated and in patients with impaired renal function.[9,175] Sirolimus was demonstrated to 
display a protective effect against the development of bronchiolitis obliterans in stable lung 
transplant patients.[1] However, it has been associated with interstitial pneumonia[176] and 
bronchial anastomotic dehiscence.[177] Consequently, in lung transplantation, it has been 
recommended not to introduce sirolimus before the third month post-transplantation. In heart 
transplantation, the safety of early CNI withdrawal has been questioned because of an 
associated increase in acute rejection rate, an observation that led to the discontinuation of a 
randomized trial of early CNI replacement by sirolimus. According to Zuckermann et al, CNI 
withdrawal should not be attempted until after the first year post-transplantation.[178]  
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These limitations and side-effects may explain why the use of sirolimus in thoracic 
transplantation has so far been limited. 
3.1.1 Pharmacokinetics 
The majority of PK studies of sirolimus were performed in healthy volunteers and kidney 
transplant recipients,[94] and we identified only one in heart transplantation.[179] This brief 
review will thus be mainly based on the PK and TDM of sirolimus in renal transplantation, as 
already reviewed in more detail in two articles.[175,180]  
The standard sirolimus dosing strategy in renal transplantation consists of a loading dose of 6 
mg/day, followed by a maintenance dose of 2 mg/day, with dose adjustment based on target 
C0 values. In patients with high rejection risks and in heart transplant recipients, the loading 
dose is 15 mg/day and the maintenance dose 5 mg/day.[175,181-183]  
In kidney transplant recipients, sirolimus exhibits wide inter- and intra-individual PK 
variability, like calcineurin inhibitors do.[52,180]  
3.1.1.1 Absorption 
Sirolimus is rapidly absorbed (tmax ranging between 0.7 and 3 hours), with an apparent oral 
bioavailability in association with cyclosporine of approx. 15% and a variable Cmax ranging 
between 14 and 355 µg/L.[52,94,175,180] Sirolimus displays an intensive intestinal and hepatic 
metabolism by CYP3A4/CYP3A5 and is a substrate of P-gp, accounting for its low 
bioavailability and high PK variability.[94,144,175]  
In a study conducted in 22 healthy adult volunteers, high fat meal decreased sirolimus AUC 
by 35%.[184] The drug should thus be administered consistently with or without food in order 
to reduce fluctuations in drug exposure.[180]  
3.1.1.2 Distribution 
In whole blood, sirolimus is extensively distributed in cellular elements (much more so than 
calcineurin inhibitors), mainly in erythrocytes (95%), lymphocytes (1%) and granulocytes 
(1%). The remaining 3% are found in plasma, where only 4% are bound to soluble plasma 
proteins, and 40% to lipoproteins, although the latter ratio goes up with increasing sirolimus 
concentrations.[94,180] Its high hydrophobic properties result in a wide distribution in lipid 
membranes of body tissues and confer sirolimus a large Vd/F (5.6-16.7 L/kg).[180]  
In a popPK study performed in 31 de novo heart transplant recipients using a one-
compartment PK model with first-order absorption and elimination, the estimated Vd/F ranged 
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approximately between 1,200 and 1,600 L, which is slightly higher than values reported in 
renal transplant recipients.[179]  
3.1.1.3 Metabolism 
Sirolimus, like cyclosporine and tacrolimus, is metabolized in the liver by the CYP3A4, and 
to a lesser extent CYP3A5 isoenzyme.[52,94] The large inter-individual variability of sirolimus 
PK may be related to the variability in its metabolism,[180] which consists mainly of O-
demethylation and/or hydroxylation.[175] Over 16 metabolites have been identified in the bile 
of rats receiving sirolimus.[180] In patients’ whole blood, concentrations of metabolites exceed 
those of the parent drug,[94] but there is no evidence that they display significant biological 
activity (< 10% of that of sirolimus at most).[180] An in vitro study with human liver 
microsomes showed that CYP3A5 exhibited a lower activity than CYP3A4 for sirolimus 
metabolism, but as CYP3A4 was more inhibited by cyclosporine, cyclosporine could unveil 
the influence of CYP3A5 and of its *1/*3 polymorphism on sirolimus disposition.[144] 
However, the CYP3A5*1/*3 polymorphism was shown to have a dramatic impact on the 
sirolimus CL/F and C0 actually achieved over the first 1-3 months post-transplantation despite 
TDM in renal transplantation, probably due to its higher impact on sirolimus intestinal 
metabolism and first pass effect.[185]  
3.1.1.4 Elimination 
Sirolimus is characterized by a long elimination half-life, varying between 44 and 87 hours, 
which allows once daily administration.[94,180] Steady-state is thus normally reached on 
average 6 days after the initiation of therapy, which justifies the use of a loading dose to 
achieve steady-state concentrations rapidly. The primary route for the clearance of sirolimus 
is biliary, over 90% of the metabolites being recovered in the faeces.[180] A large intra-patient 
(CV = 86%) and inter-patient variability (CV = 90%) on CL/F has been reported in stable 
renal transplant recipients, with 4- to 8-fold differences.[175,180]  
The only published study on the PK of sirolimus in heart transplantation aimed to build a 
popPK model to estimate sirolimus CL/F and its intra- and inter-patient variability.[179] Thirty-
one de novo, adult heart transplant recipients between 4 days and 5 years post-transplantation, 
on sirolimus, cyclosporine and oral prednisone were included. Sirolimus dose was adjusted on 
C0 (target: 8-18 µg/L, assay: LC-MS/MS), and PK modelling was performed using 
NONMEM. As the majority of blood samples were collected towards the end of the dosing 
interval with a median of 20 hours, no data was available during the absorption phase. 
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Consequently, a one compartment PK model with first-order absorption and elimination was 
used, and the rate constant of absorption ka was fixed at a value of 0.752 L/h. In this 
population, the maximum a posteriori Bayesian estimate of CL/F was 7.1 L/h (95%CI = 6.75-
7.41 L/h), which is similar to values reported in renal transplantation. A 21% increase in 
sirolimus CL/F was observed for every 100 mg increase in the cyclosporine daily dose. 
Patients with primary diagnosis of ischemic heart disease had a 62% higher CL/F compared to 
others, and patients with hypertriglyceridemia (TG ≥ 2 mmol/L) had a 38% lower CL/F 
compared to patients with TG < 2 mmol/L, though the meaning of these findings is not quite 
clear. 
3.1.1.5 Drug-drug interactions 
Concomitant administration of sirolimus with cyclosporine microemulsion (but not the oil-
based formulation) results in a 50-80% increase in sirolimus AUC because of the inhibition of 
CYP3A and P-gp by cyclosporine, with no modification of cyclosporine AUC. Moreover, a 
synergistic PD interaction between cyclosporine and sirolimus has been widely reported.[52,180] 
These are the reasons why sirolimus has been largely used as a cyclosporine-sparing agent. 
As a substrate of CYP3A4 and P-gp, sirolimus has a potential for drug interactions similar to 
that of cyclosporine.[52] In renal transplantation, the association of sirolimus with diltiazem 
and ketoconazole resulted in a 60 and 990% increase of sirolimus AUC respectively, whereas 
the association with rifampicin resulted in an 82% decrease of sirolimus AUC.[180,186] On the 
contrary, in a study in 31 de novo heart transplant patients, sirolimus C0 was lower in patients 
during diltiazem administration (14.1 µg/L, range: 9.7-21.9) than at other times (18.9 µg/L, 
range: 12.6-26.0; p < 10-5),[179] which is not consistent with the known inhibitory effect of 
diltiazem on P-gp and hepatic metabolism, nor with the calculated sirolimus clearance in the 
same paper, which was lower under diltiazem. This might be due to an error in C0 reporting in 
this paper.  
Combination of cerivastatin with cyclosporine + sirolimus may result in a significant increase 
in cerivastatin exposure, with possible HMG-CoA reductase inhibitor-associated toxicity.[175]  
3.1.2 Therapeutic drug monitoring 
A wide intra-individual variability of sirolimus PK has been reported in renal transplant 
patients, with CV = 42-82% on observed and dose-adjusted Cmax, C0 and AUC values.[180,185] 
High variability was similarly observed in 31 de novo heart transplant patients, with the C0 
ranging between 0.2 and over 70 µg/L, despite targeting 8-18 µg/L,[179] and a poor correlation 
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between the dose and C0 (r² = 0.162, n = 524, p < 0.001). The wide range of C0 in patients 
receiving the same dose is due to the variability in drug absorption and clearance.[180]  
On the other hand, better though variable correlation was reported in renal transplant patients 
between steady-state C0 and AUC (assay: LC-MS/MS), with r2 = 0.85,[52,180] or r² = 0.43[185].  
The relationship between sirolimus C0 and efficacy has been evaluated in renal 
transplantation.[175] Current TDM strategies are based on C0, but appropriate C0 for the 
prevention of acute rejection depends on the concomitant immunosuppressive regimen and 
would thus probably need to be refined. In renal transplant patients treated with sirolimus, 
cyclosporine and prednisone, C0 < 5 µg/L (assays: LC/MS, LC/UV) was associated with an 
increased risk for acute rejection episodes, whereas C0 > 15 µg/L was associated with a higher 
risk of adverse events (anemia, leukopenia, decreased platelet count, 
hypertriglyceridemia).[180] In association with cyclosporine, the following target values were 
proposed for sirolimus C0: 5 to 10 µg/L for 30% reduction in usual cyclosporine exposure, 10 
to 15 µg/L for 60% reduction in usual cyclosporine exposure, and ≥ 20 µg/L for no 
cyclosporine exposure.[52] In CNI-free studies in renal transplantation, where the C0 target was 
30 µg/L before M2 and 15 µg/L after M2, 41% and 27.5% acute rejection episodes were 
reported in patients on sirolimus associated with azathioprine and prednisone and in those on 
sirolimus associated with MMF and prednisone, respectively.[180]  
As sirolimus has a long elimination half-life, the following schedule for C0 monitoring was 
proposed: initially not more than once every 4 days, then once a week during the first month 
and once every two weeks during the second month. Moreover, sirolimus dose adjustments 
should be based on C0 obtained more than 5-7 days after a dosage change or initiation of 
therapy.[175]  
Sirolimus monitoring is a regulatory requirement in Europe. However, in a recent review, 
routine TDM of sirolimus was not deemed necessary in all patients after the first 2 months of 
dose titration, but only in case of suspected toxicity or non-compliance, and in some high-risk 
categories, identified as: young children (5-11 years), patients with hepatic impairment, 
patients on enzyme inhibitors or inducers, patients at high risk of rejection, patients on a CNI-
sparing strategy.[175]  
In conclusion, sirolimus pharmacogenetic-PK studies are required in heart or lung 
transplantation, in order for this drug to be used safely in these populations. Moreover, 
although there appears to be a relationship between sirolimus C0 and clinical outcomes, the 
value of sirolimus TDM needs to be tested in the clinical setting,[52] and the demonstration of 
the superiority of sirolimus TDM over fixed dose regimens requires controlled trials.[175]  
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3.2 Everolimus 
Everolimus (SDZ RAD, RAD, Certican®) was derived from sirolimus in order to improve its 
PK, and in particular to increase its oral bioavailability,[174,187] and decrease its half-life. It is 
currently the only mTOR inhibitor with regulatory approval in heart transplant recipients, as it 
has been shown to reduce significantly the incidence of acute rejection, CAV, graft loss, and 
death.[9,178,187,188] To date, there is limited evidence in favour of the use of everolimus in lung 
transplantation. Given the fibroproliferative process underlying the BOS and everolimus 
general antiproliferative effect, everolimus may prevent the onset of BOS after lung 
transplantation.[174] Significant clinical benefit of everolimus vs AZA on pulmonary function 
and BOS was evidenced in stable lung transplant recipients.[189]  
3.2.1 Pharmacokinetics 
The few PK studies of everolimus performed to date have been conducted in healthy 
volunteers and kidney and liver transplant recipients. Only exposure indices have been 
reported in heart and heart-lung transplantation.  
3.2.1.1 Absorption 
Everolimus is characterized by a low oral bioavailability of around 16%, with tmax ranging 
between 0.5 and 4 h depending on the type of patients (healthy volunteers, solid organ 
transplant patients).[187,190] Everolimus, like sirolimus, is a P-gp substrate, which probably 
affects its absorption.[175,190] As high-fat meals seem to influence its PK, it was recommended 
to take everolimus consistently with or without food, in order to reduce fluctuations in drug 
exposure.[190]  
The dispersible tablets tested during a pediatric development program in 19 renal transplant 
children (aged 2-16 years), showed a 10% lower bioavailability relative to the conventional 
ones.[191]  
3.2.1.2 Distribution 
In whole blood, over 75% of everolimus is partitioned into erythrocytes.[187,190] In a popPK 
analysis of everolimus (one-compartment model) in 673 kidney transplant recipients, Vd/F 
was estimated to be 110±5 L.[192]  
3.2.1.3 Metabolism 
Everolimus is metabolized extensively in the gastro-intestinal tract and liver by CYP3A4 
(mainly), 3A5 and 2C8, so the large inter-individual variability in everolimus bioavailability 
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and biotransformation is related to the variations in activity of these enzymes and P-
gp.[175,187,190] The major metabolic pathways are thought to be hydroxylation and 
demethylation, leading to the production of at least 11 metabolites, whose immunosuppressive 
or toxic activities are unknown.[190] Patients with hepatic impairment were shown to have 
significantly lower everolimus CL/F, with longer T1/2 (by 84%) and higher AUC (by 115% 
higher) compared to healthy subjects. As a consequence, it was recommended to reduce the 
everolimus dose by half in such patients.[190]  
3.2.1.4 Elimination 
About 98% of everolimus is excreted in bile as metabolites and only 2% is eliminated in 
urine.[190] Everolimus displays a shorter half-life than sirolimus, ranging between 18 and 35 
hours in kidney and liver transplant patients, which allows twice daily administration and a 
steady-state to be achieved more quickly.[187,190] In healthy volunteers, CL/F and T1/2 were 
19.7±5.4 L/h and 32.2±6.1 h, respectively.[190] As already mentioned, no clearance or half-life 
values have been reported so far in heart or lung transplant recipients.  
3.2.1.5 Drug-drug interactions 
Everolimus and cyclosporine are given as a combination therapy because of their synergistic 
interaction.[9,190] As they are both substrates for CYP3A and P-gp (cyclosporine inhibits 
whereas everolimus induces P-gp), they may interfere with each other’s absorption or 
elimination.[193] Any alteration in P-gp and inhibition of CYP3A4 metabolism may result in 
the accumulation of everolimus and/or cyclosporine.[187] In a PK study conducted in 634 heart 
transplant patients on everolimus (n = 420) or AZA (n = 214) associated with cyclosporine 
and corticosteroids, similar cyclosporine C0 were achieved with lower doses of cyclosporine 
in patients on everolimus vs those on AZA (p = 10-4), resulting in higher dose-normalized 
cyclosporine C0 in patients on everolimus vs those on AZA (p = 10-4).[193]  
Similar results were reported in a PK study conducted in 213 patients on everolimus (n = 101) 
or AZA (n = 112) associated with cyclosporine and corticosteroids, with cyclosporine C0 
during the first month of 220±102 µg/L in patients on everolimus vs 176±76 µg/L in patients 
on AZA  (p < 0.02).[194]  
A PK conversion study (switch from AZA to everolimus or from cyclosporine to tacrolimus) 
was recently performed in 12 adult heart transplant patients (2 groups of 6 patients, aged 18-
65 years) over 3 months post-transplantation.[195] Two full PK profiles per patient were 
collected, before and 6-8 weeks after conversion. Everolimus, cyclosporine and tacrolimus 
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were assayed by LC-MS/MS. The first group received tacrolimus adjusted on C0 (target: 6-10 
µg/L), and was converted from AZA to everolimus adjusted on C0 (target: 3-8 µg/L), showing 
no significant difference in the PK of tacrolimus before and after the conversion. The second 
group received everolimus adjusted on C0 (target: 3-8 µg/L) and was switched from low-dose 
cyclosporine (target C0: 60-80 µg/L) to tacrolimus (target C0: 6-10 µg/L). A significant 
decrease (p < 0.05) of everolimus exposure before and after conversion from cyclosporine to 
tacrolimus was found, on C0 (4.2±1.3 vs 2.3±1.2 µg/L), Cmax (9.1±1.9 vs 5.9±1.1 µg/L) and 
AUC0-12 calculated using the linear trapezoidal rule (64.2±6.8 vs 33.7±9.7 h.µg/L). In 
conclusion, no significant effect of everolimus on the PK of tacrolimus was evidenced, but the 
PK interaction between everolimus and cyclosporine led to 1.9-fold and 8-fold higher 
everolimus AUC0-12 and C0 on concomitant cyclosporine compared with tacrolimus. 
In healthy volunteers, rifampicin was reported to increase significantly everolimus CL/F 
(+172%), and shorten T1/2 from 32 to 24 hours (p = 10-4), with a significant decrease of its 
AUC (-63%, p = 10-4).[196] In de novo renal transplant patients, erythromycin and 
azithromycin resulted in a significant decrease in everolimus CL/F (-22 and -18%, 
respectively). Fluconazole had no significant influence, but itraconazole induced a 74% 
reduction in everolimus CL/F.[192]  
Analysis of PK profiles of everolimus in 13 lung and heart-lung transplant recipients found 
2.3-fold higher everolimus C0 in patients on azole antifungal drugs compared to others (p < 
10-4).[194] Fluconazole appeared to have minimal influence on everolimus exposure whereas 
itraconazole and ketoconazole had a stronger effect. 
3.2.1.6 Special populations 
3.2.1.6.1 Paediatric transplantation 
We found no published study in heart or lung pediatric patients. A review published in 2004 
analyzed two studies performed in pediatric renal transplant patients on everolimus associated 
with cyclosporine and prednisone.[190]  
In the first study (n = 19 stable transplant recipients), Vd/F and CL/F were positively 
correlated with age, weight and body surface area (BSA) (p < 0.001) and were significantly 
lower to those of adults, whereas elimination half-life was similar, regardless of age, and 
comparable to that of adults. The authors recommended adjustment of everolimus doses to the 
bodyweight in children.[197]  
In the second study (n = 19 de novo transplant recipients followed for 6 months after 
transplantation), a positive correlation was also found between CL/F and age, weight and 
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BSA. Intra- and inter-patient variability on AUC was 29 and 35%, respectively. The authors 
recommended adjustment of everolimus doses to the body surface area in children.[198]  
3.2.1.6.2 Cystic fibrosis 
One study reported the PK of single-dose everolimus in patients with CF, using a non-
compartmental approach.[199] This was a phase I multicenter, randomized, double-blind, cross-
over study in 19 lung and heart-lung transplant recipients (7 CF, 12 non-CF), beyond 3 
months post-transplantation treated with cyclosporine, azathioprine and prednisone. Each 
patient received everolimus at a low-dose (0.035 mg/kg without exceeding 2.5 mg) and at a 
high-dose (0.10 mg/kg without exceeding 7.5 mg), in random order and separated by a wash-
out period. Everolimus was assayed using LC-MS/MS, and AUC0-τ was calculated using the 
trapezoidal rule. Dose-normalized Cmax was significantly lower in CF patients vs non-CF 
patients (low-dose everolimus: 12.4±3.9 vs 13.8±3.1 µg.L-1; high-dose everolimus group: 
10.2±2.3 vs 12.8±2.5 µ.L-1; p = 0.03 for patients pooled across everolimus dose levels), 
whereas everolimus AUC/dose (which is the inverse of CL/F) did not differ significantly 
between the patients with and those without CF. T1/2 was similar in all groups, ranging from 
25 to 29 hours. 
Similarly, the analysis of everolimus PK profiles in 13 lung and heart-lung transplant 
recipients showed no significant difference in exposure between CF and non-CF patients.[194]  
3.2.2 Therapeutic drug monitoring 
Everolimus is characterized by a narrow therapeutic index.[187,190] Moreover, data from 
various solid organ transplant populations (adult renal, cardiac and liver transplantation and 
pediatric renal transplantation) suggests that during the first year post-transplantation, there is 
a good relationship between everolimus concentrations and the clinical outcomes (efficacy, 
thrombocytopenia).[190,200] Consequently, TDM has been recommended for everolimus.[187]  
In heart transplantation, two PK studies were conducted in the patients of study B253,[188] a 
prospective randomized double-blind efficacy trial in which 634 heart transplant patients 
(aged 52±11 years) on cyclosporine and corticosteroids were randomized to receive either 
0.75 or 1.5 mg of everolimus BID (n = 209 and 211), or azathioprine (n = 214). Based on 
exposure-efficacy and exposure-safety analyses, everolimus C0 of 3 to 8 µg/L was shown to 
ensure an optimal benefit/risk ratio.[178]  
The first study focused on the PK of everolimus (assay: ELISA) during the first 6 months 
post-transplantation.[193] A measurement of C0 was performed in all patients and AUC0-12 
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estimated in 55 of them, using the trapezoidal rule based on 5 samples drawn over 8 hours 
(C12 was extrapolated from C5 and C8 by log-linear regression). No statistically significant 
difference in dose-normalized Cmax or AUC was found between the 0.75-mg BID and the 1.5-
mg BID dose groups, showing dose proportionality. A good correlation was found between C0 
and AUC (r2 = 0.81, p < 0.001). Intra-individual variability on Cmin, Cmax and AUC was 38%, 
30% and 30%, and inter-individual variability 40%, 33% and 37%, respectively. Sixty-nine 
and 80% of patients with C0 comprised between 3.6 and 5.3 µg/L and between 5.4 and 7.3 
µg/L respectively, remained rejection-free vs 65% of patients with C0 ≤ 3.5 µg/L, and cox 
proportional hazard analysis showed that the relative risk for biopsy-proven acute rejection 
was 2.4 for C0 < 3 µg/L vs C0 in the 3-7 µg/L range (p < 10-5). However, ROC analysis 
showed that C0 = 3.4 µg/L was the best one, able to distinguish rejectors from non-rejectors, 
yielding 75% sensitivity and 47% specificity. These variable thresholds and targets, 
apparently chosen for statistical reasons are puzzling and probably weaken the conclusions of 
this study. No significant relationship was evidenced between exposure and the level of 
triglycerides or serum creatinine, but there was a significant correlation between C0 and 
thrombocytopenia (r2 = 0.85, p = 0.03). 
The second study evaluated, throughout the first year post-transplantation, the relationship 
between everolimus C0 and cyclosporine C0 on the one hand and efficacy (biopsy-proven 
acute rejection, BPAR) and safety (renal function, serum lipids, platelet counts) on the 
other.[201] Everolimus C0 were stable in the first year post-transplantation and averaged 
5.2±3.8 and 9.4±6.3 µg/L in patients treated with 1.5 and 3 mg/day, respectively. The same 
correlation as in the previous study was found between C0 and AUC (r2 = 0.81). The 
incidence of biopsy-proven acute rejection (BPAR ≥ grade 3A based on ISHT classification) 
was 44% in patients with C0 < 3 µg/L, 24% in patients with C0 = 3-8 µg/L, and 17% in 
patients with C0 ≥ 8 µg/L, leading to a relative risk of BPAR of 2.5 (p = 10-4) when C0 < 3 
µg/L vs C0 = 3-8 µg/L. The relative risk of BPAR when C0 = 3-8 µg/L vs C0 ≥ 8 µg/L was not 
significant. No effect of everolimus exposure on renal events (serum creatinine > 200 µmol/L) 
was found, but hypercholesterolemia, hypertriglyceridemia and thrombocytopenia tended to 
increase with higher everolimus C0. 
A PK study of everolimus was performed in lung and heart-lung transplant recipients (aged 
46±14 years, 3-36 months after transplantation at enrollment, 23% CF) enrolled in a 3-year 
randomized, multi-center, double-blind, parallel group study comparing everolimus (n = 89) 
and azathioprine (n = 100) as part of a cyclosporine-based immunosuppressive regimen.[194] 
Patients received an initial everolimus dose of 1.5 mg BID, stabilized at 1.2±0.4 mg BID 
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between M3 and M12. Everolimus concentration time profiles were obtained in 13 patients 
(assay: LC-MS). AUC0-12 was calculated (method: N/R) using 5 blood samples drawn 
between 0 and 8 hours and considering C12 equal to C0 at steady-state. Tmax ranged between 1 
and 5 hours, and dose-normalized C0 were regarded as stable throughout the observation 
period, with intra- and inter-individual CV of 35 and 37%, respectively (C0: 7.3±2.6 µg/L at 
M2, 9.2±4.7 µg/L at M6, 7.6±3.1 µg/L at M12). Everolimus AUC was 130±31 h.µg/L at M2 
(n = 13), 144±52 h.µg/L at M6 (n = 9) and 138±32 h.µg/L at M12 (n = 7). Over the range of 
everolimus C0 measured throughout the study (2-36 µg/L), the exposure-efficacy relationship 
(efficacy criteria: FEV1, BOS and BPAR) appeared to be in the near-maximal plateau region. 
A significant relationship was found between everolimus C0 over the first 2 months and the 
incidence of cholesterol > 6.5 mmol/L (r2 = 0.95, p = 0.025) as well as the incidence of 
triglycerides > 2.9 mmol/L (r2 = 0.96, p = 0.022). A significant relationship was also found 
between everolimus C0 during the first month and platelet count < 100 G/L (r2 = 0.93, p = 
0.038). A tendency was found between renal impairment and the increase in everolimus C0 (p 
= 0.051), which might be attributed to the synergistic nephrotoxic effect of cyclosporine 
associated with everolimus, as already described for sirolimus in vitro.[202,203] From data 
obtained in this population, the everolimus C0 range of 3 to 12 µg/L was considered as safe 
and well tolerated. Unfortunately, the number of AUC values available in this study was too 
small to be able to study the AUC – effect relationships. 
In conclusion, clinical evidence suggests that TDM of everolimus is probably beneficial in 
thoracic transplantation, C0 as measured by LC-MS/MS being a good predictor of clinical 
efficacy. The recommended minimum effective concentration for everolimus when used in 
conjunction with a cyclosporine-corticosteroid immunosuppressive regimen in heart and lung 
transplant recipients is 3 µg/L. The upper bond has not been formally established because 
patients have tolerated levels up to 15 µg/L without damage. These levels are usually 
achieved within 1 to 2 weeks, and everolimus dose adjustment should always be based on 
blood trough levels obtained at least 4-5 days after the previous dose change. It is noticeable 
that correlation coefficients between C0 and AUC are suboptimal, which suggests that AUC 
monitoring might represent further improvement in everolimus dose personalisation, but 
almost everything remains to be done, particularly AUC-effects observational studies and 
C0/AUC comparative trials. 
In heart transplant patients, cyclosporine dose reduction coupled with everolimus TDM could 
optimize immunosuppressive efficacy while reducing treatment-related toxicity.[178,187,194,200] 
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The use of everolimus in CNI-free regimens, maybe with higher C0 (or AUC) targets to 
maintain immunosuppressive efficacy has not been studied extensively.[178]  
4 Discussion 
The increasing success of thoracic transplantation is largely attributable to the development of 
effective immunosuppressive strategies. However, there is still a high rate of mortality on the 
mid- and long-term, as the percentage of 5-year survival is still only 70% after heart 
transplantation and 50% after lung transplantation.[2,3] Substantial improvement of the long-
term survival after thoracic transplantation may be obtained by adapting to some extent the 
immunosuppression to the recipient’s rejection risk factors. In other solid organ 
transplantations, TDM derived from PK studies has been demonstrated to be crucial to 
improve patients’ outcome, by targeting individualized doses of different 
immunosuppressants.[11] An overview of the PK and the clinical evidence in favour of the 
TDM of immunosuppressants in thoracic transplantation has been lacking.  
4.1 Pharmacokinetics 
Like in other solid organ transplant populations, the pharmacokinetics of the 
immunosuppressive agents in thoracic transplant recipients is characterized by wide inter- and 
intra-individual variability. A number of studies have been performed in order to compare the 
PK of Neoral® to that of Sandimmune® in heart and, to a lesser extent, in lung transplantation. 
Indeed, the old oil-based cyclosporine formulation Sandimmune®, which was characterized 
by erratic PK and consequently random efficacy was replaced in the mid 90’s by the 
microemulsion Neoral®, characterized by less variability and consequently a more constant 
efficacy. Little is known about the pharmacokinetics of MPA and tacrolimus in heart and lung 
transplant recipients, even though both have been available for around 15 years. Their 
introduction into the immunosuppressive armamentarium occurred progressively in both heart 
and lung transplantation, based on clinical experience, though in most countries tacrolimus 
and MMF have still not been approved by health authorities for lung transplantation. Given 
their increased use in thoracic transplant recipients, their PK deserves to be explored more in 
depth.  Moreover, with the recent approval of another formulation of tacrolimus (Advagraf®) 
by the EMEA, further investigation of its PK will also be necessary. Finally, there are hardly 
any studies on the pharmacokinetics of the mTOR inhibitors sirolimus and everolimus after 
thoracic transplantation, probably because they have been developed and released more 
recently. Sirolimus use in heart and lung transplantation has been questioned due to a poor 
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benefit/risk ratio with the prescription schemes proposed. To our knowledge, the vast majority 
of studies on the PK of sirolimus were performed in healthy volunteers and in kidney 
transplant recipients, while its PK in thoracic transplantation was studied by only one 
team.[179] There are only few studies of the PK of everolimus in thoracic transplantation, as it 
is the drug most recently developed and introduced in the maintenance immunosuppressive 
strategy. Its anti-proliferative activity slowing down the process of cardiac vessels intima 
thickening, a major mechanism of cardiac allograft vasculopathy, makes it a very promising 
molecule.[204-207] Moreover, its synergistic immunosuppressive activity with cyclosporine 
allows the use of low doses of cyclosporine and makes it a key drug in calcineurin inhibitor-
sparing strategies, which is of major interest in patients with renal dysfunction, but its 
potential synergistic effect on cyclosporine nephrotoxicity reinforce the need for combined 
pharmacokinetic studies in heart and lung transplant recipients. 
4.2 Therapeutic drug monitoring 
4.2.1 Evidence-based TDM 
TDM comprises the measurement and interpretation of drug exposure and aims at assisting 
physicians in the choice of drug dose for an individual patient. The state of the art of 
evidence-based TDM should be consistent comparative, randomized clinical trials showing 
the superiority of TDM vs fixed dose, on hard clinical outcomes (morbidity, mortality, graft 
function). Despite the paucity of such trials (althought there might be a publication bias by 
which small studies with negative outcome are less likely to be published than studies of 
similar size but with a positive outcome), the clinical benefits of TDM have been validated by 
usage and are now well recognized in most situations. In clinical practice, TDM is even 
mandatory for calcineurin inhibitors and mTOR inhibitors due to the poor relationship 
between the dose given and the systemic concentrations achieved. Consequently, one may 
question the actual necessity of imposing upon the medical staff and patients similar clinical 
trials with different graft types, when a clear effect has already been demonstrated, for 
instance in renal transplantation. Indeed, once the clinical usefulness of TDM has been 
demonstrated in a given graft type, it might be acceptable to extrapolate the results to the 
other graft types, provided a case-control or a cohort study (regarded as of a lower evidence 
level) confirms a good exposure-outcome relationship. A good example for that would be 
MMF, for which no clear correlation has been established between dose and MPA plasma 
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levels, much like with calcineurin inhibitors and mTOR inhibitors, and which probably 
deserves to be monitored as much as the other molecules. 
The gold-standard exposure index is in most cases the full AUC, but when it is not easy to 
measure, a surrogate marker (abbreviated AUC, AUC calculated using sparse sampling 
algorithms or Bayesian estimators, single concentrations) can be proposed based on tight 
correlation with the former. These correlation studies are indeed of the lowest evidence level 
but can be useful to evaluate the pertinence of a simplified TDM strategy.  
4.2.2 Is there clinical evidence for TDM of the immunosuppressants after thoracic 
transplantation? 
TDM of cyclosporine has been recognized as an essential tool in the management of allograft 
transplant recipients and has been performed routinely in transplantation for almost 20 
years.[52,53] However, much of the information available has been obtained in renal and liver 
transplantation, where there is still no clear consensus about the optimal monitoring method. 
We found very little data on the practices and outcomes of cyclosporine monitoring after 
thoracic transplantation. Various observational studies sought for a relationship between C0 
and clinical outcome, with sometimes positive[28,74-79] and sometimes negative[20,54,80] results. 
Similarly, a number of authors found a relationship between C2 and clinical outcomes and 
thus advocated for C2 monitoring,[10,56,84-88] while such a relationship could not be evidenced 
in a number of other studies.[20,22,28,51,89-92] The superiority of C2 over C0 monitoring in terms 
of clinical outcome has been demonstrated in few studies, either in terms of efficacy, or in 
terms of toxicity (nephrotoxicity, infections).[10,55,79,86] There is no published consensus to date 
for C2 target levels after heart or lung transplantation, although tentative targets have been 
suggested based upon retrospective or single-center experience on small numbers of adult 
patients.[10,23,56,89] Our literature search allowed us to identify only two studies evaluating the 
potential relationship between AUC and clinical outcomes in heart transplant recipients, with 
diverging results,[54,55] and none in lung transplant recipients. A few methods have been 
proposed to estimate the AUC using a limited number of samples, three of which seem 
clinically applicable, one based on blood samples taken at 1 and 4 hours and multilinear 
regression,[21] the other two requiring 3 samples (0, 1 and 3 hours) and Bayesian 
estimation.[31,32] However, to date, the cyclosporine AUC target values have not been 
established and no studies in heart or lung transplantation have demonstrated the superiority 
of AUC management over C0 or C2 monitoring in terms of clinical outcomes. 
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Tacrolimus dosage after thoracic transplantation is generally adapted to C0 levels, mainly 
based on the results of clinical studies in kidney or liver transplantation. Studies of the 
relationship between C0 and AUC0-12 in thoracic transplant recipients have reported a wide 
range of correlation coefficient values.[103,104,109,111] Some authors proposed to monitor 
tacrolimus C3[110] or C4[104,105,109] levels because of their good (and sometimes better) 
correlation with AUC0-12. AUC0-4 was proposed as a surrogate exposure index for heart[109] 
and heart-lung[110,112] transplant patients. Sparse sampling strategies have been proposed for 
the determination of the tacrolimus inter-dose AUC, based either on multilinear regression 
and 2 blood samples (C0 and C2) or 3 blood samples (C0, C2 and C4),[109] or on Bayesian 
estimators and 3 blood samples taken at 0, 1 and 3 hours and 0, 1.5 and 4 hours for non-CF 
and CF patients, respectively.[112] Unfortunately, up until now, no prospective study has been 
conducted in thoracic transplantation to investigate the relationships between tacrolimus 
AUC0-12, AUC0-4 or single concentration-time points and clinical outcomes (acute rejection or 
toxicity), compare them and propose target levels. 
Unlike calcineurin inhibitors, MPA TDM is not mandatory and MMF is usually administered 
at a fixed oral dose. Consequently, MPA levels have not been routinely monitored, despite 
variability in its pharmacokinetics and its pharmacodynamics comparable to that of other 
immunosuppressants,[8,124,163] and TDM guidelines for MMF in heart and lung transplantation 
are very limited. When performed, despite poor correlation between MPA C0 and AUC0-12, 
the TDM of MMF is often based on C0,[132,134,135,137] with a recommended target range in heart 
transplantation of 1.2-3.5 mg/L (MPA assayed by HPLC).[120] The relationship between MPA 
C0 and efficacy was evaluated in a few studies in heart transplantation,[129,132,136,139,163,170] and 
in a single one in lung transplantation,[142] showing that a higher rejection incidence was 
related to lower C0. No abbreviated AUC has been proposed as a surrogate for inter-dose 
AUC in thoracic transplantation, and the experience of sparse sampling strategies using 
multilinear regression equations is limited to two studies with small numbers of 
patients.[121,138] Even though it was clearly demonstrated in renal transplantation,[120] the 
relationship between MPA AUC0-12 and rejection, or between any exposure index and toxicity 
(such as gastro-intestinal side-effects, the mechanism of which is still debated) has not been 
demonstrated in thoracic transplantation yet.[94,133,161] To date, no study comparing the 
different exposure indices in thoracic transplant recipients has been performed and no AUC 
target established and MMF dose individualization has not been validated vs. fixed-dose 
regimens. However, there is increasing evidence in favour of the clinical benefit of MPA 
AUC0-12 monitoring, particularly in renal transplantation.[16,120]  
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The current TDM strategies for both sirolimus and everolimus are based on C0. There appears 
to be a good relationship between C0 and clinical outcomes for both molecules. Most studies 
on sirolimus were performed in renal transplantation, and we found none evaluating the 
clinical benefits of sirolimus C0 monitoring in thoracic transplantation. Everolimus was 
evaluated in various solid organ transplant populations, including heart transplantation. A 
target everolimus C0 range of 3 to 8 µg/L was proposed for heart transplant recipients, based 
on the results of only 2 studies where a limited number of patients were enrolled.[193,201] The 
only study performed in lung transplantation failed to show a relationship between everolimus 
C0 and efficacy, but a significant relationship was found between C0 and toxicity.[194] Based 
on these results, an everolimus C0 target range of 3 to 12 µg/L was proposed for lung 
transplant recipients. We found no study in thoracic transplant patients evaluating the 
relationship between sirolimus or everolimus AUC and effect or looking for the best TDM 
tools in this population.  
Because appropriate exposure for the prevention of acute rejection depends on the 
concomitant immunosuppressive regimen, the use of sirolimus or everolimus in CNI-free 
regimens in stable patients, maybe with higher C0 (or AUC) targets to maintain 
immunosuppressive efficacy, also needs to be studied extensively. 
Induction therapy with a polyclonal anti-lymphocyte or anti-thymocyte globulin is now used 
in around 50% of thoracic transplant recipients, with a significant decrease of the prevalence 
of acute graft rejection episodes.[2,3] Induction therapy allows a quicker and stronger 
immunosuppression peri-operatively, and one could hypothesize that the level of maintenance 
immunosuppression should be driven by the presence or not of induction. The therapeutic 
benefit of a higher level of immunosuppression, in terms of rejection, might be however 
counterbalanced by a higher risk of toxicity, in particular infections and lymphoproliferative 
disorders. Anyway, the TDM of immunosuppressants used as maintenance therapy may be as 
relevant in patients with induction as in those without, but specific targets for CNI, MPA or 
mTOR inhibitors levels should then be defined in these patients in order to avoid 
overimmunosuppression and optimize the benefit/risk ratio.  
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4.3 What are the needs to improve the therapeutic management of thoracic transplant 
patients? 
4.3.1 Development of sophisticated TDM tools 
Heart and lung transplantations are not comparable with kidney transplantation. Firstly, the 
incidence of acute rejection is higher. Secondly, where graft failure in kidney transplant 
recipients can be handled by dialysis, graft loss in heart or lung transplant patients generally 
leads to death. Thirdly, patients with thoracic transplantation are more often administered 
drugs that intensively interact with the PK of the immunosuppressants (azole antifungals, 
calcium channel blockers, HMG-CoA reductase inhibitors), implying that the 
immunosuppressive treatment has to be closely monitored to avoid under- or over-
immunosuppression. Therefore, it is legitimate to expect the development of sophisticated 
TDM tools dedicated to thoracic transplantation, in order to evaluate accurately and precisely 
patients’ exposure to the drugs at large, and to immunosuppressants in particular. Bayesian 
forecasting presents two major advantages compared to AUC monitoring based on the 
measurement of full concentration profiles or AUC estimation with multiple linear regression 
algorithms or from a single concentration: (i) it is characterized by a high flexibility in 
sampling times, as long as the true sampling times are known; (ii) in addition to the AUC, it 
can estimate several PK parameters and exposure indices simultaneously. Therefore, it can 
help identify absorption and elimination problems in specific populations such as for instance, 
diabetic or CF patients. 
The use of Bayesian estimators for cyclosporine and MMF monitoring has been validated in 
renal transplantation by clinical studies.[16,208] In thoracic transplantation, although Bayesian 
estimators have been set up for the calculation of the AUC of cyclosporine[30-32] and of 
tacrolimus,[112] they remain to be validated as TDM tools. Indeed, the implementation in 
routine clinical practice of efficient Bayesian estimators requires prior validation in large, 
collaborative, prospective clinical trials. Bayesian estimators should also be developed for the 
TDM of MMF, sirolimus and everolimus in thoracic transplant patients. Furthermore, as 
multiple immunosuppressive strategies now arise and as these patients often receive 
interacting drugs, Bayesian estimators should be built, and ideally validated, for the different 
immunosuppressive associations, and for the association of the immunosuppressant of interest 
with other types of interacting drugs. 
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4.3.2 Clinical trials dedicated to TDM and dose individualization 
Once relationships have been established between clinical outcome and different markers of 
drug exposure, the steps necessary towards optimal TDM and dose adjustment are: (i) to 
identify the most predictive exposure index, either retrospectively from the exposure-effects 
relationships, or prospectively (which is seldom the case) by comparing the clinical outcome 
of different groups monitored using different exposure indices and their appropriate targets; 
(ii) to determine the target values for this exposure index, i.e. those associated with the best 
benefit/risk ratio, which again can be done retrospectively (such as with ROC curve analyses) 
or prospectively (concentration-controlled studies); and (iii) to validate the clinical usefulness 
of TDM using this marker and these target values in comparative trials vs. the standard of care 
at the time of the trial. In conclusion, large cohort TDM studies definitely need to be 
conducted in thoracic transplant patients. 
One difficulty with the immunosuppressants is that they are always used in combination 
regimens, making the establishment of therapeutic ranges for individual drugs complex, as the 
exposure – effect relationship for a given drug may not be the same depending on the nature  
or even the dose of the molecules it is associated with. 
Another difficulty is that patients’ follow-up in clinical trials is most of the time limited to the 
first one to three years post-transplantation, focusing on the incidence of acute rejection as the 
primary efficacy endpoint and on primary toxicity endpoints related with over-
immunosuppression (infections, cancer, post-transplant lymphoproliferative disorders) or on 
molecule-specific side effects (nephrotoxicity, hypertension, hypertrichosis, gingivitis, 
diabetes for calcineurin inhibitors; gastro-intestinal and haematological toxicity for MMF; 
hyperlipidemia for sirolimus; nephrotoxicity, hyperlipidemia, thrombocytopenia for 
everolimus). Such short follow-up durations consequently limit the conclusions to the short-
term outcomes and lead to underestimate the incidence and/or severity of cumulative 
toxicities (which can be particularly pertinent in lung transplantation where the doses given 
are higher than in other types of transplantation). If one wants to validate the benefits of 
therapeutic or TDM strategies in these populations and improve the evaluation of their risk, 
longer follow-up periods using hard clinical outcomes (morbidity, mortality, graft function) 
and other long-term outcomes (cardiac allograft vasculopathy, bronchiolitis obliterans 
syndrome, long-term cumulative toxicity such as renal insufficiency, metabolic disorders, 
etc.) should be considered. Long-term clinical trials are often expensive and complicated to 
conduct. One option could thus be to switch from clinical trials to large epidemiologic or 
cohort studies collecting all the information on therapeutic and monitoring strategies, 
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compliance, side effects and quality of life, together with clinical outcomes. This would allow 
comparing the different therapeutic strategies and exposure levels, thus helping delineate the 
best therapeutic regimen and define precise exposure targets for each clinical condition and in 
each situation in the different transplant (sub)populations. 
4.3.3 Perspectives 
Increased knowledge and a better use of older drugs would also be of great interest. Even 
though they probably are the oldest and most widely used immunosuppressive drugs in 
medicine, there is almost no published experience regarding the application of TDM to 
corticosteroid therapy. Despite the emergence of steroid-sparing strategies, prednisolone 
therapy is still largely used, sometimes at high doses, in paediatric and adult thoracic 
transplant patients.[3,42] High doses of corticosteroids are believed to induce the expression of 
a number of enzymes, including UGTs, which may interfere with the disposition of MPA.[157] 
Moreover, inter-individual variability of the pharmacokinetics of prednisolone has been 
reported in lung[209] and in heart transplant recipients,[210] suggesting that optimization of 
corticosteroid therapy using TDM might also improve the management of thoracic transplant 
patients. 
It has been suggested that pharmacodynamic monitoring of the cellular targets of 
immunosuppressant drugs may better reflect clinical outcomes than drug level monitoring. 
For instance, IMPDH pretransplant activity has been demonstrated to be associated with 
clinical outcome after renal transplantation.[211] Thus, pharmacodynamic monitoring of 
calcineurin activity, IMPDH activity or IL2 levels may address some of the limitations of PK 
monitoring, either alone or associated with PK monitoring. However, the assays available for 
the pharamcodynamic monitoring are either non-existant or technically challenging, 
expensive and time-consuming, which could limit their use in routine monitoring and dose 
adjustment. Moreover, pharmacodynamic monitoring has not yet reached the level of 
evidence PK monitoring has. Although promising, its complementarity with, or superiority 
over PK monitoring still has to be proven.[162]  
Finally, in the last decade, single nucleotide polymorphisms (SNPs) have been intensively 
investigated and found on the genes encoding P-glycoprotein (P-gp), the cytochromes P450 
(CYP450) and the uridine-diphosphate glucuronyl-transferases (UGT), all of which are 
involved in the disposition of most immunosuppressants. Some of the SNPs were found to be 
associated with altered protein expression or function, and with drug PK variability. A few 
SNPs have also been reported for IMPDH and IL2,[212-214] involved in the immunosuppressive 
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response, some of which are potentially associated with pharmacodynamic variability. The 
implications of these findings are important for transplant patients’ care, as the efficacy and 
toxicity of a given drug or association of drugs may be different depending on the genotype. 
Moreover, the combination of multiple substrates for P-gp, CYP450’s and UGTs can cause 
competitive inhibition of the proteins or up-regulate their function. Therefore, the addition of 
such agents to a transplant patient’s drug regimen may be accompanied by modifications in 
drug disposition or effect, which may be different depending on the genotype of the patient. 
Therefore, pharmacogenetic characterization of transplant patients (such as MDR1 and 
CYP3A5 genotypes for  calcineurin inhibitors and mTOR inhibitors, and UGT1A9 and MRP2 
for mycophenolate) may have the potential to optimize immunosuppressive therapy, in 
addition or, less likely as a replacement to the TDM approach. However, the level of evidence 
is low once again. Further investigations are thus needed in thoracic transplant patients in 
order to verify the clinical significance of these SNPs, before being able to conduct 
prospective, comparative trials investigating the impact of treatment individualisation based 
on this approach. If confirmed, a priori genotyping may become a new useful tool to help 
select the appropriate drugs and optimal starting doses for an individual patient, and thus 
improve clinical outcomes and participate in thoracic transplantation progress. 
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Table I. Cyclosporine exposure indices in cohort studies 
Results are expressed as mean±SD, unless otherwise specified 
 
Ref Number of patients 
Post-transplant 
period Cyclosporine dose 
Co-
administered 
immunosup-
pressant 
Assay Measured AUC (h.µg/L) C0 (µg/L) C2 (µg/L) Cmax (µg/L) Tmax (h) 
HEART TRANSPLANTATION 
Non-compartmental PK analysis; AUC0-12 Trap 
 
 NEO 
AUC/D: (h.µg/L)/mg 
cyclosporine 
 
C0/D: (µg/L)/mg 
cyclosporine 
 
 Cmax/D: (µg/L)/mg 
cyclosporine 
 
 
6,521±1,940 
AUC0-12/D = 34.2±12.6 
 
329±119 
C0/D = 1.8±0.8 
-- 1,136±315 
Cmax/D = 6.0±2.1 
1.9±0.6 Week 1 200±58 mg 
r² C0-AUC0-4 = 0.16; r² C2-AUC0-4 = 0.6 
 
6,214±1,760 
AUC0-12/D = 39.4±7.3 
 
287±99 
C0/D = 1.9±0.6 
-- 1,368±369 
Cmax/D = 8.8±1.8 
1.8±0.4 Week 12 159±40 mg 
r² C0-AUC0-4 = 0.4; r² C2-AUC0-4 = 0.4 
 
6,111±1,627 
AUC0-12/D = 38.4±10.3 
284±74 
C0/D = 1.8±0.5 
 
-- 1,256±379 
Cmax/D = 7.9±2.2 
 
2.2±0.6 
[23]
 16 adults 
(out of 35 in the 
global trial) 
Week 52 162±37 mg 
N/R FPIA 
TDx 
r² C2-AUC0-4 = 0.7 
 
NEO and SAND 
1.14±0.4 mg/kg TID 
 
Non-compartmental PK analysis; AUC0-8 Trap 
SAND 3,278±682 297±62 
 
-- 732±178 
 
2.63±1.21 
[29]
 20 male adults 
 
58.8±10.2 years 
Stable 
36.8±27.1 months 
NEO 
N/R 
No 
corticosteroids 
FPIA 
TDx 
3,798±757 
(p < 0.001) 
312±49 (ns) -- 935±250 
(p < 0.001) 
 
1.36±0.49 
(p < 0.001) 
NEO + SAND(1) 47 adults 
 
Stable 
 D 
(mg/kg/day) 
EMIT Non-compartmental PK analysis; AUC0-12 Trap [19] 
54±12 years 49±19 months None 3.90±1.03 
N/R 
SAND 3,655±1,120 167±77 -- 827±204 2.27±0.47 
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n = 11 NEO 4,911±935 
(p < 0.05) 
 
179±64 
(p < 0.02) 
 1,147±307 
(p < 0.01) 
 
1.55±0.52 
(p < 0.001) 
SAND 3,605±1,079  147±79 -- S: 816±183 2.09±0.54 52±8 years 61±15 months DILT 
n = 11 
2.98±0.64 
NEO 4,747±923 
(p < 0.05) 
 
171±61 
(p < 0.02) 
 
 1,288±415 
(p < 0.01) 
 
1.45±0.69 
(p < 0.05) 
 
SAND 3,601±933 194±72 -- 480±164 2.61±0.96 52±9 years 32±15 months KETO 
n = 13 
0.79±0.27 
NEO 3,703±772 
(ns) 
 
189±54 
(p < 0.02) 
 
 532±93 
(ns) 
 
2.00±0.57 
(p < 0.05) 
 
SAND 4,070±1,090 201±68 -- 574±192 2.58±0.90 47±12 years 28±5 months DILT + 
KETO 
n = 12 
0.90±0.54 
NEO 4,369±993 
(ns) 
 
181±62 
(p < 0.02) 
 
 652±204 
(p < 0.01) 
 
2.33±0.49 
(ns) 
 
NEO(1) 
 D (mg/day) 
Non-compartmental PK analysis; AUC0-12 and AUC0-5 Trap 
 
AUC0-12 = 4,912±935 
AUC0-5 = 3,356±641 
 
179±64 1,088±165 1,147±307 
(CV = 27%) 
1.5±0.5 
(CV = 33%) 
None 
n = 11 
302±68 
r² C0-AUC0-5 = 0.710 (p = 0.001); r² C2-AUC0-5 = 0.197 (p = 0.17) 
 
AUC0-12 = 4748±924 
AUC0-5 = 3,304±655 
 
171±61 
 
1,022±237 
 
1,222±501 
(CV: 41%) 
1.4±0.7 
(CV: 50%) 
DILT 
n = 11 
243±55 
r² C0-AUC0-5 = 0.650 (p = 0.005); r² C2-AUC0-5 = 0.650 (p = 0.005) 
 
AUC0-12 = 3,703±824 
AUC0-5 = 1,980±414 
(vs  “none”, p < 0.05) 
 
201±48 
 
 
503±110 503±110  
(CV: 22%) 
 
2.2±0.5 
(CV: 23%) 
KETO 
n = 14 
66±35 
N/R EMIT 
r² C0-AUC0-5 = 0.176 (p: N/R); r² C2-AUC0-5 = 0.870 (p = 10-4) 
 
AUC0-12 = 4,386±1,082 
AUC0-5 = 2,406±675 
(vs  “none”, p < 0.05) 
 
179±68 
 
627±209 
 
659±224 
(CV: 34%) 
 
2.4±0.5 
(CV: 21%) 
[58]
 47 adults Stable 
DILT  + 
KETO 
n = 12 
87±60   
r² C0-AUC0-5 = 0.022 (p: N/R); r² C2-AUC0-5 = 0.898 (p = 10-4) 
 
Non-compartmental PK analysis; AUC0-12 Trap 
 
1,285±367 
Cav = 371±123 
 
162±55 
 
-- 1,101±326 
 
1.1±0.4 
 
[21]
 15 adults 
48±10 years 
Clinically stable 
5.2±4.4 years 
NEO 
2.7±0.7 mg/kg/day 
D adjusted on Cav = 200-
300 µg/L 
 
 
ATG 
AZA 
Prednisolone 
FPIA 
TDx 
r² C0-AUC0-12 = 0.60; r² C2-AUC0-12 = 0.94; r² C4-AUC0-12 = 0.95 
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Until Year 4 NEO(2) 
 
ATG 
Prednisone 
 
Non-compartmental PK analysis; 2 consecutive periods 
Month 1 -- 
 
197±98 1199±476  -- 
 
-- 
 
Month 3 -- 
 
222±60 1202±587 -- 
 
-- 
 
Month 6 -- 
 
218±83 999±467 -- 
 
-- 
 
Month 12 -- 
 
-- 
 
664±203 -- 
 
-- 
 
Month 24 -- 
 
-- 
 
593±208 -- 
 
-- 
 
Month 36 
Group I 
D adjusted on C0 
 
MMF 
D = 1g BID 
-- 
 
-- 
 
561±147 -- 
 
-- 
 
Month 1 -- 
 
-- 
 
809±160 
(p = 0.02) 
 
-- 
 
-- 
 
Month 3 -- 
 
-- 
 
644±178 
(p = 0.003) 
 
-- 
 
-- 
 
Month 6 -- 
 
-- 
 
665±169 
(p = 0.02) 
 
-- 
 
-- 
 
Month 12 -- 
 
-- 
 
616±221 
(ns) 
 
-- 
 
-- 
 
Month 24 -- 
 
-- 
 
464±234 
(ns) 
 
-- 
 
-- 
 
[22]
 22 adults 
Month 36 
Group II 
D adjusted on C2 
 
MMF 
D = 1.5 g BID 
EMIT 
-- 
 
-- 
 
451±164 
(ns) 
 
-- 
 
-- 
 
Exposure indices and PK parameters estimated using ITS method, Ciclo 1.3 software 
Absorption model based on a gamma distribution 
 
3 PK 
profiles/patient 
NEO 
D adjusted on C0 
AUC0-12/D: (h.µg/L)/mg 
cyclosporine 
C0/(100-mg D): 
(µg/L)/100 mg 
cyclosporine 
 
C2/D: (µg/L)/mg 
cyclosporine 
Cmax/D: (µg/L)/mg 
cyclosporine 
 
[31]
 14 patients 
de novo  
Week 1 (W1) 200±61.2 mg BID 
N/R FPIA 
TDx 
6,395±1,921 
AUC0-12/D = 34±13 
310±134.6 
C0/(100-mg D) 
= 156±70 
 
C2/D =  5.47±2.33 1,128±299 
Cmax/D = 6±2 
 
1.78±0.46 
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Month 3 (M3) 152±36.0 mg BID 
(vs W1, p<0.05) 
 
5,780±1,365 
AUC0-12/D = 37±8 
270±66.7 
C0/(100-mg D) 
= 163±34 
 
C2/D = 7.78±1.05 
(vs  W1, p < 0.05) 
 
1,380±371 
Cmax/D = 9±2 (vs  
W1, p < 0.05) 
1.63±0.40 
Year 1 (Y1) 164±40.1 mg BID 5,967±1,600 
AUC0-12/D = 38±10 
284±74.2 
C0 (100-mg D) 
= 163±48 
 
C2/D = 6.98±2.17 
(vs  W1, p < 0.05) 
 
1,216±410 
Cmax/D = 8±2 
 
1.22±0.41 
  Bayesian estimator (AUC0-12), best sampling times: C0, C1, C3 for the three periods 
BE vs Trap: bias% = -0.20 to +3.06, ns; RMSE% = 1.61 to 18.59% 
 
LUNG TRANSPLANTATION 
 Non-compartmental PK analysis; AUC0-12 Trap – Crossover study 
 
Capsules (1 week) 4,164±1,467 
 
-- 
 
-- 
 
613±242 
 
3.64±2.16 
 
NEO (1 week) 5,318±1,670 
 
-- 
 
-- 
 
931±458 
 
2.27±1.2 
(p = 0.23) 
 
[24]
 11 adults 
All CF 
SL 
> 6 months 
Medically stable 
 
 
Ratio NEO/Capsules 
N/R SRIA 
1.48 (p = 0.047) 
 
-- 
 
-- 
 
1.91 (p=0.045) 
 
-- 
 
Stable,  > 3 
months 
 
NEO, D (mean, range) = 
330 mg/day (150-50) 
D adjusted on C0: 
Non-compartmental PK analysis; AUC0-4 Trap; data are presented as mean (range) 
< 1 year 
n = 10 
 
M1-M3 
M4-M12 
  
350-400 
300-350 
 
3,700 (2,400-5,700) 
 
322 (248-492) 
 
1,180 (890-1,700) 
 
1,057 (303-2,337) 
 
-- 
 
1-3 years 
n = 8 
 
M13-M24  
M25-M36 
 
N/A 
250-300 
2,440 (1,030-3,600) 
 
222 (68-403) 780 (380-1,500) 929 (401-1,360) -- 
 
> 3 years 
n = 2 
 
> M36 150-200 N/R (990-2,050) 
 
N/R (134-143) N/R (270-670) N/R (333-804) -- 
 
[4]
 20 adults 
1 CF 
 
8 SL, 12 DL 
 
 
  
ATG (n = 6) 
MMF 
Steroids 
 
 
FPIA Mc  
r² C0-AUC0-4 = 0,64; r² C1-AUC0-4 = 0,44; r² C2-AUC0-4 = 0,85; r² C3-AUC0-4 = 0,67; 
r² C4-AUC0-4 = 0,64 
 
Non-compartmental PK analysis; AUC0-12 Trap 
 
[66]
 14 adults 
8 SL, 6 DL 
Stable NEO 
Steady-state 
N/R FPIA 
TDx 
5,183±1,835 
 
-- 
 
-- 
 
-- 
 
-- 
 
[6]
 12 adults 
53.2±7.4 years 
Weeks 1 & 2 NEO 
D adjusted on C0 = 300-
Daclizumab 
Prednisolone 
EMIT Non-compartmental PK analysis; AUC0-6 Trap (interpolation of C5 values) 
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3,443±1,451 361±118 
 
C1 = 481±231 
C2 = 682±314 
C3 = 715±347 
C4 = 658±271 
C6 = 571±260 
 
-- 
 
-- 
 
400 µg/L MMF 
r² C0-AUC0-6 = 0.31 (p = 0.001); r² C1-AUC0-6 = 0.73 (p < 0.001); r² C2-AUC0-6 = 0.88 (p < 0.001) 
r² C3-AUC0-6 = 0.89 (p < 0.001); r² C4-AUC0-6 = 0,84 (p < 0.001) ; r² C6-AUC0-6 = 0.54 (p = 0.001) 
 
HEART AND LUNG TRANSPLANTATION 
22 adults(3) D adjusted on C and 
clinical data 
 
Non-compartmental PK analysis 
11 CF 16.7±7.2 mg/kg/day 
 
[27]
 
11 non-CF 
Month 1 
8.2±1.9 mg/kg/day 
(p<0.01) 
 
AZA 
Prednisolone 
Pc 
NSRIA 
-- 
 
892±385 
CF vs non-CF: 
p = 0.58 
 
-- 
 
-- 
 
-- 
 
Non-compartmental PK analysis; AUC0-12 Trap; data are presented as median (range) 
Crossover study; 9 PK profiles for each cyclosporine formulation 
Stable 
10 months – 7.5 
years 
 
 
Switch from SAND to 
NEO 
D adjusted on C0 
mean±SD 
median (range) 
 
AUC/D: (h.µg/L)/mg 
cyclosporine 
Cmin/D: 
(µg/L)/mg 
cyclosporine 
 
 Cmax/D: (µg/L)/mg 
cyclosporine 
 
 NEO 
12.6±6.7 mg/kg/day 
450 mg/day (125-500) 
 
6,032 
(3,931-11,939) 
 
AUC0-12/D = 19,76 
(8,73-47,97) 
(CV = 51%) 
Cmin = 224  
(131-393) 
 
Cmin/D = 0.60 
(0.29-2.37) 
 
CV on C0: 
Intra-ind. 36% 
Inter-ind. 79% 
 
-- 1,360 
(729-2,360) 
 
Cmax/D = 4.53 
(1.62-7.69) 
 
1.0 
(1.0-4.0) 
[26]
 9 patients(4) 
All CF 
12-32 years 
 
 SAND 
8.5±3.6 mg/kg/day 
450 mg/day (125-1000)  
 
N/R SRIA 
4,179 
(3,377-7,833) 
 
AUC0-12/D = 9,29 
(4,92-29,61) 
(CV = 63%) 
Cmin = 172 
(85-443) 
 
Cmin/D = 0.43 
(0.17-3.22) 
 
CV on C0: 
-- 595 
(402-1,065) 
 
Cmax/D = 1.32 
(0.65-3.22) 
 
3.0 
(0.0-6.0) 
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Intra-ind.45% 
Inter-ind.130% 
 
NEO/SAND 
 
1.77 (0.56-4.35) 
 
1.58 (0.41-9.71) 
 
-- 2.17 (0.78-8.51) 
 
-- 
 
f/up: 12 months D adjusted on C0 (µg/L) =  
M1-M2: 300-400 
M3-M12: 200-300 
 
Non-compartmental PK analysis ; 289 PK profiles ; AUC0-6 Trap 
AUC0-6 CF vs non-CF: ns 
AUC0-6/D: CF < non-CF (p<0.001) 
 
Week 2 
 
3,582-6,822 
 
-- 
 
-- 
 
-- 
 
-- 
 
Week 4 
 
4,601-9,536 
 
-- 
 
-- 
 
-- 
 
-- 
 
Month 6 
 
2,955-6,478 
 
-- 
 
-- 
 
-- 
 
-- 
 
Month 9 
 
3,698-6,365 
 
-- 
 
-- 
 
-- 
 
-- 
 
 
NEO 
n = 28 
r² C0-AUC0-6 = 0.671; r² C2-AUC0-6 = 0.962; r² C6-AUC0-6 = 0.651 
 
Week 2 
 
735-5,526, p < 0.001 
 
-- 
 
-- 
 
Week 4 
 
1,256-8,199, p < 0.001 
 
 -- 
 
Month 6 
 
550-7,839, p < 0.001 
 
-- 
 
-- 
 
Month 9 
 
586-9,400, p < 0.001 
 
C0/D, NEO vs  
SAND: ns 
C2/D: NEO > 
SAND 
(significant) 
 
C6/D, NEO vs 
SAND: ns 
-- 
 
-- 
 
[28]
 50 adults 
9 CF 
 
19 SL, 9 DL 
22 HL 
 
 
 
 
SAND 
n = 22 
RATG 
AZA 
Prednisolone 
EMIT 
r² C0-AUC0-6 = 0.574; r² C2-AUC0-6 = 0.890; r² C6-AUC0-6 = 0.608 
 
20 patients Clinically stable 
Median: 
 
Non-compartmental PK analysis; AUC0-12 Trap 
 
AUC0-12 = 7,639±3,353 
to 8,388±2,859 
 
AUC0-4 = 3,876±2,876 
to 4,481±1,311 
 
267±96 to 
269±85 
 
1,219±802 to 
1,603±614 
1,664±824 to 
1,874±539 
 
1.40±0.39 to 
2.11±1.39 
(CF & non-
CF) 
[25]
 
10 CF 
6 DL, 4 HL 
21 months 
NEO 
D adjusted on C0 = 250-
350 µg/L 
N/R EMIT 
r² C2-AUC0-12 = 0.76; r² C3-AUC0-12 = 0.87 
r² C2-AUC0-4 = 0.90; r² AUC0-4 – C3 = 0.81 
 
 76 
AUC0-12 = 7,202±1,610 
to 7,447±1,870 
 
AUC0-4 = 4,081±1,135 
to 4,348±1,262 
 
AUC/D: CF < non-CF 
 
300±392 to 
346±112 
1,372±337 to 
1,545±530 
 
1,710±482 to 
1,862±572 
1.40±0.39 to 
2.11±1.39 
(CF & non-
CF) 
10 non-CF 
5 DL, 5 HL 
36.5 months 
r² C2-AUC0-12 = 0.66; r² C3-AUC0-12 = 0.82 
r² C2-AUC0-4 = 0.78; r² C3-AUC0-4 = 0.63 
 
PK parameters estimated using ITS method, CICLO 1.3; absorption described by a gamma distribution 
3 consecutive PK profiles (P)/patient within 5 days 
Parameters standardized to a 100-mg dose 
 
19 adults NEO 
D adjusted on C0 = 250-
350 µg/L 
AUC/D: (h.µg/L)/mg 
cyclosporine 
 
    
[32]
 
9 CF 
6 L, 3 HL 
Stable (no 
evidence of 
rejection within 
previous 3 
months) 
250±76 mg BID 
(175-425) 
N/R EMIT 
AUC0-12  
P1: 7.97±2.46  
P2: 8.33±3.25 
P3: 8.23±3.25 
CV%: 
Inter: 31.2; Intra: 10.6 
 
AUC0-12/D 
P1: 34.6±1.30 
P2: 35.6±13.0 
P3: 34.6±16.9 
CV%: 
Inter: 41.3; Intra: 10.6 
 
AUC0-4 
P1: 4.54±1.50 
P2: 4.63±1.31 
P3: 4.43±1.51 
CV%: 
Inter: 29.5; Intra: 9.5 
 
AUC0-4/D 
P1: 20.1±8.7  
P2: 20.1±7.0 
P3: 19.8±9.7 
CV%: 
Inter: 39.3; Intra: 9.7 
P1: 254±92  
P2: 258±87 
P3: 254±102 
 
CV%: 
Inter: 32.2 
Intra: 13.3 
P1: 1641±638  
P2: 1544±621 
P3: 1492±678 
 
CV%: 
Inter: 34.7 
Intra: 14.7 
P1: 1,952±732  
P2: 1,977±479 
P3: 1,966±708 
 
CV%: 
Inter: 29.0 
Intra: 11.1 
P1: 1.47±0.24  
P2: 1.33±0.34 
P3: 1.33±0.34 
 
CV%: 
Inter: 13.2 
Intra: 15.9 
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AUC0-12 (ns) 
P1: 7.44±1.79  
P2: 7.29±1.98 
P3: 7.11±1.66 
 
CV%: 
Inter: 23.8; Intra: 7.4 
 
AUC0-12/D (p < 0.005) 
P1: 41.6±7.7  
P2: 41.2±9.5 
P3: 40.6±8.5 
CV%: 
Inter: 19.7; Intra: 7.5 
 
AUC0-4 (ns) 
P1: 4.19±1.19  
P2: 4.30±1.27 
P3: 4.05±1.15 
CF vs non-CF :  
CV%: 
Inter: 27.3; Intra: 10.3 
 
AUC0-4/D (p < 0.005) 
P1: 23.4±3.9  
P2: 24.2±5.4 
P3: 22.7±4.9 
CV%: 
Inter: 18.2; Intra: 10.4 
 
P1: 346±112  
P2: 309±90 
P3: 300±92 
CF < non-CF 
 
CV% 
Inter: 28.9; 
Intra: 11.9 
 
C0/D: 
CF < non-CF 
(p<0.01) 
P1: 1545±530  
P2: 1500±426 
P3: 1372±337 
(ns) 
 
CV% 
Inter: 26.5 
Intra: 12.9 
 
C2/D: 
CF < non-CF 
(p<0.01) 
P1: 1,752±427  
P2: 1,959±576 
P3: 1,802±587 
 
 
CV%: 
Inter: 26.9 
Intra: 12.6 
P1: 1.62±0.31  
P2: 1.34±0.19 
P3: 1.55±0.46 
 
 
CV%: 
Inter: 17.6; 
Intra: 15.1 
10 non-CF  
5 L, 5 HL 
175±52 mg BID 
(125-275) 
p<0.025 
 
Bayesian estimator (AUC0-12), best sampling times: C0, C1, C3 
BE vs Trap on AUC0-12, AUC0-4, Cmax, tmax, C0: bias% < 5.3; RMSE%  < 15  
 
(1) Co-administration of enzyme inhibitors for minimum 2 years 
(2) In absence of ARE, dose decreased if SCr increased > 20% from baseline 
(3) Only adults except for 4 patients ≤ 16 years 
(4) 10 patients planned in the study: 9 L and 1 HL 
 
Legend: 
ARE: Acute rejection episode – ATG: Anti-thymocyte globulin – AZA: Azathioprine – BE: Bayesian estimator – C: concentration – CF: Cystic fibrosis – D: Dose – DILT: Diltiazem – DL: 
Double lung transplantation – f/up: follow-up – HL: Heart-lung transplantation – Intra-ind.: Intra-individual – Inter-ind.: Inter-individual – KETO: Ketoconazole – MMF: Mycophenolate mofetil 
– NEO: Neoral – N/R: not reported – SAND: Sandimmune – SCr: Serum creatinine – SL: Single lung transplantation – Trap: Trapezes. 
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Table II. Cyclosporine pharmacokinetic parameters in cohort studies 
Results are expressed as mean±SD, unless otherwise specified 
 
Ref Number of patients 
Post-transplant 
period Cyclosporine dose 
Co-
administered 
immunosup-
pressant 
Assay F, transfer k 
Vd/F 
(unless otherwise 
specified) 
CL/F 
(unless otherwise 
specified) 
t1/2 (h) 
(unless otherwise 
specified) 
HEART TRANSPLANTATION 
 NEO 
 
Non-compartmental PK analysis 
 
Week 1 
 
200±58 mg 
 
-- 
 
-- 
 
-- 
 
-- 
 
Week 2 
 
159±40 mg 
 
F = 57±9% -- 
 
-- 
 
-- 
 
[23]
 16 adults 
(out of 35 in the 
global trial) 
Week 52 
 
162±37 mg 
N/R FPIA 
TDx 
-- 
 
-- 
 
-- 
 
-- 
 
2-compartment open model: 1-order absorption, 1-order elimination 
 
NEO and SAND 
1.14±0.4 mg/kg TID 
 k: h-1 
 
V1, V2: L/kg 
 
CL: L.h-1/kg 
 
 
SAND F = 66±16% 
ka = 1.99±1.42  
k10 = 0.23±0.07 
k12 = 0.37±0.14 
k21 = 0.12±0.04 
 
V1 = 1.16±0.77  
V2 = 5.38±1.37  
CL = 0.22±0.04 
 
 
17.27±3.23 
NEO F = 75±19% (p<0.001) 
ka = 2.71±1.47 (p<0.05) 
k10 = 0.24±0.07 (ns) 
k12 = 0.41±0.16 (ns) 
k21 = 0.12±0.05 (ns) 
 
V1 = 1.00±0.43 (ns) 
V2 = 5.84±1.37 (ns) 
CL = 0.21±0.04 (ns) 
 
 
18.83±3.58 (ns) 
[29]
 20 male adults 
58.8±10.2 years 
Stable 
36.8±27.1 months 
After IV infusion 
N/R 
No 
corticosteroids 
FPIA 
TDx 
 V1 = 1.86±0.72 (ns) 
V2 = 5.58±1.57 (ns) 
 
CL = 0.20±0.04 (ns) 17.68±4.29 (ns) 
NEO + SAND(1) 
 
Non-compartmental PK analysis 
 
47 adults 
 
Stable 
 D 
(mg/kg/day) 
N/R EMIT 
t1/2 abs: h 
 
 CL/F: L/h  
SAND t1/2 abs = 2.72±1.45 -- 46.7±21.1 -- 
[19]
 
54±12 years 49±19 months None 
n = 11 
3.90±1.03  
NEO t1/2 abs = 0.51±0.28 
(p < 0.001) 
-- 31.8±9.5 
(p<0.05) 
-- 
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SAND t1/2 abs = 1.44±1.16 -- 36.7±14.1 -- 52±8 years 61±15 months DILT 
n = 11 
2.98±0.64  
NEO t1/2 abs = 0.58±0.62 
(p < 0.05) 
 
-- 26.8±9.0 
(p<0.05) 
 
SAND t1/2 abs = 1.65±1.22 -- 9.7±4.3 -- 52±9 years 32±15 months KETO 
n = 13 
0.79±0.27  
NEO t1/2 abs = 0.67±0.34 
(p < 0.01) 
 
-- 9.1±3.8 
(ns) 
-- 
SAND t1/2 abs = 1.81±1.09 -- 10.1±6.4 -- 47±12 years 28±5 months DILT + 
KETO 
n = 12 
0.90±0.54  
NEO t1/2 abs = 1.07±0.57 
(p < 0.05) 
 
-- 9.1±4.9 
(ns) 
-- 
NEO + SAND(1) 
 
 
2-compartment PK analysis using ABBOTTBASE pharmacokinetic system (PKS); Structural model and 
PK parameters selected from a study in stable heart transplant recipients by Baraldo et al[29] 
 
Stable (months) 
 D 
(mg/kg/day) 
k: h-1 
 
V1: L/kg 
 
CL: L.h-1/kg 
 
 
49±19 None  
n = 11 
 
3.90±1.03 
61±15 DILT 
n = 11 
 
2.98±0.64 
F = 75% (fixed) 
ka = 2.7 h-1 (fixed) 
k12 = 0.41 h-1 (CV = 39%) 
k21 = 0.12 h-1 (CV = 42%) 
 
V1 = 1 
(CV = 43%) 
 
CL = 0.21 
(CV = 19%) 
 
-- 
 
32±15 KETO 
n = 14 
 
0.79±0.27 
[30]
 47 adults 
28±5 DILT + 
KETO 
n = 11 
 
0.90±0.54 
N/R EMIT 
With no covariate:  
• r² = 0.871 (p<0.001); bias% = 11.7; RMSE% = 13.4 
• Underestimation of AUC 
With “disposition factor”: (0.5 for CL if K or K+D; 0.76 for Vd if K+D) 
• r² = 0.698 (p<0.001); bias% = 2.2; RMSE% = 16.6 
• Overestimation of AUC in patients on diltiazem 
Bayesian model: best sampling strategy: C0, C1, C2 
 
Non-compartmental PK analysis using non linear regression program WinNonLin 
 
 Vd/F: mL/kg 
 
CL/F: mL.min-1/kg 
 
 
[21]
 15 adults 
48±10 years 
Clinically stable 
5.2±4.4 years 
NEO 
2.7±0.7 mg/kg/day 
D adjusted on Cav = 200-
300 µg/L 
 
ATG 
AZA 
Prednisolone 
FPIA 
TDx 
-- 
 
2,421±945 
 
5.7±1.7 
 
5.0±1.3 
 
Population exposure indices and PK parameters estimated using ITS method, CICLO 1.3 
Absorption model based on a gamma distribution 
 
[31]
 14 patients 
de novo 
3 PK profiles/patient NEO 
D adjusted on C0 
N/R FPIA 
TDx 
MAT, SDAT: h A, B: L-1   λ1, λ2: h-1 
t1/2(λ1), t1/2(λ2): h 
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Week 1 200±61.2 mg BID   MAT = 1.25±0.40 
SDAT = 0.48±0.20 
A = 0.307±0.167 
B = 0.637±0.267 
 
-- 
 
λ1 = 5.78±3.32 
λ2 = 0.47±0.17 
t1/2(λ1) = 0.26±0.40 
t1/2(λ2) = 1.90±1.09 
 
Mont 3 152±36.0 mg BID 
(vs W1, p<0.05) 
 
  MAT = 1.27±0.40 
SDAT = 0.45±0.19 
A = 0.771±0.630 
B = 0.799±0.299 
-- 
 
λ1 = 3.18±2.19 
λ2 = 0.52±0.13 
t1/2(λ1) = 0.28±0.13 
t1/2(λ2) = 1.47±0.63 
 
Year 1 164±40.1 mg BID   MAT = 1.59±0.47 
SDAT = 0.66±0.32 
A = 0.690±0.445 
B = 0.783±0.229 
-- 
 
λ1 = 2.595±1.368 
(vs W1, p<0.05) 
λ2 = 0.529±0.097 
t1/2(λ1) = 0.35±0.22 
t1/2(λ2) = 1.36±0.27 
 
LUNG TRANSPLANTATION 
[66]
 14 adults 
8 SL, 6 DL 
 
Stable NEO 
Steady-state 
 
N/R FPIA 
TDx 
 
-- 
 
-- 
 
-- 
 
9.52±5.71 
HEART AND LUNG TRANSPLANTATION 
PK parameters estimated using a Bayesian program for parameter estimation[48] 
 
22 adults(2) D adjusted on C and 
clinical data 
  Vd/F: L/kg 
 
CL/F: mL.min-1/kg 
 
 
11 CF 16.7±7.2 mg/kg/day 
 
-- 
 
7.2±5.3 
 
3.5±1.3 
 
-- 
 
[27]
 
11 non-CF 
Month 1 
8.2±1.9 mg/kg/day 
(p<0.01) 
 
AZA + 
prednisolone 
Pc 
NSRIA 
-- 
 
4.3±2.2 (ns)  
 
1.7±0.5 (p=0.003) 
 
-- 
 
PK parameters estimated using ITS method, CICLO 1.3; absorption described by a gamma distribution 
3 consecutive PK profiles (P)/patient within 5 days 
Parameters standardized to a 100-mg dose 
 
19 adults Stable (no evidence 
of rejection within 
previous 3 months) 
NEO 
D adjusted on C0 = 250-
350 µg/L 
MAT, SDAT: h V1/F: L 
F.A, F.B: L-1 
 
CL/F: L/h λ1, λ2: h-1 
[32]
 
9 CF 
6 L, 3 HL 
 250±76 mg BID 
(175-425) 
N/R EMIT 
F set to 1 
MAT = 1.00±0.21 
SDAT = 0.30±0.09 
 
V1/F = 88±41 
F.A = 0.72±0.70  
F.B = 0.68±0.34 
 
50±20 λ1 = 4.14±3.01 
λ2 = 0.36±0.11 
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10 non-CF  
5 L, 5 HL 
 175±52 mg BID 
(125-275) 
p<0.025 
 
F set to 1 
MAT = 1.13±0.28 (ns) 
SDAT = 0.37±0.15 (ns) 
V1/F = 74±44 (ns) 
F.A = 1.13±1.36 (ns) 
F.B = 0.77±0.30 (ns) 
 
50±14 (ns) λ1 = 2.16±1.75 (p < 0.01) 
λ2 = 0.49±0.12 (p < 0.01) 
 
(1) Co-administration of enzyme inhibitors for minimum 2 years 
(2) Only adults except for 4 patients ≤ 16 years 
 
Legend: 
ATG: Anti-thymocyte globulin – AZA: Azathioprine – C: concentration – CF: Cystic fibrosis – D: Dose – DILT: Diltiazem – DL: Double lung transplantation – F.A and F.B: estimated 
intravenous coefficients – f/up: follow-up – HL: Heart-lung transplantation – KETO: Ketoconazole – λ1, λ2: disposition rate constants – MAT: Mean absorption time – MMF: Mycophenolate 
mofetil – NEO: Neoral – N/R: not reported – SAND: Sandimmune – SDAT: Standard deviation of absorption time – SL: Single lung transplantation – V1: volume of central compartment – V2: 
volume of peripheral compartment. 
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Table III. Cyclosporine population pharmacokinetic studies 
 
Ref Study Subjects PK parameters, exposure indices ISV (%) RRV Covariates Comments 
HEART TRANSPLANTATION 
[33]
 Retrospective data from 
patients who underwent 
routine cyclosporine PK 
monitoring (HPLC-UV) 
 
NONMEM 
ADVAN2 TRANS2 
One-compartment PK model 
First order absorption and 
elimination 
 
 
2 groups of patients: 
• Index 
n = 36; 51 years (18-63) 
• Predictive performance 
n = 33; 50 years (25-65) 
 
Oral SAND for at least 3 
months post-transplantation 
 
+ AZA + prednisone 
k = CL/V 
Fixed ka = 0.3 h-1 
Fixed V = 4 x WT 
 
Initial analyses, F = 0.3 – then adjusted: 
F = 0.2 + 10 x POD-7│/[(POD + 10) x 60] 
 
Cl = 0.281 x WT x (0.629 x DIL + 1 – DIL) 
CL: 20.2 Add. 77.4 µg/L POD 
Diltiazem 
Over-prediction of concentrations (from 
150 to 400 µg/L), especially within the first 
two weeks post-transplantation 
 
Predictive performance on concentrations: 
• When F = 0.3: 
ME = 42.1 µg/L [35.6-48.6] 
RMSE = 102.2 µg/L [61.0-143.4] 
• When F adjusted: 
ME = 21.3 µg/L [15.0-27.6] 
RMSE = 92.5 µg/L [54.0-131.0] 
 
HEART AND LUNG TRANSPLANTATION 
[34]
 Retrospective PK analysis of 
study performed by Trull et 
al. TDM 1999 (NEO vs 
SAND) – EMIT 
 
NONMEM 
ADVAN2 TRANS2 
One-compartment PK model 
First order absorption and 
elimination 
 
48 adults (8 CF)  
18 SL, 9 DL, 21 HL 
NEO, n = 27 – SAND, n = 21 
(D = 417±218 mg/day) 
 
+ ATG, AZA, prednisolone  
 
Follow-up: Week 1 to week 52 
 
 
 
1,004 samples collected 
 
CL/F (L/h) = 22.1 (19.5-24.7) 
 
Vd/F (L) = 147 (130-164) 
CL/F: 17.1 Prop. 44.0% 
Add. 76.4 µg/L 
On CL/F: 
Itraconazole, 
CF, WT 
 
On F: 
SAND, time 
post-
transplantation 
 
 
Comments of Saint-Marcoux[37] 
• Underestimation of C
 2 values 
(95%CI = +5 to +115 µg/L) 
• Overestimation of C6 values 
(95%CI = -127 to -69 µg/L) 
• Final model not validated, robustness not 
tested 
• ISV of Vd/F not estimated 
• Influence of individual factors tested 
only against CL/F 
 
 
Legend 
Add.: Additive – AZA: Azathioprine – CF: Cystic fibrosis – ISV: Inter-subject variability – ME: Mean error – NEO: Neoral – POD: post-operative day – Prop.: Proportional – RMSE: Root 
mean square error – RRV: Residual random variability – SAND: Sandimmune – WT: Weight. 
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Table IV. Pharmacokinetic methods for therapeutic drug monitoring of cyclosporine after thoracic 
transplantation (derived from Fernandez de Gatta et al. Clin Pharmacokinet 2002 and Dumont RJ et al. Clin 
Pharmacokinet 2000).[43,53] 
 
Method Advantages Limitations 
Single concentration 
C0 • Standard method: simple and practical 
(inpatients and outpatients) 
• Does not reflect absorption, drug exposure, or 
elimination 
• Does not give information on other PK 
parameters 
• Prediction of clinical outcome: conflicting data 
C2 • Surrogate marker of absorption (Neoral®) 
• Higher sensitivity as indicator of AUC and 
clinical effect than C0 
• Rigid collection time 
• No distinction between poor absorbers and 
slow absorbers 
• Prediction of clinical outcome: conflicting data 
Other time points 
(C3, C4, C6) 
• C0 better correlated with AUC • Rigid collection time 
• No distinction between poor absorbers and 
slow absorbers 
• Hardly any data on their relationship with 
clinical outcomes 
AUC 
Full • The best indicator of drug exposure, 
absorption profile and clinical outcome 
• Characterization of abnormal absorption 
patterns on concentration-time profile 
• Allows the calculation of oral 
pharmacokinetic parameters 
• Reduces analytical variability 
• Need for multiple blood samples: impractical 
for routine clinical use 
• Expensive 
• Inconvenient for patients (outpatients ++) 
• Optimal targets to be defined for most 
immunosuppressants 
Abbreviated 
(ex: 4 h post-dose) 
• Good predictor of absorption profile and 
full AUC 
• Further studies required  
• Optimal targets to be defined 
Sparse sampling 
strategies 
• Balance between precision and practicality 
• Acceptable predictor of AUC 
• Multi-linear regression not based on a PK 
model. Equations result from correlations and 
cross-correlations between sampling times and 
AUC 
• Rigid collection times 
• Analytical method- and centre-specific, often 
not validated in independent populations  
Bayesian forecasting 
 
• Flexibility in sampling times 
• Limited number of samples needed 
• Can easily be integrated in clinical practice 
• Simultaneous estimation of individual PK 
parameters and exposure indices 
• Identification of absorption or elimination 
problems (e.g., gastroparesis) 
• Only a few studies in small populations 
• Predictive performance not tested 
• Requires sophisticated PK models and software 
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Table V. Summary of selected sparse sampling strategies for cyclosporine monitoring after Neoral® 
administration 
 
Ref Patient group 
Number of 
patients 
AUC 
interval (h) Equation r² %PE 
[21]
 
HTx 
Stable 15 12 AUC0-12 = 531 + 0.64*C1 + 8.12*C4 0.973 N/R 
HTx   
Week 1 0.951 -8.68 to +6.24 
Month 3 0.918 -7.3 to +8.58 
[215]
 
Year 1 
20 
Validation: 
17[215] then 14[31] 
12 AUC0-12 = 330.841 + 2.235*C2 + 7.970*C6 
0.949 -5.33 to +6.49 
[6]
 
LTx 
< Week 2 12 N/R AUC0-6 = 0.496*C2 + 0.517*C3 + 776.9 0.94 NR 
AUC0-τ = 185.62 + 1.75*C1 + 4.91*C3 0.904 -6.96 to +13.05 [66]
 
LTx 
Stable 
8 
Validation: 6 τ, N/R AUC0-τ = 53.54 – 5.47*C0 + 2.11*C1 + 6.44*C3 0.908 -10.31 to 22.43 
 
Legend 
HTx: Heart transplantation – LTx: Lung transplantation – N/R: not reported – PE: Prediction error. 
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Table VI. Cyclosporine exposure – efficacy studies 
Results are presented as mean±SD, unless otherwise specified 
 
Ref Number of patients Immonsuppressants 
Sampling 
periods Analytical method, exposure Event (number of episodes) Comments 
HEART TRANSPLANTATION 
HPLC-UV 
Calculation of AUC: 
AUC0-12: MAP-BE[1] or sparse-sample algorithms[2-4] 
AUC0-4: sparse-sample algorithm[5] 
 
Routine surveillance EMB (ISHLT) 
C0 
C2 
AUC0-12 
AUC0-4 
215±68 µg/L 
949±204 µg/L 
4,875±956 to 5,897±1,457 h.µg/L 
2958±579 h.µg/L 
 
Rejection (≥ grade 2) 
n = 3 patients; all had C2 < 1250 µg/L 
[54]
 31 adults 
OHT 
52±10 years 
 
 
Cyclosporine D adjusted 
on C0: 
< M6 200-275 µg/L 
M6-M12  150-250 µg/L 
> M12 100-200 µg/L 
 
D = 194±57 mg BID 
(4.8±1.4 mg/kg BID) 
244±178 days 
Median (range): 
223 (22-582) 
C0 
C2 
AUC0-12 
AUC0-4 
 
242±62 µg/L (ns) 
1,359±474 µg/L (ns) 
6,723±2,119 to 7,445±1,871 h.µg/L (ns) 
3970±1150 h.µg/L vs. 2958±579 (ns) 
 
No rejection (< grade 2) 
Trend for a significant relationship 
between C2 values and the incidence 
of rejection. 
 
Number of patients experiencing 
rejection too small: 
• To reach statistical significance 
based on C0 or C2 thresholds; 
• To perform ROC curve. 
FPIA-AxSYM 
4 AUC/patient = 240 AUC, calculated from C0, C2, 
C4, C6 
 
At least one ARE grade 3A (ISHLT) in 20/60 
patients 
 
Constant absorbers,  AUC CV < 15% (n = 21) 
AUC = 6,521 h.µg/L 
Acute rejection 
n = 4 patients (19%) 
[93]
 60 adults Cyclosporine D adjusted 
on C0: 
Y1 300-400 µg/L 
Y2  200-250 µg/L 
Y3  150-180 µg/L 
> Y3  > 150 µg/L 
 
ATG 
Corticosteroids until M12 
AZA or MMF (n = 10) 
 
3-60 months 
Inconstant absorbers, AUC CV > 15% (n = 39) 
AUC = 6,751 h.µg/L (ns) 
Acute rejection 
n = 16 patients (41%), p < 0.05 
 
No difference between “rejection” 
and “no rejection” groups on mean 
C2. 
 
Variability on absorption = risk 
factor for rejection. 
[55]
 10 children out 
of 50 in the 
global trial 
SAND or NEO, D 
adjusted on C0 (and blood 
cell count): 
≤ M1 200-300 µg/L 
> M1  150-200 µg/L 
(D: median, range) 
 
ATG 
De novo 
≥ 2 months 
HPLC/MS Rejection: IMEG, echocardiography, TDE, 
BPAR (≥ grade 2 – ISHLT) 
 
ROC analysis: best sensitivity and specificity 
for C2 < 600 µg/L – Se = 100%, Sp = 83% 
• C2 < 600: rejection 14, no rejection 0 
• C2 > 600: rejection 6, no rejection 30 
Prospective blinded analysis 
 
Small number of patients with 
rejection: study not powerful 
enough? 
 
Impossible to define different C2 
target levels in relation to adjunctive 
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AZA or MMF 
 
C2 345±163 µg/L < Y1: 456±164 µg/L 
Y1-Y2: 428±196 µg/L 
Y2-Y5: 244±147 µg/L 
8.1±6.3 years D = 8.6 mg/kg (4-21)  
 
2.2±1.6 years 
Cmin 
Cmax 
AUC0-12 
AUC0-4 
 
213±29 µg/L 
467±38 µg/L 
3,615±508 h.µg/L 
1,498±132 h.µg/L 
 
Rejection (BPAR: n = 14) 
n = 5 patients 
C0: ns 
C2 = 952±310 µg/L 
(p<0.001) 
 
< Y1: 1,134±356µg/L 
Y1-Y2: 996±266 µg/L 
Y2-Y5: 859±274 µg/L 
8.9±5.6 years D = 7.9 mg/kg (3.7-24), ns 2.4±1.8 years 
Cmin 
Cmax 
AUC0-12 
AUC0-4 
219±32 µg/L (ns) 
966±231 µg/L (p<0.001) 
5,530±889 h.µg/L (p < 0.001) 
2,713±536 h.µg/L (p<0.001) 
No rejection 
n = 5 patients 
immunosuppressants 
 
Impossible to assess chronic 
rejection 
HEART AND LUNG TRANSPLANTATION 
SRIA 
 
[80]
 31 adults 
(12 CF) 
 
HL 
 
Cyclosporine median D 
(mg/kg/day) 
• starting: 2.7 
• maintenance: 10.3 
(CF patients: TID) 
 
ATG, AZA, Prednisone 
 
< 3 months 
Observed C0 (median): < W3: 347.5 µg/L 
W3-M3: 445.5 µg/L 
Treated ARE (66% BPAR) 
 
If C0 CV > 40%: 
RR = 1.51 (95%CI = 1.01-2.27) 
 
 
Variability on C0: risk factor for 
subsequent rejection; no such 
relationship for C0 itself 
EMIT 
289 PK profiles 
 
 
C0 = 394 µg/L 
 
Patients with at least one treated ARE 
 
[28]
 50 patients 
(9 CF) 
 
19 SL, 9 DL, 22 
HL 
 
NEO (n = 28) vs SAND (n 
= 22), D adjusted on C0: 
M1-M2 300-400 µg/L 
M3-M12 200-300 µg/L 
 
ATG, AZA, prednisolone 
 
12 months 
C0 = 449 µg/L (p = 0.042) 
 
Patients with no ARE 
Study designed to compare the PK of 
NEO vs SAND, not to establish a 
relationship between drug exposure 
and efficacy 
 
Relationship C2, C6 or AUC0-6 – 
incidence of treated AR: ns 
 
[20]
 48 patients 
 
SL, DL, HL 
NEO (n = 27) vs SAND (n 
= 21), D adjusted on C0: 
M1-M2 300-400 µg/L 
M3-M12 200-300 µg/L 
(CF patients: TID) 
 
Weeks 1, 2, 3, 4, 
13, 26, 39, 52 
EMIT 
341 AUC0-6  
 
3 groups based on C2 (µg/L) at M1: low, < 1000 (18); 
intermediate, 1000-1500 (16); high >1500 (14) 
 
 
ARE frequency similar in the 3 C2 groups 
AR-free periods: 
Intermediate C2 (226 days) >> low C2 (197 
days) and high C2 (191 days) (p<0.0001) 
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C2 
AUC0-6 
875±546 µg/L 
4,036±1,904 h.µg/L 
 
Median number of ARE > 2 
C2 
AUC0-6 
1,114±633 (p = 0.01) 
4,870±2,182 (p = 0.01) 
ATG, AZA, prednisolone 
C0 and C6: ns 
 
Median number of ARE ≤ 2 
 
Legend 
ARE: Acute rejection episode – ATG: Antithymocyte globulin – AZA: Azathioprine – BPAR: Biopsy-proven acute rejection – CF: Cystic fibrosis – D: Dose – DL: Double lung transplantation – 
EMB: Endomyocardial biopsy – HL: Heart-lung transplantation – IMEG: Intramyocardial electrocardiogram – MAP-BE: Maximum a posteriori Bayesian estimation – MMF: mycophenolate 
mofetil – NEO: Neoral – OHT: Orthotopic heart transplantation – SAND: Sandimmune – SL: Single lung transplantation – TDE: Tissue Doppler echocardiography. 
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Table VII. Cyclosporine exposure – toxicity studies 
Results are presented as mean±SD, unless otherwise specified 
 
Ref Number of patients Immunosuppressants 
Sampling 
periods Analytical method, exposure Event (number of episodes) Comments 
HEART TRANSPLANTATION 
HPLC-UV 
Calculation of AUC: 
AUC0-12: MAP-BE[1] or sparse-sample algorithms[2-4] 
AUC0-4: sparse-sample algorithm[5] 
Rejection vs no rejection: 
 
C0 
C2 
AUC0-12 
AUC0-4 
215±68 µg/L 
949±204 µg/L 
4,875±956 to 5,897±1,457 h.µg/L 
2958±579 h.µg/L 
 
[54]
 31 adults 
OHT 
52±10 years 
 
 
Cyclosporine D adjusted 
on C0: 
< M6 200-275 µg/L 
M6-M12  150-250 µg/L 
> M12 100-200 µg/L 
 
D = 194±57 mg BID 
(4.8±1.4 mg/kg BID) 
244±178 days 
Median (range): 
223 (22-582) 
C0 
C2 
AUC0-12 
AUC0-4 
 
242±62 µg/L (ns) 
1,359±474 µg/L (ns) 
6,723±2,119 to 7,445±1,871 h.µg/L (ns) 
3970±1150 h.µg/L vs. 2958±579 (ns) 
 
Impairment of renal function: 
• If SCr > 2.5 mg/dL 
• n = 5 patients 
 
No relationship between cyclosporine C0 or C2 and 
impairment of renal function. 
 
FPIA-AxSYM 
4 AUC/patient = 240 AUC, calculated from C0, C2, 
C4, C6 
 
Mean SCr rise of 50% from baseline in both groups (ns) 
 
% patients:  
Constant absorbers,  AUC CV < 15% (n = 21) 
AUC = 6,521 h.µg/L 
Hypertension 
Neurological events 
Gum hyperplasia 
New onset hyperlipidemia treated with statins 
 
48% 
24% 
14% 
48% 
 
[93]
 60 adults Cyclosporine D adjusted 
on C0: 
Y1 300-400 µg/L 
Y2  200-250 µg/L 
Y3  150-180 µg/L 
> Y3  > 150 µg/L 
 
ATG 
Corticosteroids until M12 
AZA or MMF (n = 10) 
 
3-60 months 
Inconstant absorbers, AUC CV > 15% (n = 39) 
AUC = 6,751 h.µg/L (ns) 
Hypertension 
Neurological events 
Gum hyperplasia 
New onset hyperlipidemia treated with statins 
 
56% 
41% 
18% 
51% 
 
 
LUNG TRANSPLANTATION 
EMIT 
 
 
[79]
 15 adults (0 CF) 
3 SL, 12 DL 
Cyclosporine D adjusted 
on C0  = 200-300 µg/L 
 
42-359 days 
 
C0 = 289±93 µg/L CMV infection or disease 
• C0 and C2: same 
sensitivity (84.6%) 
• Better specificity of C0 
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C2 = 1,583±421 µg/L 
 
n = 9 patients (13 episodes) AZA, methylprednisolone 
 
C0 = 222±82 µg/L (p<0.05) 
C2 = 1,074±423 µg/L (p<0.05) 
 
No CMV infection or disease 
(66.7%) vs C2 (57.1%) 
 
HEART AND LUNG TRANSPLANTATION 
[77]
 32 patients 
24 HTx, 28 HL 
Cyclosporine D adjusted 
on C0 (target: N/R) 
 
ATG, AZA, steroids 
< 3 months SRIA 
First 5 postoperative days, 88% C0 < 200 µg/L 
Renal function (624 complete sets of dose, C0 and SCr) 
No correlation between dose and change in renal 
function 
Correlation between log C0 and 1/SCr: 
• Simultaneous measurements: 
r² = -0.33 (95%CI = -0.52;-0.10) 
• In the subsequent 5-day period: 
r²=-0.69 (95%CI = -0.69;-0.15) 
 
Exclusion of all data up to 
the first nadir in plasma 
creatinine following 
transplantation (mean 
time: 6.7±3.6 days) 
EMIT 
289 PK profiles 
 
Patients with at least one treated ARE 
C0 = 394 µg/L 
 
[28]
 50 patients 
(9 CF) 
 
19 SL, 9 DL, 22 
HL 
 
NEO (n = 28) vs SAND (n 
= 22), D adjusted on C0: 
M1-M2 300-400 µg/L 
M3-M12 200-300 µg/L 
 
ATG, AZA, prednisolone 
 
12 months 
Patients with no ARE 
C0 = 449 µg/L (p = 0.042) 
 
Renal function: 
None of C0, C2, C6 or AUC0-6 correlated with any of the 
markers of cyclosporine nephrotoxicity 
Study designed to 
compare the PK of NEO 
vs SAND, not to establish 
a relationship between 
drug exposure and 
efficacy 
 
EMIT 
341 AUC0-6  
 
3 groups based on C2 (µg/L) at M1: low, < 1000 (18); 
intermediate, 1000-1500 (16); high >1500 (14) 
 
Median number of ARE > 2 
C2 = 875±546 µg/L 
AUC0-6 = 4,036±1,904 h.µg/L  
 
[20]
 48 patients 
 
SL, DL, HL 
NEO (n = 27) vs SAND (n 
= 21), D adjusted on C0: 
M1-M2 300-400 µg/L 
M3-M12 200-300 µg/L 
(CF patients: TID) 
 
ATG, AZA, prednisolone 
Weeks 1, 2, 3, 4, 
13, 26, 39, 52 
Median number of ARE ≤ 2 
C2 = 1,114±633 (p = 0.01) 
AUC0-6 = 4,870±2,182 (p = 0.01) 
C0 and C6: ns 
 
Infections (71 episodes): 
• Patients with infection episodes > 2 vs ≤ 2: C0, C2, 
C6, AUC ns 
• Number of infection episodes ns among patients 
stratified on C2 
 
Renal function (1,693 observations): 
• Difference between groups: ns 
 
Blood pressure (1,891 measurements): 
• Linear trend  BP – C2 strata (p < 0.001) 
• No correlation between BP and exposure indices 
 
 
Legend: 
ARE: Acute rejection episode – ATG: Antithymocyte globulin – AZA: Azathioprine – BP: Blood pressure – CF: Cystic fibrosis – D: Dose – DL: Double lung transplantation – HL: Heart-lung 
transplantation – HTx: Heart transplantation – MAP-BE: Maximum a posteriori Bayesian estimation – MMF: Mycophenolate mofetil – NEO: Neoral – N/R: not reported – OHT: Orthotopic 
heart transplantation – SAND: Sandimmune – SCr: Serum creatinine – SL: Single lung transplantation. 
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Table VIII. Cyclosporine TDM or concentration-controlled studies 
 
Ref Study Patients Time post-transplant Immunosuppressants 
Analytical method, exposure 
index and target Evaluated endpoints and results Comments 
HEART TRANSPLANTATION 
20 adults < 1 year 
 
EMIT BPAR: ISHLT classification 
Group I 
53±8 years 
n = 10 
11±2 months D adjusted on 
C0 = 150-250 µg/L 
Efficacy: 
• BPAR: 50% (grade I: 70/172 biopsies: 40.7%) 
Others: 
• Cyclosporine D at end of f/up : 3.5±1 mg/kg/day 
• Mean cyclosporine D adjustment/patient: 1/month 
• Total cyclosporine cost: 5,106±1,045 CDN $ 
 
[59]
 Prospective study 
Consecutive patients, 
randomized in 2 
groups 
Group II 
58±4 years 
n = 10 
10±3 months 
SAND 
 
Thymoglobuline 
AZA 
Prednisone 
D adjusted on 
C6 = 150-250 µg/L 
Efficacy: 
• BPAR: 50% (grade I: 47/111 biopsies: 29.7%, p=0.04) 
• Left VEF and graft atherosclerosis similar in both groups 
Toxicity: 
• Renal function similar in both groups (SCr, GFR) 
Others: 
• Cyclosporine D at end of f/up : 2.6±0.6 mg/kg/day 
(p=0.002) 
• Mean cyclosporine D adjustment/patient: 1/month 
• Total cyclosporine cost: 3,589±1,116 CDN $ (p=0.005) 
 
 
30 adults 
 
 
EMIT 
 
Routine biopsies and after each dose reduction 
No instance of BPAR ≥ grade 2 (ISHLT classification) 
 
[56]
 Prospective study 
Randomization to C0 
or C2 monitoring 
Follow-up: 6 months 
 
Group I 
59±7 years 
n = 15 
Stable, ≥ 1 year 
No BPAR in 
previous 6 months 
SCr < 250 µmol/L 
NEO 
(Week 0: conversion 
from SAND to NEO) 
 
Thymoglobuline 
AZA 
Prednisone 
• Week 2: D adjusted on 
C0 = 100-200 µg/L 
• ≥ Week 6: D adjusted on 
C2 = 300-600 µg/L 
D increase in 8 patients after the first visit 
D reduction in all patients after the second visit 
• C0 = 147±39 µg/L 
• C1 = 762±385 µg/L 
• C2 = 835±320 µg/L 
• C4 = 379±138 µg/L 
• AUC0-4 (Trap) = 2,467±804 h.µg/L 
 
No comparison of 
outcome between two 
groups based on 
monitored exposure 
index: this study 
rather looked for a 
correlation between a 
single time-point 
concentration and 
AUC0-4 and AUC0-12 
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Group II 
56±9 years 
n = 15 
• Week 2: D adjusted on 
C2 = 200-400 µg/L 
• ≥ Week 6: D adjusted on 
C2 = 300-600 µg/L 
D reduction after the first visit 
• C0 = 102±35 µg/L (p = 0.0001) 
• C1 = 621±402 µg/L (ns) 
• C2 = 555±271 µg/L (p = 0.01) 
• C4 = 218±83 µg/L (p = 0.001) 
• AUC0-4 (Trap) = 1,723±808 h.µg/L (p = 0.02) 
 
 
NEO 
 
ATG (most patients) 
Cyclosporine 
monotherapy (7.9%) 
or + AZA + prednisone 
(40.3%) 
or + AZA (36%) 
or + prednisone (15.8%)  
 
EMIT Primary endpoint: clinical benefit = composite measure 
• Positive cardiac outcomes (no mortality, no acute 
rejection, no decrease in LVEF > 10%), and 
• Positive renal outcomes (absence of increase in SCr > 
10%) 
Phase 1 (10±4 months) 
 
D adjusted on 
C2 = 300-600 µg/L 
 
Initial 
D = 2.6±0.8 mg/kg/day 
 
C0 = 136±42 µg/L 
C2 = 776±316 µg/L 
Final 
D = 1.9±0.6 mg/kg/day 
 
C0 = 87±36 µg/L 
C2 = 422±153 µg/L 
Primary endpoint: 
• Clinical benefit: 69.3% 
Secondary endpoints: 
• Incidence of acute rejection: 0.87% 
• Incidence of mortality: 7.9% 
• Incidence of increase in SCr > 10%: 18.1% 
Phase 2 (10±2 months) 
 
Dose adjusted on 
C0 = 100-200 µg/L 
 
Initial 
D = 1.9±0.6 mg/kg/day 
 
 
C0 = 86±35 µg/L 
C2 = 428±159 µg/L 
 
[10]
 Longitudinal follow-
up of all patients 
followed at heart 
transplantation clinic 
2-phase study 
114 adults 
57±9 years 
Stable, ≥ 1 year 
Final 
D = 2.4±0.6 mg/kg/day 
 
 
C0 = 134±46 µg/L 
C2 = 592±156 µg/L 
 
Primary endpoint: 
• Clinical benefit: 43.3% 
RR = 1.6 (p = 10-5) 
Secondary endpoints: 
• Incidence of acute rejection: 0.96% (ns) 
• Incidence of mortality: 9.6% (ns) 
• Incidence of increase in SCr > 10%: 48.9% 
RR = 0.37 (p<10-4) 
• LVEF: stable across both time periods 
Limitation: sequential 
longitudinal 
assessment of two 
strategies for NEO D 
adjustment in the 
same patients 
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 NEO 
In absence of ARE, D 
decreased if SCr 
increased > 20% from 
baseline 
 
ATG, MMF, prednisone 
 
EMIT Efficacy 
• Routine EMB: ARE ≥ grade 3A (ISHLT classification) 
• Echocardiography 
• Coronary angiography 
Toxicity 
• Renal function: SCr, ClCr (Cockroft-Gault), GFR 
 
13 adults 
54±9 years 
Group I 
(MMF D: 1 g BID) 
• < M9: D adjusted on C0 
 
< M3: 200-300 µg/L 
M4-M6: 150-250 µg/L 
M6-M9: 100-200 µg/L 
 
• > M9: D adjusted on C2 = 
400-600 µg/L 
Efficacy 
• Incidence of ARE ≥ grade 3A 
o Month 6: 38.5% 
o Month 12: 38.5% 
o Month 24: 46% 
o Month 36: 54% 
• Time to acute rejection: 363±462 days 
• 3 deaths 
• LVEF: 58±5 (M3) to 60±5% (M12) 
• Incidence of graft atherosclerosis at M12: 11% 
 
[22]
 Prospective analysis 
of 2 consecutive 
periods 
9 adults 
53±12 years 
De novo  
f/up: 4 years 
Group II 
(MMF D: 1.5 g BID) 
• D adjusted on C2 
< M3: 600-800 µg/L 
M4-M6: 500-700 µg/L 
> M6: 400-600 µg/L 
Efficacy 
• Incidence of ARE ≥ grade 3A (ns) 
o Month 6: 11% 
o Month 12: 44% 
o Month 24: 56% 
o Month 36: 56% 
• Time to acute rejection: 344±237 days (ns) 
• No death 
• LVEF: 59±2 (M36) to 61±2% (M24) (ns) 
• Incidence of graft atherosclerosis at M12: 0% (ns) 
Toxicity: 
• Renal function, incidence of infections: ns 
 
MMF D: group 1 ≠ 2 
D/kg different at M1 
[86]
 2-phase prospective 
study 
Paired determination 
of C0 and C2 
Investigators blinded 
58 adults 
56±11 years 
 
2.03±1.28 years 
(0.3-3.6) 
Cyclosporine 
ATG or basiliximab  
Prednisone 
AZA or MMF 
FPIA-TDx Toxicity: 
• Incidence of life-threatening infections 
• Renal dysfunction (SCr, ClCr) 
Efficacy 
• BPAR ≥ grade 2 (ISHLT) 
Short follow-up in 
both phases. 
 
C0 or C2 values in the 
whole population for 
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Phase I (6 months): D adjusted 
on C0 
• M3-M6: 300-350 µg/L 
• M6-M12: 250-300 µg/L 
• M12-M24: 200-250 µg/L 
• >M24: 150-200 µg/L 
Toxicity 
• 8 infection episodes 
• Renal function deterioration in 2 patients 
Efficacy: 
• ARE ≥ grade 3, 7/58 patients 
• Rejection vs no rejection: 
C0 = 195±121 vs 197±100, ns 
C2 = 777±326 vs 1,015±422, p=0.022 
 
to exposure index 
Phase II (6 months): D adjusted 
on C2 associated with no 
rejection during phase I 
• M3-M6: 1,403±285 
• M6-M12: 1,175±215 
• M12-M24: 947±170 
• >M24: 824±120 
Toxicity 
• 6 infection episodes (ns) 
• Renal function deterioration in 1 patient; no difference 
in SCr and calculated ClCr 
Efficacy: 
• ARE ≥ grade 3, 6/56 patients (ns) 
• Rejection vs no rejection: 
C0 = 204±85 vs 209±138, ns 
C2 = 765±297 vs 967±470, p=0.03 
 
each phase: N/R. 
 
No monitoring of 
MPA levels. 
125 adults Stable, > 1 year CEDIA 
 
 
Group I 
n = 62 
55±10 years 
6.4±2.8 years D adjusted on 
C0 = 80-120 µg/L 
Primary endpoint 
• Decrease of cyclosporine D: 11 mg/day 
Secondary endpoints 
• Deaths: 1 patient 
• ARE: no suspicion 
• Infections: 9.7% 
• ClCr: + 0.54 mL/min 
 
[51]
 Prospective 
randomized controlled 
study 
f/up: 6 months  
Group II 
n = 63 
55±9 years 
6.4±2.5 years 
Cyclosporine 
 
± Prednisone 
± MMF or AZA 
D adjusted on 
C2 = 300-600 µg/L 
Primary endpoint 
• Decrease of cyclosporine D: 26 mg/day (p = 0.0025) – 
C0 in target range 
Secondary enpoints 
• Deaths: 1 patient 
• ARE: no suspicion 
• Infections: 15.9% (p = 0.14) 
• ClCr: -0.16 mL/min (p = 0.61) 
 
Short follow-up 
duration. 
 
Low incidence of AR  
after the first year 
post-transplant. 
 
Study not powered to 
detect a small possible 
effect of C2 vs C0 
monitoring on AR. 
HEART AND LUNG TRANSPLANTATION 
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Single center study 
using historic controls 
Intent-to-treat analysis 
 
 De novo  
 
 
Cyclosporine 
 
 
 
EMIT 
 
 
Transplantation 
between 1989 and 
2000 
 
338 patients 
124 SL, 150 
DL, 64 HL 
 ATG(1) 
AZA 
Prednisolone 
 
C0 group 
Target: N/R 
Primary endpoint : efficacy (ISHLT classification) 
• Freedom from AR: 
M3: 51% – M6: 45% – M12: 41%  
• Freedom from BOS: 
Y1: 87% – Y3: 53% – Y5: 36% 
• Actuarial survival: 
30-days: 93% – Y1: 83% – Y3: 66% – Y5 : 55% 
Secondary endpoint: toxicity 
• Chronic renal failure within 5 years: 18 patients 
 
C2 group 
[88]
 
Transplantation 
between 2001 and 
2002 
 
 
 
 
 
50 patients 
3 SL, 44 
DL, 3 HL 
f/up: 
16-1,790 days 
(1,185±426) 
 
AZA (n = 15) or MMF 
(n = 35) 
Prednisolone 
Day 0-2  
Day 2-7  
Day 8-30 
Day 30-60 
Day 61-90 
Day 91-180 
Day 181-365 
Day >365 
> 800 
> 1,200 
1,200-1,700 
1,200-1,500 
800-1,200 
700-1,000 
600-900 
600-800 
Primary endpoint : efficacy (ISHLT classification) 
• 15 patients with ARE (23 episodes/171 TBB) 
18/23 episodes within 2 weeks of subtherapeutic level 
• 12 patients with ARE/25 with C2 subtherapeutic levels  
• Freedom from AR (p = 0.001) 
M3: 74% – M6: 69% – M12: 69% 
• Freedom from BOS (p = 0.002) 
Y1: 98% – Y3: 79% – Y5: 59% 
• Actuarial survival (p = 0.029) 
30-days: 98% – Y1: 94% – Y3: 82% – Y5 : 77% 
Secondary endpoint: toxicity 
• Chronic renal failure in one patient, with SCr > 250 
mg/L (needed dialysis and renal transplantation); 
(p > 0.10) 
• SCr = 122±64 mg/L 
 
Larger proportion of 
DL (p < 0.01) and of 
CF patients (p < 0.01) 
in C2 vs C0 group. 
 
 
LUNG TRANSPLANTATION 
36 adults 
(17 CF) 
DL 
 
Cyclosporine 
 
Prednisolone  
EMIT 
 
 
n = 18 AZA (n = 14) 
or MMF (n = 4) 
 
D adjusted on C0 
Week 1: 450 µg/L 
Month 3: 250 µg/L 
 
[92]
 Sequential groups 
n = 18 
De novo 
f/up: 3 months 
AZA (n = 2) D adjusted on C2 
Efficacy 
• FEV1 at M3: no difference 
• AR (A and B): similar rates in both groups (numbers: 
N/R) 
• Survival at M3: 100% 
C0 group older than 
C2 group 
 
Baseline SCr lower in 
C0 group 
 
Associated 
immunosuppressants 
different between the 
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or MMF (n = 16) 
 
Week 1: 1,200 µg/L 
Month 3: 800 µg/L 
 
Toxicity 
• SCr: greater increase from baseline in C0 group 
• Infections: similar rates in both groups (1.85 vs. 1.79 
events per 100 patients-days) 
 
2 groups 
[87]
 Uncontrolled single-
center pilot study 
15 adults 
with renal 
dysfunction 
(5 CF) 
5 SL, 10 DL 
 
 
 
3.5±2.7 years 
(0.2-9.0) 
Cyclosporine 
 
AZA (n = 10) or MMF 
(n = 5) 
Prednisolone  
EMIT 
 
Switch from C0 to C2 
monitoring 
C2 = 300-600 µg/L 
Primary endpoint 
• Renal function improvement at 3 and 12 months: 
SCr = 0.20±0.07 mmol/L at baseline 
to 0.15±0.05 mmol/L at M3 (p < 0.001) 
Secondary endpoint 
• Stable lung function except for 1 ARE 
Cyclosporine D (mg/kg/day) divided by two within 3 
months: 
6.4±7.3 to 3.9±3.7 at M3 (p = 0.031) 
to 3.1±2.7 at M12 (p = 0.041) 
 
 
(1) Patients transplanted before 1995 
 
Legend 
AR: Acute rejection – ARE: Acute rejection episode – ATG: Antithymocyte globulin – AZA: Azathioprine – BOS: Bronchiolitis obliterans syndrome – BPAR: Biopsy proven acute rejection – 
ClCr: Creatinine clearance – D: dose – EMB: Endomyocardial biopsy – f/up: Follow-up – GFR: Glomerular filtration rate – LVEF: Left ventricular ejection fraction – M: Month – MMF: 
Mycophenolate mofetil – NEO: Neoral – N/R: not reported – SAND: Sandimmune – SCr: Serum creatinine – TBB: Transbronchial biopsy – Y: Year. 
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Table IX. Tacrolimus exposure indices in cohort studies 
Results are expressed as mean±SD (range), unless otherwise specified 
 
Ref Number of patients 
Post-
transplant 
period 
Tacrolimus dose 
Co-
administered 
Immunosup-
pressant 
Assay Measured AUC C0 (µg/L) Cmax (µg/L) tmax (h) Others 
HEART TRANSPLANTATION 
Non-compartmental PK analysis using Pharm-NCA computer program; AUC Trap; median (range) 
PK profiles after the first dose of tacrolimus  
 
AUC0-12 = 155.6 
(103.5-728.7) 
 
AUC0-∞ = 285.3 
(121.8-1540.0) 
 
--  23.0 
(10.7-84.4) 
2 (1-4) Cmin = 8.3 
(< 5-54.1) 
 
[102]
 14 adults 
 
55.5 years 
(23-61) 
< 6 months  First D = 0.03-0.40 mg/kg  
(median: 0.052 mg/kg) 
 
ATG 
AZA 
Prednisone 
MEIA – 
IMx  
Best correlation: C12-AUC: C12 = 0.0371 x AUC0-∞ – 2.1; r² = 0.98 (p<0.001) 
 
 First  D up to 0.15 mg/kg BID 
D adjusted on C0 < 15 µg/L 
 
 Non-compartmental PK analysis using TOPFIT v2.0; tmax: median (range) 
 
ELISA AUC0-∞ = 191.8±137.1 
(32.9-422.2) 
CV = 72% – n = 7 
 
-- 23.6±22.4 (1.3-76.6) 
CV = 95% – n = 10 
2.84 (2-9.5) 
n = 10 
-- Profile 1 
(day 1) 
NG tube 
D = 0.053±0.031 mg/kg 
(0.026-0.143) 
CV = 59% 
HPLC-
MS/MS 
AUC0-∞ = 141.9±93.6 
(41.6-254.9) 
CV = 66% – n = 5 
 
-- 20.8±15.9 (2.1-49.4) 
CV = 77% – n = 10 
2.75 (1.5-9.5) 
n = 10 
-- 
ELISA AUC0-∞ = 257.4±76.3 
(144.8-442.7)  
CV = 30% – n = 10 
 
-- 34.2±18.2 (19.0-84.7) 
CV = 53% – n = 10 
1.96 (0-4) 
n = 10 
-- 
[100]
 11 adults 
OHT 
Profile 2 
(last day) 
Hard capsules 
D = 0.076±0.069 mg/kg 
(0.013-0.250) 
CV = 91% 
N/R 
HPLC-
MS/MS 
AUC0-∞ = 211.1±77.2 
(104.2-362.9) 
CV = 37% – n = 10 
 
-- 33.1±14.8 (13.3-66.6) 
CV = 45% – n = 10 
1.5 (1-8) 
n = 10 
-- 
[103]
 25 adults 
47±10 years 
Immediate post-
transplantation 
 Induction: 
ATG/OKT3  
HPLC-
MS/MS 
Non-compartmental analysis using computer program PC Modfit v/6; AUC0-12 Trap 
 
97 
 
 
D = 0.075 mg/kg/day       
 First dose 78.1±59.0 -- 14.7±7.8 2.1±1.7 -- 
n: N/R 
 Steady-state 186±68.7  26.6±9.5 1.9±1.2  
D = 0.15 mg/kg/day      
 First dose 142±116 -- 24.5±13.7 1.9±1.2 -- 
n: N/R 
 Steady-state 198±73.1  29.9±14.5 1.8±0.6  
 
period 
 r² Cmin – AUC0-12: first D = 0.86; steady-state = 0.79 
 
 
 
2-compartment open model using P-Pharm popPK software 
 
PK1 (day 10) 
 
--  12.5 
 
-- --  -- 
[115]
 19 adults 
46 years 
(28-48) 
OHT 
 
 
PK2 (month 2) 
 
D = 0.06 mg/kg/day 
(0.04-0.08) 
D adjusted on C0 = 5-20 µg/L 
ATG 
AZA 
Prednisone 
MEIA – 
IMx 
--  15.0 
 
-- --  -- 
Non-compartmental PK analysis using PK Calc software; AUC Trap; Mean (range) 
 
AUC0-12 = 151.7 
(129.2-174.2) 
 
AUC0-∞ = 317.5 
(189.2-445.7) 
 
7.9  
(6.0-9.7)  
22.9 
(18.3-27.5) 
2.2 
(1.5-2.9) 
C12 = 7.6 
(6.2-9.0) 
(vs C0: ns) 
[111]
 8 adults 
45-60 years 
4 to 16 months 
(mean: 10.6) 
D = 0.02-0.1 mg/kg/day 
D adjusted on C0 = 5-12 µg/L 
MMF 
Prednisone 
MEIA II 
– IMx  
r² AUC0-12: 
• C0, C1, C2, C3 = 0.09 to 0.26 (ns) 
• C4, C5, C6, C7, C8 = 0.53 to 0.64 (p < 0.05) 
• C9, C10, C11, C12 = 0.70 to 0.80 (p < 0.01) 
 
Non-compartmental PK analysis using MOMENT software (n = 25 PK profiles); AUC Trap 
 
AUC0-12 = 236.3±88.6 
(81.5-419.8) 
 
AUC0-4 = 93.5±40.8 
(35.9-180.9) 
14.8±5.7 
(3.9-25.9) 
 
30.5±13.8 
(10.3-57.8) 
 
2.3±1.5 
(0.5-6.0) 
Cav = 19.7±7.4 
(6.8-35.0) 
 
[109]
 22 adults 
55±8 years 
(36-64) 
OHT 
< Year 1 D = 0.3 mg/kg/day 
D adjusted on C0 = 10-20 µg/L 
Steady-state 
MMF or AZA 
Steroids 
MEIA – 
IMx 
r² AUC0-12: 
• C0 = 0.80 
• C1 = 0.40 
• C2 = 0.81 
• C4 = 0.90 
• C12 = 0.89 
r² AUC0-4: 
• C0, C1 = 0.70 
• C2 = 0.96 
• C4 = 0.73 
Sparse sampling algorithms for AUC0-12: 
• 3.75 + 5.52*C0 + 6.97*C4 – r² = 0.95 
• 0.98 + 4.17*C0 + 2.29*C2 + 5.3*C4 – r² = 0.97 
[104]
 13 patients  D adjusted on C0 = 10-15 µg/L ATG N/R Non-compartmental PK analysis performed using WinNonlin; AUC Trap 
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AUC/D: (µg.h/L)/mg 
tacrolimus 
 
    
AUC0-∞ = 186.7±96.6 
CV = 52% 
 
AUC0-∞/D = 46.0±24.3 
 
-- -- -- -- First dose D = 0.077±0.011 mg/kg BID 
r² AUC0-∞: 
• C0.5 = 0.020; p = 0.66 
• C1 = 0.143; p = 0.226 
• C2, C3, C4, C6, C8, C10 = 0.764 to 0.88; p < 0.05 
• C12 = 0.895; p < 0.05 
 
AUC0-12 = 202.6±61.3 
CV = 30% 
 
AUC0-12/D = 69.0±43.9 
 
-- -- -- -- First month 
Steady-state 
D = 0.068±0.047 mg/kg BID 
r² AUC0-12: 
• C0 = 0.841; p < 0.05 
• C1 = 0.469; p = 0.014 
• C0.5, C2, C3, C10, C12 = 0.640 to 0.822; p < 0.05 
• C4, C6, C8 = 0.902 to 0.976; p < 0.05 
 
 Non-compartmental PK analysis 
 
First dose AUC0-12 = 116.3±58.9 
Best r² C4-AUC = 0.93 
 
-- 18.8±7.7 2.1±1.4 C12 = 5.8±2.7 
Day 3 AUC0-12 = 149.7±63.2 
Best r² C4-AUC = 0.92 
 
-- 23.7±10.4 2.2±1.3 C12 = 10.6±3.8 
[105]
 23 patients 
38 years 
(18-56) 
Day 7 
D = 0.10 mg/kg/day 
D adjusted on C0 = 10-20 µg/L 
N/R MEIA – 
IMx  
AUC0-12 = 216.6±89. 4 
Best r² C4-AUC = 0.95 
 
-- 32.4±11.5 1.9±0.8 C12 = 17.7±6.4 
LUNG TRANSPLANTATION 
20 patients  D adjusted on C0 = 7-12 µg/L 
 
Non-compartmental PK analysis [117] 
8 CF 326 days 7.9±2.8 mg/day 
Patients 
converted 
from 
N/R 
-- 10.3±2.6 -- -- -- 
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(120-689) 
 
(0.16±0.06 mg/kg/day) 
 
 
12 non-CF 436 days 
(155-714) 
6.4±3.7 mg/day (p = 0.14) 
0.11±0.06 mg/kg/day (p = 
0.08) 
 
cyclospsorine 
to tacrolimus 
(rescue 
therapy) 
-- 10.7±1.6 (ns) 
 
-- -- -- 
Non-compartmental PK analysis (n = 22 profiles) 
 
AUC0-8 = 115.8±45.2 
(41.0-212.3) 
 
AUC0-4 = 67.9±31.1 
(20.7-146.9) 
 
10.5±5.7 
(3.4-30.4) 
 
21.6±11.8 
(5.9-50.0) 
 
2.3±1.3 
(0.0-5.0) 
C2 = 19.1±11.7 
(4.6-50.0) 
 
[114]
 16 adults 
(5 CF) 
45.5±3.4 years 
98±19 wks D = 3.6±2.5 mg BID 
(0.25-7.0) 
D adjusted on C0 = 5-15 µg/L 
 
N/R HPLC-
MS/MS 
r² C2-AUC0-8 = 0.50; r² C4-AUC0-8 = 0.53 
 
HEART AND LUNG TRANSPLANTATION 
Non-compartmental PK analysis – 3 full PK profiles/patient within 1 week; AUC trap; Median (range) 
 
22 adults  D adjusted on C0 = 8-12 µg/L 
Steady-state 
 
Low-dose 
corticoids 
AUC/D: (h.µg/L)/mg 
tacrolimus 
 
C0/D: (µg/L)/mg 
tacrolimus 
Cmax/D: (µg/L)/mg 
tacrolimus 
  
[110]
 
11 CF 
30 years 
(21-43) 
36.1 months D = 12 mg/day (5-25) AZA (n = 5) 
or MMF (n = 
2) 
MEIA – 
IMx 
AUC0-12 
V1: 170 (140-260) 
V2: 180 (110-310) 
V3: 160 (100-270) 
 
AUC0-12/D 
V1: 14 (8-34) 
V2: 17 (8-33) 
V3: 12 (9-32) 
 
AUC0-4 
V1: 80 (60-150) 
V2: 100 (50-170) 
V3: 70 (40-180) 
 
AUC0-4/D 
V1: 8 (4-6) 
V2: 10 (3-13) 
V3: 7 (4-14) 
 
C0 
V1: 8.2 (6.0-14.0) 
V2: 9.2 (4.7-13.2) 
V3: 8.5 (5.2-13.2) 
 
C0/D 
V1: 0.7 (0.5-2.3) 
V2: 0.7 (0.4-1.7) 
V3: 0.7 (0.3-1.7) 
Cmax 
V1: 23.4 (16.6-64.8) 
V2: 25.6 (15.6-65.7) 
V3: 23.4 (10.6-76.8)  
 
Cmax/D 
V1: 2.6 (1.2-4.7) 
V2: 3.2 (1.1-3.9) 
V3: 2.2 (1.2-3.4) 
tmax 
V1: 1.5 (0.5-6.0) 
V2: 1.5 (1.0-8.0) 
V3: 1.5 (0.5-5.0) 
C3 
V1: 16.2 
(11.4-30.5) 
 
V2: 21.6 
(10.1-33.0) 
 
V3: 16.4 
(6.5-26.0) 
 
C3/D 
V1: 1.5 
(0.7-3.3) 
 
V2: 1.7 
(0.6-3.6) 
 
V3: 1.4 
(0.9-3.3) 
100 
 
AUC/D smaller by about 50% in CF patients: AUC0-12/D, p < 0.004; AUC0-4/D,  p < 0.001 
 
 
r² AUC0-12: 
• C0.5 = 0.35 
• C0, C1, C1.5 = 0.53 to 0.58 
• C2, C2.5, C4 = 0.71 to 0.80 
• C3 = 0.86 
 
r² AUC0-4: 
• C0 = 0.34 
• C0.5, C4 = 0.46-0.53 
• C1, C1.5, C3 = 0.79 to 0.83 
• C2, C2.5 = 0.89-0.90  
 
32.6 months 
p = 0.97 
 AUC0-12 
V1: 210 (120-270) 
V2: 180 (80-270) 
V3: 170 (80-240) 
 
AUC0-12/D 
V1: 31 (17-71) 
V2: 33 (12-72) 
V3: 30 (12.69) 
 
AUC0-4 
V1: 110 (60-140) 
V2: 80 (40-150) 
V3: 90 (40-130) 
 
AUC0-4/D 
V1: 15 (6-43) 
V2: 15 (6-42) 
V3: 16 (6-39) 
 
C0 
V1: 9.9 (6.4-14) 
V2: 10.9 (5.0-17) 
V3: 9.8 (5.4-13.7) 
 
C0/D 
V1: 1.8 (1.0-2.4) 
V2: 1.9 (0.7-3.1) 
V3: 2.0 (0.8-3.4) 
Cmax: 
V1: 32.8 (15.5-57.8) 
V2: 29.1 (11.1-68.0) 
V3: 30.6 (11.6-43.5) 
 
Cmax/D: 
V1: 5.5 (2.4-15.2) 
V2: 6.5 (1.4-14.1) 
V3: 5.6 (1.6-4.5) 
tmax  
V1: 1.5 (1.0-4.0) 
V2: 1.0 (0.5-5.0) 
V3: 1.5 (1.0-3.0) 
C3 
V1: 19.4 
(12.5-25.0)  
 
V2: 16.3 
(9.4-26.9) 
 
V3: 16.9 
(11.0-26.4) 
 
C3/D 
V1: 3.5 
(1.9-8.3) 
 
V2: 3.6 
(1.2-7.2) 
 
V3: 2.8 
(1.6-6.3) 
11 non-CF 
51 years 
(31-56) 
p < 0.01 
 
D = 6.1 mg/day (3-10) 
p = 0.008 
AZA (n = 5) 
r² AUC0-12: 
• C0, C0.5 = 0.44-0.58 
• C1, C1.5, C2 = 0.72 to 0.76 
• C2.5, C4 = 0.84-0.87 
• C3 = 0.92 
 
r² AUC0-4: 
• C0, C0.5 = 0.44-0.48 
• C1, C1.5, C2, C2.5, C3, C4 = 0.83 to 0.88 
PK analysis using a one-compartment model with first-order elimination convoluted with a double gamma 
absorption phase – PK software Ciclo®2.3 
3 full PK profiles/patient within 5 days (V1, V2, V3) 
 
22 adults    
AUC/D: (h.µg/L)/mg 
tacrolimus 
 
C0/D: (µg/L)/mg 
tacrolimus 
 
Cmac/D: (µg/L)/mg 
tacrolimus 
 
  
[112]
 
11 CF 
30 years 
(21-43) 
3-116 months D = 0.23 mg/kg/day 
(0.09-0.47) 
AZA (n = 5) 
or MMF (n = 
2) 
MEIA-
IMx 
AUC0-12 
V1: 182.3±48.2 
V2: 187.4±66.0 
C0 
V1: 9.05±2.29 
V2: 8.91±3.20 
Cmax 
V1: 31.9±16.9 
V2: 32.4±18.4 
tmax 
V1: 1.5±0.6 
V2 : 2.1±1.8 
-- 
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V3: 169.7±60.5 
 
AUC0-12/D 
V1: 18.8±9.1 
V2: 18.5±8.2 
V3: 16.5±6.3 
 
AUC0-4 
V1: 81.3±39.0 
V2: 80.2±39.3 
V3: 71.0±35.0 
 
AUC0-4/dose 
V1: 8.1±3.9 
V2: 7.6±3.5 
V3: 6.3±2.7 
 
V3: 8.52±3.10 
 
C0/D 
V1 : 0.98±0.61 
V2: 0.89±0.45 
V3: 8.52±3.10 
V3: 26.2±17.7 
 
Cmax/D 
V1: 3.0±1.3 
V2: 2.9±1.2 
V3: 2.2±0.7 
V3: 1.7±1.2 
Bayesian estimator (AUC0-12): best sampling times: C0, C1.5, C4; r² = 0.91, mean bias -1.1% (-18.6;16.7%) 
BE vs Trap on AUC0-12, AUC0-4, Cmax, tmax, C0: bias% < 7.3%; RMSE% < 15% 
 
AUC0-12 
V1: 184.0±55.1 
V2: 180.2±59.6 
V3: 183.4±47.0 
 
AUC0-12/D 
V1: 33.5±14.7 
V2: 33.9±16.7 
V3: 35.8±18.3 
 
AUC0-4 
V1: 83.7±28.0 
V2: 80.3±33.7 
V3: 80.1±25.9 
 
AUC0-4/D 
V1: 15.3±7.8 
V2: 15.1±8.5 
V3: 15.9±9.3 
 
C0 
V1: 9.62±2.54 
V2: 9.87±2.85 
V3: 9.98±2.49 
 
C0/D 
V1: 1.71±0.49 
V2: 1.82±0.72 
V3: 1.90±0.81 
Cmax 
V1: 33.1±15.0 
V2: 31.1±17.4 
V3: 30.1±10.8 
 
Cmax/Dose : 
V1: 5.9±3.4 
V2: 6.0±3.8 
V3: 5.7±3.5 
tmax 
V1: 1.4±0.7 
V2: 1.6±1.4 
V3: 1.5±0.8 
-- 11 non-CF 
51 years 
(31-56) 
p < 0.01 
9-86 months D = 0.1 mg/kg/day 
(0.06-0.19) 
AZA (n = 6) 
Bayesian estimator (AUC0-12): best sampling times: C0, C1, C3; r² = 0.96, mean bias -3.6% (-17.4;6.8%) 
BE vs Trap on AUC0-12, AUC0-4, Cmax, tmax, C0: bias% < 4.6; RMSE%  < 15.6 
 
 
Legend: 
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AIV: intravenous coefficient – ATG: Anti-thymocyte globulin – AZA: Azathioprine – BE: Bayesian estimator – D: Dose – CF: Cystic fibrosis – MMF: Mycophenolate mofetil – NG: Nasogastric 
– N/R: not reported – Trap: Trapezes. 
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Table X. Tacrolimus pharmacokinetic parameters in cohort studies 
Results are expressed as mean±SD (range), unless otherwise specified 
 
Ref Number of patients 
Post-transplant 
period Tacrolimus dose 
Co-administered 
immunosuppres-
sant 
Assay F, transfer k 
Vd/F 
(unless otherwise 
specified) 
CL/F 
(unless otherwise 
specified) 
T1/2 (h) 
HEART TRANSPLANTATION 
PK parameters after the first dose of tacrolimus 
 
ka, kel: h-1 
Lag-time: h 
 
Vd/F: L/kg CL/F: L.h-1/kg  
Non-compartmental PK analysis using Pharm-NCA computer program 
 
-- 2.4±0.79 0.21±0.08 8.7±3.5 
kel = .091±0.040 
 
One-compartment open model with first-order elimination using P-Pharm computer program 
 
[102]
 14 adults 
 
55.5 years 
(23-61) 
< 6 months  First D = 0.03-0.40 mg/kg  
(median: 0.052 mg/kg) 
 
ATG 
AZA 
Prednisone 
MEIA – 
IMx  
ka = 1.26±0.61 
Lag-time = 0.22±0.13 
2.0±0.4 (1.3-3.9) 
CV = 33% 
0.23±0.08 (0.098-0.328) 
CV = 36.3% 
6.5±2.4 
kel  = 0.116±0.034 
 
 First  D up to 0.15 mg/kg BID 
D adjusted on C0 < 15 µg/L 
 
 Non-compartmental PK analysis using TOPFIT v2.0 software 
 
Profile 1 
(day 1) 
NG tube 
ELISA 
 
-- -- -- 7.1±4.3 (2.4-15.9) 
CV = 60% – n = 7 
 
 
D = 0.053±0.031 mg/kg 
(0.026-0.143) 
CV = 59% 
HPLC-
MS/MS 
 
-- -- -- 4.0±1.0 (2.8-5.3) 
CV = 24% – n = 5 
 
Profile 2 
(last day) 
Hard capsules 
ELISA 
 
-- -- -- 14.1±6.3 (7.1-19.5) 
CV = 32% – n = 10 
 
[100]
 11 adults 
OHT 
 
D = 0.076±0.069 mg/kg 
(0.013-0.250) 
CV = 91% 
N/R 
HPLC-
MS/MS 
 
-- -- -- 10.7±5.3 (1.8-18.5) 
CV = 50% – n = 10 
 
[103]
  Immediate post-
transplantation 
period 
 N/R HPLC-
MS/MS 
Non-compartmental PK analysis using PC Modfit v/6 software 
CL: L/h 
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10 adults 
57±9 years 
IV, continuous infusion 
D = 0.01 to 0.02 mg/kg/day 
Induction: N/R -- -- CL = 2.4 -- 
25 adults 
47±10 years 
 
Oral    After the first dose: 
n: N/R D = 0.075 mg/kg/day -- -- -- 10.9±7.0 
 
 D = 0.15 mg/kg/day 
Induction: 
ATG/OKT3 
-- -- -- 9.8±5.2 
 
2-compartment open model – PK analysis using P-Pharm popPK software 
 
 
 
ka: h-1 
Lag-time: h 
 
V1/F: L/kg CL/F: L.h-1/kg  
PK1 (day 10) ka = 1.1±0.5 (0.3-1.6)  
CV = 42% 
 
Lag-time = 0.22±0.09 
(0.1-0.45)  CV = 41% 
 
V1/F = 1.7±0.6 (0.7-
3.5) 
CV = 36% 
0.19±0.08 (0.09-0.38) 
CV = 42% 
-- 
[115]
 19 adults 
46 years 
(28-48) 
OHT 
 
 
PK2 (month 2) 
D = 0.06 mg/kg/day (0.04-
0.08) 
D adjusted on C0 =  5-20 
µg/L 
ATG 
AZA 
Prednisone 
MEIA – 
IMx 
ka = 1.0±0.5 (0.1-1.8) 
CV = 48% 
 
Lag-time = 0.44±0.05 
(0.29-0.50) – p ≤ 0.05 
CV = 11% 
 
V1/F  = 1.1±0.4 
(0.3-1.8) – p < 0.01 
CV = 34% 
0.23±0.15 (0.04-0.62) 
CV = 65% 
-- 
Non-compartmental PK analysis using PK Calc software  
 
[111]
 8 adults 
45-60 years 
4 to 16 months 
(mean: 10.6) 
D = 0.02-0.1 mg/kg/day 
D adjusted on C0 = 5-12 µg/L 
MMF 
Prednisone 
MEIA II – 
IMx  
-- -- -- Mean = 13.8 
(95% CI = 7.0-20.7) 
 
Non-compartmental PK analysis using MOMENT software (n = 25 PK profiles) 
CL/F: L/h 
 
[109]
 22 adults 
55±8 years 
(36-64) 
OHT 
First year D = 0.3 mg/kg/day 
D adjusted on C0 = 10-20 
µg/L 
Steady-state 
MMF or AZA 
Steroids 
MEIA – 
IMx 
-- -- 11.6±5.5 (3.8-23.5) -- 
 
 Non-compartmental PK analysis 
 
First dose -- -- -- 11.1±6.3 
 
[105]
 23 adults 
38 years 
(18-56) 
Day 3 
D = 0.10 mg/kgd 
D adjusted on C0 = 10-20 
µg/L 
N/R MEIA – 
IMx  
-- -- -- 10.6±5.8 
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Day 7 -- -- -- 9.8±5.5 
 
LUNG TRANSPLANTATION 
Non-compartmental PK analysis (n = 22 profiles) 
 
[114]
 16 adults 
(5 CF) 
45.5±3.4 
years 
98±19 wks D = 3.6±2.5 mg BID 
(0.25-7.0) 
D adjusted on C0 = 5-15 µg/L 
 
N/R HPLC-
MS/MS 
-- -- -- 7.9±2.3 (4.0-12.0) 
 
HEART-LUNG TRANSPLANTATION 
One-compartment model with first-order elimination convoluted with a double gamma absorption phase 
– PK analysis using Ciclo®2.3 software 
 
22 adults 
 
  
MAT, SDAT: h 
AIV: L-1 
 
V1/F: L CL/F: L/h; λ: h-1  
11 CF 
30 years 
(21-43) 
3-116 months D = 0.23 mg/kg/day (0.09-
0.47) 
 MAT1  = 1.10±0.68 
SDAT1 = 0.27±0.15 
 
MAT2 = 5.14±2.11 
SDAT2 = 1.96±0.68 
 
AIV = 4.03±1.67 
r = 0.58±0.22 
 
V1/F = 2,011±1,740 68.22±29.80 λ = 0.64±0.33 
 
[112]
 
11 non-CF 
51 years 
(31-56) 
p < 0.01 
9-86 months D = 0.1 mg/kg/day (0.06-
0.19) 
AZA (n = 6) 
MEIA – 
IMx 
MAT1 = 0.92±0.43 (ns) 
SDAT1 = 0.30±0.10 (ns) 
 
MAT2 = 5.47±2.30 (ns) 
SDAT2 = 1.89±0.71 (ns) 
 
AIV = 9.36±4.98 
(p < 0.01) 
 
r = 0.62±0.12 (ns) 
 
V1/F = 444±326 
(p < 0.01) 
36.49±18.98 
(p < 0.05) 
λ = 0.80±0.31  
(p < 0.01) 
 
Legend 
ATG: Antithymocyte globulin – AZA: Azathioprine – CF: Cystic fibrosis – D: Dose – NG: Nasogastric – N/R: not reported – OHT: orthotopic heart transplantation – r: fraction of the dose 
absorbed by the faster phase. 
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Table XI. Mycophenolate exposure indices in cohort studies 
Results are expressed as mean±SD unless otherwise specified 
 
Ref Number of patients 
Post-
transplant 
period 
MMF dose Co-administered immunosuppressant 
Analytical 
method, 
molecule 
Measured AUC 
(h.mg/L) C0 (mg/L) Cmax (mg/L) tmax (h) Others 
HEART TRANSPLANTATION 
First 10 days  HPLC-UV 
 
Non-compartmental PK analysis; AUC Trap; data are presented as median (range) 
 
 
MMF 
AUC0-6 
7.5 (4.2-37.2) 
 
 
-- 
 
4.7 (2.2-18.4) 
 
 
2.0 (1.0-3.0)  
 
Day 3 
 
MPA 
MPAG 
AcMPAG 
AUC0-12 
34.2 (22.3-52.1) 
1,030 (537-2,049) 
8.5 (5.6-11.9) 
 
 
0.65 (0.24-1.35) 
69 (34-153) 
0.36 (0.09-0.69) 
 
10.2  (7.6-16.7) 
110  (65-187) 
 1.31 (0.99-1.68) 
 
 2.0 (1.0-3.0) 
3.0 (2.5-3.5) 
1.3 (1.0-1.7) 
 
-- 
 
MMF 
AUC0-6 
6.5 (5.0-26.3) 
 
 
-- 
 
3.7 (2.3-10.3) 
 
2.0 (1.0-2.0)  
Day 5 
IV, D = 1.5 g BID 
Infusion over 3 hours 
(day 0 – day 5) 
 
MPA 
MPAG 
AcMPAG 
 
AUC0-12 
33.8 (23.7-43.1) 
881 (456-1,584) 
5.4 (1.8-9.3) 
 
0.96 (0.26-1.11) 
 63 (34-135) 
 0.25 (<0.05-0.59) 
 
9.8 (6.1-11.2) 
109 (51-166) 
0.86 (0.38-1.22) 
 
2.0 (2.0-3.0) 
3.2 (3.0-4.0) 
3.0 (3.0-4.0) 
 
-- 
Day 6  
MPA 
MPAG 
AcMPAG 
 
AUC0-12 
29.7 (22.3-37.6) 
959 (471-1,216) 
5.1 (3.2-5.9) 
 
0.56 (0.24-1.12) 
56 (26-82) 
0.14 (<0.05-0.4) 
 
6.0 (4.4-10.5) 
96 (51-111) 
0.77 (0.48-1.30) 
 
2.0 (0.33-6.0)  
4.0 (0.67-8.0) 
2.0 (0.67-6.0) 
 
-- 
[122]
 9 patients 
55±11 years 
(33-71) 
Day 10 
Oral, D = 1.5 g BID 
(day 5 – day 10) 
Cyclosporine (same 
dose throughout the 
period) 
Prednisolone 
 
MPA 
MPAG 
AcMPAG 
 
AUC0-12 
33.8 (26.6-40.3) 
1,032 (573-1,498) 
6.4 (4.5-10.7) 
 
0.95 (0.48-1.39) 
79 (28-122) 
0.32 (0.19-0.85) 
 
9.0 (3.6-10.8) 
108 (59-179) 
0.90 (0.44-1.36) 
 
 
1.25 (0.67-1.25)  
2.5 (1.25-4.0) 
2.0 (1.25-4.0) 
 
-- 
Non-compartmental PK analysis (n = 44 full MPA profiles); AUC0-12 Trap 
 
[121]
 9 patients 
Mean: 59 
years 
Weeks 1, 2, 4, 
8, 12 
D = 1 g or 1.5 g BID Cyclosporine 
Prednisone 
HPLC-UV 
45.9±15.4 
(13.4-91.7) 
 
--  10.4±6.6 1.25 -- 
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r² C2-AUC0-12 = 0.610; r² C12-AUC0-12 = 0.003 
Recommended sparse sampling algorithms: 
• AUC0-12 = 5.568 + 0.902*C1.25 + 2.022*C2 + 4.594*C6; r² = 0.926 
• AUC0-12 = 3.800 + 1.015*C1.25 + 1.819*C2 + 1.566*C4 + 3.479*C6; r² = 0.948 
 
N/R Method for PK analysis: N/R 
 
MPA AUC0-12 = 63±11 
 
-- -- 1-2 
 
Cav = 5.2±1.0 
 
[137]
 14 patients 
57±13 years 
54±42 months 
 
D = 35±7 mg/kg/day Cyclosporine 
 r² AUC0-12 
• C0 = 0.48 
• C1, C2 = 0.08-0.09 
• C3, C4, C6, C8, C12 = 0.23 to 0.60 
 
HPLC-UV MPA AUC0-12 calculated from a 2-hour abbreviated AUC developed in renal transplant patients[216] 
 
 
MPA 
Free MPA 
 
AUC0-12 
44.5±16.1 
0.83±0.30 
 
 
1.2±0.6 
 
-- 
 
-- 
 
f  = 1.9±0.4% 
[132]
 38 patients 
OHT 
53±10 years 
310±278 days Steady-state 
 
D = 1.1±0.4 g BID 
(13.6±4.9 mg/kg BID) 
 
 
No induction 
Cyclosporine 
Prednisone 
 r² MPA C0-AUC0-12 = 0.40 (p = 0.01) 
r² MPA C0-MPA free fraction : ns 
 
Non-compartmental PK analysis; AUC0-12 estimated from C0, C30, C120 using a sparse sampling algorithm 
developed in renal transplant patients[120] 
 
62 patients 
Mean: 59 
years 
Stable,  > 1 
year 
Steady-state  EMIT 
AUC/D: (h.mg/L)/g 
MMF 
 
C0/D: (mg/L)/g 
MMF 
Cmax/D: 
(mg/L)/g MMF 
  
AUC0-12 
41.9±14.1 (19.7-81.8) 
< 40 in 50% pts with 
dose ≥ 3 g/day 
 
AUC0-12/D = 
31.9±16.1 (13.4-82.3) 
 
C0/D = 1.41±0.95  Cmax/D = 18.9 Med.: 40 min 
Mean: 75 min 
-- 
[134]
 
n = 47 
57±9 years 
 
3.6±4.0 years D = 2.9±0.8 g/day 
D ≥ 3 g/d, n = 32 
Cyclopsorine 
Corticosteroids (45% 
patients) 
 
MPA 
r² AUC0-12 
• C0 = 0.36, p < 0.01 
• C40, C75, C120 = 0.62-0.64, p < 0.01 
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AUC0-12 
51.1±15.8 (34.4-
87.6); p < 0.03 
< 40 in 27% pts with 
dose = 1-3 g/day 
 
AUC0-12/D = 
61.0±27.4 (23.7-
131.5); p < 0.001 
 
C0/D =  5.10±3.41 
p < 0.001 
Cmax/D = 21.8 (ns) Med.: 40 min 
Mean: 75 min 
-- n = 15 
64±10 years 
 
8.5±3.6 years 
(p < 0.01) 
D = 1.9±0.7 g/day 
p < 0.001 
D = 1-3 g/day, n = 15 
Sirolimus 
Corticosteroids (13% 
patients; p < 0.01) 
 
MPA 
r² AUC0-12 
• C0, C75, C120 = 0.56-0.61, p < 0.01 
• C40 = 0.82, p < 0.01  
 
Mean D      
Before the switch: 
2.9±1.0 g/day 
 
AUC0-12 
49.9±12.4 (34.3-56.9) 
 
AUC0-12/D = 
37.5±19.9 (20.6-73.6) 
 
C0/D = 4.85±4.39  
(0.44-5.20) 
 
-- -- -- 
56 years 3.4 years 
After the switch: 
2.0±0.7 g/day (p < 0.01) 
Switch group 
(cyclosporine to 
sirolimus), n = 9 
 
 
MPA 
 
37.5±20.0 (34.6-70.1)  
(p < 0.001) 
 
AUC0-12/D = 
58.3±32.5 (27.7-
131.5); p < 0.001 
 
C0/D = 2.00±1.68 
(0.33-14.6) 
p < 0.001 
 
-- -- -- 
HPLC Non-compartmental PK analysis; 120 samples 
 
MPA 
 
-- 2.2±2.0 
C0 ≥ 1 mg/L in 
50% of patients 
 
-- -- -- 
26 patients 
15±10 years 
(1 month – 
33 years)  
50% < 1 year 
50% > 1 year 
Steady-state 
 
D = 37.9±12.5 mg/kg 
= 1.207±0.302 g/m2 
Cyclosporine or 
tacrolimus 
Corticosteroids 
MPAG -- 48±4 
 
-- -- -- 
MPA 
 
-- 1.6±1.5 
 
-- -- -- 
MPAG 
 
-- 49±38  
 
-- -- -- 
[136]
 
 
16 children  1.1±0.3 g/m2/day Cyclosporine, n = 8 
40 samples 
 
MPAG/MPA 
 
-- 25.2±21.7 
 
-- -- -- 
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MPA 
 
 
-- 3.0±2.2 
(vs children on 
CsA, p = 0.04) 
 
-- -- -- D: N/R Tacrolimus, n = 8 
42 samples 
 
MPAG 
 
-- 36±17 
(vs children on 
CsA, p = 0.04) 
 
-- -- -- 
MPA 
 
-- 2.3 ±2.2 
(vs children on 
CsA, ns) 
 
-- -- -- 
MPAG 
 
-- 98±47 
(vs children on 
CsA, p < 0.0001) 
 
-- -- -- 
10 adults  1.3±0.4 g/m2/day 
(vs. children on 
cyclosporine, ns) 
Cyclosporine, n = 10 
37 samples 
 
MPAG/MPA -- 37.7±40.2 
(vs children on 
CsA, p = 0.016) 
 
-- -- -- 
Non-compartmental PK analysis 
 
[143]
 7 patients 
21-63 years 
6-23 days Steady-state 
 
D = 1 or 1.5 g BID 
Cyclosporine 
Corticosteroids 
HPLC-UV 
-- -- -- -- fMPA = 3.6±3.9% 
 
fMPA – total MPA 
r2 = 0.20 
 
fMPAG = 26±8% 
 
fMPAG – total 
MPAG 
r2 = 0.87 
 
fMPA – fMPAG :  
r2 = 0.83 
 
23 adults Stable, > 1 
year 
Steady-state  Non-compartmental analysis – AUC0-12 Trap [135] 
n = 14 
57±13 years 
 34.6±6.0 mg/kg/day Group 1 
Cyclosporine 
EMIT 
62.8±11.5 
 
2.9±1.3 -- 1-2 -- 
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r2 AUC0-12 
• C30, C1, C2 = 0.06-0.09 
• C0, C3, C4, C8, C12 = 0.23-0.69 
• C6 = 0.60 
 
55±24 
 
2.4±1.2 -- 30 min-1 h -- n = 9 
54±12 years 
 24.3±11.6 mg/kg/day Group 2 
Tacrolimus 
r2 AUC0-12 
• C30 = 0.04 
• C0, C1, C2, C3, C12 = 0.38-0.72 
• C4, C6, C8 = 0.85-0.93 
 
Non-compartmental PK analysis –AUC0-12 Trap 
 
42.0±18.3 (12.2-79.8) 
 
2.0±1.2 
 
-- 
 
-- 
 
C12h = 2.0±1.7 
 
[167]
 28 patients 
54 years 
(19-67) 
Stable, > 1 
year 
2.5±3 years 
1.5 g/day (0.5-4.0) 
D adjusted on C0 = 1.5-
4 mg/L 
Tacrolimus HPLC-UV 
r2 AUC0-12 
• C0, C3 = 0.14-0.17 
• C2, C10, C12 = 0.25-0.39 
• C0.5, C1, C6, C8 = 0.48-0.57 
Recommended sparse sampling algorithms: 
• AUC0-12 = 1.11*C0.5 + 1.16*C1 + 3.72*C2; r² = 0.84 
• AUC0-12 = 3.37*C0 + 0.97*C0.5 + 1.20*C1 + 2.70*C2; r² = 0.87 
 
HEART TRANSPLANT RECIPIENTS + LUNG TRANSPLANT RECPIENTS 
 Steady-state 
2-3 g/day 
 
Non-compartmental PK analysis using WinNonlin in the 7 patients on cyclosporine (4 HTx, 3 LTx) 
AUC0-τ, τ = N/R 
 
Period 1 
15±13 days 
(n = 10) 
 
2.4±0.5 g/day 
 
AUC = 30.1±18.2  
DN-AUC = 26.0±15.0 
fAUC = 2.22±2.32 
 
 
3.79±4.04 
 
Cmax = 9.34±4.24 
DN-Cmax = 8.00±4.15 
 
4.0±4.2 
 
Cmin = 0.33±0.58 
f  = 6.1±2.8 % 
[124]
 
 
9 patients  
(5 HTx, 4 
LTx) 
53±11 years 
Period 2 
56±33 days 
(n = 46) 
 
2.4±0.5 g/day 
ATG in HTx patients 
Cyclosporine (n = 7) 
or tacrolimus (n = 2) 
Prednisone 
 
HPLC-UV 
 
Total and 
unbound 
MPA 
 
AUC = 19.8±11.0  
DN-AUC = 18.2±12.0 
fAUC = 1.01±0.81 
 
 
2.21±2.63 
 
 
Cmax = 8.30±4.19  
DN-Cmax = 7.20±3.81 
 
0.7±0.4 
 
Cmin = 0.28±0.50 
f  = 4.3±2.4 % 
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Period 3 
125±73 days 
(n = 114) 
 
2.2±0.4 g/day 
 
AUC = 36.8±29.7 
DN-AUC = 32.5±23.7 
fAUC = 1.50±2.16 
 
 
2.20±2.29 
 
 
Cmax = 10.32±7.86 
DN-Cmax = 9.49±7.78 
 
1.7±1.3 
 
Cmin = 1.21±1.78 
f  = 4.4±3.0 % 
50 patients 
56.5 years 
(20.7-77.6) 
 
 Steady-state 
 
 HPLC-UV Non-compartmental PK analysis using WinNonlin 
Prednisone  (n = 27)       
 
MPA 
MPAG 
AcMPAG 
DN-AUC0-12 
18.6 (3.4-35.1) 
387 (152-909) 
8.7 (ND-147) 
 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC0-6 
14.3 (2.5-28.2) 
226 (69-495) 
5.8 (ND-76) 
 
MPA 
MPAG 
AcMPAG  
 
 
DN-AUC6-12 
6.5 (0.9-16.8) 
162 (61-427) 
3.0 (ND-70) 
 
MPA 
 
AUC6-12/AUC0-12 ratio 
0.27 (0.12-0.55) 
fAUC: N/R 
 
Cyclosporine (n = 11) 
 MPAG/MPA = 28.5 
(9.8-55.2) 
AcMPAG/MPA = 0.4 
(ND-12.3) 
 
-- 
-- 
-- 
DN-Cmax 
5.66 (0.64-15.53) 
-- 
-- 
 
1.0 (0.3-6.0) 
-- 
-- 
MPA DN-Cmin  
0.44 (ND-1.05) 
 
fMPA: N/R 
[130]
 
27 LTx 
(6 CF) 
49.9 years 
(20.7-70.5) 
2.1 years 
(0.2–14.0) 
1.5 g BID (0.50–1.50) 
 
0.034 g/kg/day 
(0.013–0.054) 
Tacrolimus (n = 16)  
MPA 
 
MPAG 
AcMPAG 
DN-AUC0-12 
41.4 (8.3-115.31) 
(p = 0.022) 
471 (72-928) 
12.7 (0.7-160) 
 
 
-- 
 
-- 
-- 
DN-Cmax 
8.24 (1.81-37.11) 
 
-- 
-- 
 
1.1 (0.3-10.0) 
 
-- 
-- 
MPA DN-Cmin  
1.13 (0.17-3.64) 
(p = 0.002) 
 
fMPA = 1.9% 
(0.7-3.8) 
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MPA 
 
MPAG 
AcMPAG 
DN-AUC0-6 
25.4 (5.5-96.1) 
(p = 0.046) 
257 (43-603) 
4.6 (0.5-101) 
 
 
MPA 
 
MPAG 
AcMPAG 
 
DN-AUC6-12 
14.8 (2.8-26.4) 
(p = 0.007) 
166 (29-389) 
7.40 (ND-59) 
 
 
MPA 
 
AUC6-12/AUC0-12 ratio 
0.33 (0.17-0.56) 
fAUC = 1.73 
(0.51-2.43) 
 
 MPAG/MPA = 12.6 
(2.4-25.8) 
(p = 0.002) 
AcMPAGMPA = 0.3 
(0.05-2.4) 
 
Prednisone  (n = 1)       
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC0-12 
50.9 (16.9-218.7) 
219 (50–1869) 
17.9 (2.2-178) 
 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC0-6 
34.9 (10.7-134.0) 
408 (35-1142) 
7.7 (1.2-101) 
 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC6-12 
18.9 (5.3-102.2) 
287 (14-726) 
6.6 (0.8-77) 
 
21 HTx 
(and heart + 
kidney) 
59.8 years 
(23.3-77.6) 
(p < 0.05) 
4.0 years 
(0.4–19.7) 
0.75 g BID (0.25–1.50) 
(p < 0.05, lung vs heart) 
 
0.019 g/kg/day 
(0.008–0.038) 
(p < 10-4, lung vs heart) 
Cyclosporine (n = 14) 
 
MPA 
AUC6-12/AUC0-12 ratio 
0.33 (0.16-0.49) 
fAUC =1.38 
(0.05-12.26) 
 
 
-- 
-- 
-- 
DN-Cmax 
16.8 (3.6–47.3) 
-- 
-- 
 
1.5 (0.3–12.0) 
-- 
-- 
MPA DN-Cmin  
1.45 (0.34-3.02) 
 
fMPA = 2.2% 
(0.2-15) 
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 MPAG/MPA = 11.9 
(0.9-28.6) 
AcMPAG/MPA = 0.2 
(0.07-2.03) 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC0-12 
106.8 (40.9-180.5) 
717 (113-1723) 
20.1 (2.6-109) 
 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC0-6 
58.1 (23.9-90.1) 
419 (40-940) 
13.4 (1.7-80.3) 
 
 
MPA 
MPAG 
AcMPAG 
 
DN-AUC6-12 
29.2 (9.9-89.8) 
298 (60–829) 
9.4 (0.9-62.6) 
 
 
MPA 
AUC6-12/AUC0-12 ratio 
0.42 (0.23-0.61) 
fAUC = 3.54 
(0.85-18.89) 
 
Tacrolimus (n = 9) 
 MPAG/MPA =  8.7 
(2.3-13.4) 
AcMPAG/MPA = 0.3 
(0.06-0.87) 
 
 
-- 
-- 
-- 
DN-Cmax 
21.8 (9.9-44.5) 
-- 
-- 
 
1.0 (0.4–10.0) 
-- 
-- 
MPA DN-Cmin  
3.28 (1.29-8.40) 
(p = 0.009) 
 
fMPA: 3.5%  
(0.5-14) 
LUNG TRANSPLANTATION 
Non-compartmental analysis using WinNonlin 
AUC0-τ, τ = N/R 
 
[119]
 7 patients 
50±10 years 
4.4±3.9 years 
(0.3-11.5) 
Steady-state, 1-3 g/day 
2.4±0.9 g/day 
(35.5±14.1 mg/kg/day) 
Cyclosporine 
Prednisone 
HPLC-UV 
 
Total 
Unbound AUC = 45.8±18.4 
DN-AUC = 23.6±15.8 
fAUC = 1.29±0.50 
 
-- Cmax = 17.37±7.69  
DN-Cmax = 9.30±9.66 
1.2±0.4 
 
Cmin = 3.12±1.41  
f  = 2.9±0.6% 
Non-compartmental analysis using WinNonlin 
 
[138]
 19 adults 
(4 CF) 
48±15 years 
Stable 
4.2±3.7 years 
Steady-state 
2.5±0.5 g/day 
Prednisone 
 
Cyclosporine (n = 9) 
or tacrolimus (n = 10) 
HPLC-UV 
29.4±17.9 
 
-- -- -- -- 
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r² C0-AUC0-12 = 0.714; r² C2-AUC0-12 = 0.663; r² C8-AUC0-12 = 0.884 ; otherwise, r² = 0.176-0.732 
 
Recommended sparse sampling algorithms: 
• log(AUC0-12) = 1.140 + 0.241*log(C0) + 0.406*log(C2); r² = 0.828, ME = -5.8%, RMSE = 6.0% 
• log(AUC0-12) = 1.09 + 0.202*log(C0) + 0.411*log(C1.5); r² = 0.791, ME = -5.7%, RMSE = 7.0% 
 
 
Legend 
D: Dose – DN: Normalized to a 1000 mg MMF dose – f: Free fraction – HTx: Heart transplantation – LTx: Lung transplantation – N/R: not reported – OHT: Orthotopic heart transplantation. 
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Table XII. Mycophenolate pharmacokinetic parameters in cohort studies 
Results are expressed as mean±SD, unless otherwise specified 
 
Ref Number of patients 
Post-transplant 
period MMF dose 
Co-administered 
immunosuppressant 
Analytical 
method, 
molecule 
F, transfer k 
Vd/F 
(unless otherwise 
specified) 
CL/F 
(unless otherwise 
specified) 
T1/2 (h) 
HEART TRANSPLANTATION 
First 10 days  Non-compartmental analysis – Data presented as medians (range) 
IV/PO AUC and Cmax ratios were calculated using log-transformed data and are presented as 
mean [90%CI] 
 
Day 3 
 
-- -- -- -- 
Day 5 
 
IV (infusion over 3 hours) 
D = 1.5 g BID (days 0–5) 
-- -- -- -- 
Day 6 Day 6/Day 3: 
F = 82.9% [71.4-96.3] 
Cmax PO/IV  = 63% [48-82] 
 
Day 6/Day 5: 
F = 91.6% [79-106] 
Cmax PO/IV  = 74% [57-95] 
 
-- -- -- 
[122]
 9 patients 
55±11 years 
(33-71) 
Day 10 
Oral 
D = 1.5 g BID (days 5 – 10) 
Cyclosporine (same 
dose throughout the 
period) 
 
Prednisolone 
HPLC-UV 
 
MPA 
Day 10/Day 3: 
F = 97.5% [83-114] 
Cmax PO/IV  = 77% [60-99] 
 
Day 10/Day 5: 
F = 108% [93-125] 
Cmax PO/IV  = 90% [71-115] 
 
-- -- -- 
Method for PK analysis: N/R 
 
[137]
 14 patients 
(57±13 yrs) 
54±42 months 
 
D = 35±7 mg/kg/day Cyclosporine N/R 
-- -- 23.3±6.5 L/min -- 
HEART TRANSPLANT RECIPIENTS + LUNG TRANSPLANT RECPIENTS 
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Non-compartmental PK analysis using WinNonlin 
 
 
50 patients 
56.5 years 
(20.7–77.6) 
2.7 years 
(0.2–19.7) 
D = 1 g BID (0.25–1.50) 
0.028 g/kg/d (0.008–0.054) 
 
Steady-state 
 
 
 Vd/F: L 
 
CL/F: L 
 
 
Prednisone (27)     
Cyclosporine (11) 
 
-- 248.1 (54.1-644.6) 
 
53.9 (28.5-294.7) -- 
LTx (n = 27) 
(6 CF) 
49.9 years 
(20.7–70.5) 
 
2.1 years 
(0.2–14.0) 
1.5 g BID = (0.50–1.50) 
0.034 g/kg/d (0.013–0.054) 
Tacrolimus (16) 
 
-- 124.8 (29.8-607.1) 20.8 (8.7-120.5) 
(p = 0.026) 
-- 
Prednisone (1)     
Cyclosporine (14) -- 
 
101.5 (36.6-1141.1) 
 
21.2 (4.6-59.2) 
 
-- 
 
[130]
 
HTx (n = 23) 
(5 HTx + KTx) 
59.8 years 
(23.3–77.6) 
(p < 0.05) 
 
4.0 years 
(0.4–19.7) 
D = 0.75 g BID (0.25–1.50) 
(p < 0.05) 
 
0.019 g/kg/d (0.008–0.038) 
(p < 10-4) 
Tacrolimus (9) 
HPLC-UV 
 
MPA 
MPAG 
AcMPAG 
-- 
 
111.0 (53.2-261.3) 
 
11.0 (5.5-24.4) 
 
-- 
 
 
Legend 
CF: Cystic fibrosis – D: Dose – HTx: Heart transplantation – KTx: Kidney transplantation – LTx: Lung transplantation – N/R: not reported. 
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Table XIII. MMF exposure – effect studies in heart transplantation 
Results are expressed as mean±SD, unless otherwise specified 
 
Ref Immunosuppressants Number of patients 
Sampling 
periods Exposure (analytical method) Event (Number of episodes) Comments 
MPA AUC, fAUC, C0 (HPLC-UV) 
MPA AUC0-12 calculated from a 2-hour abbreviated 
AUC developed in renal transplant patients[216]  
 
3 groups (ISHLT classification) 
AUC 
fAUC 
C0 
 
42.8±14 
0.81±0.25 
1.20±0.58 
 
Grade 0 
n = 22 patients 
 
AUC 
fAUC 
C0 
 
51.7±17.5 
0.95±0.34 
1.24±0.72 
Grade 1 
n = 13 patients 
 
[132]
 MMF, steady-state 
1.1±0.4 g BID 
(13.6±4.9 mg/kg BID) 
38 patients 
OHT 
53±10 years 
310±278 days 
AUC 
fAUC 
C0 
 
26.1±6.6 (p < 0.05 vs grade 0 and 1) 
0.49±011 (p < 0.05, vs grades 0 and 1) 
0.65±0.15 (ns vs  grades 0 and 1) 
Grade 2/3 
n = 3 patients 
 
No significant 
differences in 
cyclosporine exposure 
Prednisone dose 
varying among the 
patients 
 
Small sample size (3 
patients in the grade 
2/3 rejection group) 
 
Patients sampled at 
varying times 
throughout their post-
transplantation course 
 
MMF, steady-state 
Increased to the maximal 
tolerated dose 
D = 2.1±0.9 g/day (1.0-4.0) 
 
Corticosteroids (50%)  
 
MPA and MPAG C0 (HPLC-UV) 
“Therapeutic” C0 levels: 
• MPA > 2 mg/L 
• Cyclosporine ≥ 175 µg/L 
• Tacrolimus ≥ 10 µg/L 
48 routine EMB at time of blood sampling (ISHLT) 
Grade 0, 46%; grade 1A/1B, 33%; grade 2, 8%; grade 3A, 
4% 
MPA C0 vs overall incidence of rejection: ns 
Cyclosporine (42%) 
MMF D = 2.4±0.9 g/day 
n = 19 samples 
MPA C0 = 1.65±0.97 
MPAG C0 = 128.9±55.6 
 
Overall rejection ≈ 20% 
Cyclosporine C0 < 175 µg/L in 100% of patients 
[163]
 
Tacrolimus (58%) 
MMF D = 1.8±0.8 g/day 
(p = 0.01) 
 
26 patients 
54±14 years 
(22-72) 
3.0±1.7 years 
(1.0-7.8) 
n = 29 samples 
MPA C0 = 2.86±2.07 (p = 0.02) 
MPAG C0 = 101.1±84.9 (ns) 
 
Overall rejection ≈ 60% (significantly higher, p: N/R) 
Tacrolimus C0 < 10 µg/L in 52% of patients 
 
MPA and MPAG C0 (HPLC) 78 EMB (ISHLT classification) 
 
MPA C0 = 2.5±2.3 Grade < 2 (n = N/R) 
 
[136]
 MMF, steady-state 
D = 37.9±12.5 mg/kg = 
1.207±0.302 g/m2 
 
Cyclosporine or tacrolimus 
Corticosteroids 
26 patients 
(16 children, 
10 adults) 
15±10 years 
(1 month – 33 
years) 
50% < 1 year 
50% > 1 year 
MPA C0 = 1.2±0.9 (p = 0.02) Grade ≥ 2, (n = N/R) 
More frequent with MPA C0 ≥ 2.5 mg/L (p = 0.03) 
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MPA C0 (EMIT) 
Median: 1.51 (DF50 = 0.96-2.23) 
 
147 EMB (ISHLT) 
Difference in cyclosporine and MPA C0 between 
categories of biopsies: ns 
 
Grade 0, n = 54; grade 1A, n = 61; grade 2, n = 16, grade 
3A, n = 16 
Median MPA C0: 1.76 
(range: 0.496-7.65) 
 
Patients without AR, n = 9 
[170]
 MMF, 1.5 g BID (decreased 
based on clinical symptoms 
of toxicity) 
 
Cyclosporine (possibly 
converted to tacrolimus) 
Prednisone 
20 patients < 1 year 
(mean: 10.1 
months) 
Median MPA C0: 1.36 
(range: 0.26-6.13); p = 0.015 
 
Patients with AR, n = 11 
 
MMF, 2 g/day  
D adjusted on C0: 2-4 mg/L 
 
Cyclosporine (89%) or 
tacrolimus (11%) 
D adjusted on C0 
Prednisone (all) 
 
215 patients 
36±14 yrs 
 
 MPA C0 (EMIT); 892 plasma samples 
(3 groups based on C0: < 2, 2-4, > 4, or 2 groups 
based on C0 < 2 and C0 ≥ 2, to compare the incidence 
of rejection) 
 
Scheduled EMB 
Acute rejection if grade ≥ 3A (ISHLT) 
 
 
 
Rejectors: 
2.8±0.8 g/day 
 
Non rejectors: 
2.8±0.7 g/day (ns) 
 
No difference in mean C0 between patients with (C0 = 
2.2±2.0 mg/L) and without (C0 = 2.3±1.7 mg/L) AR 
 
Higher proportion of C0 < 2 in rejectors (n = 34/54) vs 
non rejectors (n = 194/401), p = 0.05 
No difference in AR incidence between the 3 C0 groups (p 
= 0.1): 7.8 to 14.9% 
 
Period I 
n = 104 
< 6 months 
Difference in cyclosporine or tacrolimus C0 between MPA C0 groups: ns 
Mean daily MMF dose to reach MPA C0 > 2, cyclosporine group vs tacrolimus group: ns 
• When MPA C0 < 2, no difference on AR incidence in relation to therapeutic or subtherapeutic cyclosporine or 
tacrolimus C0 (14.4 vs 13.9%, ns) 
• When MPA C0 > 2, AR incidence is significantly reduced if cyclosporine or tacrolimus C0 are therapeutic vs 
subtherapeutic (3.6 vs 15.4%, p = 0.002) 
 
Rejectors: 
2.5±1.0 g/day 
 
Non rejectors: 
2.6±0.7 g/day (ns) 
Period II 
n = 90 
6-12 months No difference in mean C0 between patients with (C0 = 
2.0±1.5 mg/L) and without (C0 = 2.7±2.0 mg/L) AR 
 
Higher proportion of C0 < 2 in rejectors (n = 9/14) vs 
non rejectors (n = 71/188), p = 0.05 
 
No difference in AR incidence between the 3 C0 groups (p 
= 0.15): 4.0 to 11.3% 
 
2.3±0.8 g/day 
[139]
 
2.3±0.8 g/day (ns) 
Period III 
n = 71 
> 12 months No difference in mean C0 between patients with (C0 = 
2.4±2.0 mg/L) and without (C0 = 2.6±2.2 mg/L) AR 
 
Comparable proportion of C0 < 2 in rejectors (n = 
No difference in AR incidence between the 3 C0 groups (p 
= 0.13): 2.6 to 15.1% 
 
 
50 patients had 
samples taken on more 
than one occasion 
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13/27) vs non rejectors (n = 98/208), p = 0.92 
 
 
MMF 
 
Tacrolimus 
Prednisone (weaning at 6 
months) 
 
45 adults 
Primary OHT 
 MPA C0 (EMIT) 
Tacrolimus C0 (IMx) 
 
EFFICACY 
Patient survival 
EMB (ARE, ISHLT 
classification) 
TOXICITY 
GI toxicity 
Infections 
Mean MPA levels (Months 0-6) Patient survival: 100% 
Tacrolimus C0, patients with 
vs without AR: ns 
3.6±0.4 
 
0 ARE/patient, n = 5 
 
2.2±0.4 
 
1-2 ARE/patient 
n = 7 patients 
 
MMF D = 2 g/d (fixed) 
Tacrolimus D adjusted on C0 
Phase I 
n = 15 
51±11 years 
696±62 days 
(606-790) 
1.4±0.2 
 
3 ARE/patient, n = 3 
 
GI toxicity: n = 6 (40%) 
 
Infections: 
Bacterial, n = 10 (66.7%) 
Fungal, n = 8 (53.3%) 
Viral, n = 9 (60.0%) 
[129]
 
 
MMF and tacrolimus D 
adjusted on C0 
 
Phase II 
n = 30 
54±9 yeras 
436±88 days 
(175-562) 
MPA C0 target: 2.5-4.5 27 patients: rejection-free 
3 patients with AR had 
confounding factors 
GI toxicity: n = 9 (30%) 
 
Infections: 
Bacterial, n = 17 (56.7%) 
Fungal, n = 5 (16.7%) 
Viral, n = 7 (23.3%) 
 
 
Legend: 
AR: Acute rejection – ARE: Acute rejection episode – CF: Cystic fibrosis – D: Dose – f: Free fraction – EMB: Endomyocardial biopsy – GI: Gastro-intestinal – N/R: not reported. 
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